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SUMMARY 
AMP-activated protein kinase (AMPK) is a master regulator of energy homeostasis and 
metabolism, both at the cellular and at the whole body level. It acts as a cellular fuel 
gauge, sensing changes in AMP: ATP or ADP: ATP ratios. Once activated by energy 
deficit, AMPK switches on catabolic processes, generating ATP, and inhibits 
biosynthetic processes, consuming ATP, thus conserving cellular energy. AMPK also 
regulates metabolism at the whole-body level, for example, by controlling appetite and 
entraining feeding with the circadian clock. AMPK regulates the cell cycle and 
modulates neuronal excitability. In recent years, it has been found that AMPK acts 
downstream of the tumour suppressor LKB1, that the AMPK signalling pathway is 
down-regulated in some tumours, and that diabetics treated with the AMPK-activating 
drug metformin exhibit a lower incidence of cancer. These results suggest that AMPK 
may itself be a tumour suppressor, although direct evidence has so far been lacking.   
 This thesis provides genetic evidence that AMPK functions as a tumour 
suppressor in vivo. A T cell-specific mouse tumour model was developed to delineate 
the role of AMPK in cancer. T cell-specific deletion of PTEN in mice causes 
development of T cell lymphomas at a median age of 85 days (43-214 days), while T 
cell-specific deletion of AMPK as well as PTEN caused development of lymphomas 
much sooner, at a median age of 65 days (46-87days, p<0.0001, hazard ratio = 6.3). The 
distribution of tumours was also significantly different between the two groups; the 
PTEN-null mice developed lymphomas in the thymus as well as in peripheral lymphoid 
organs such as lymph nodes and spleen, while the PTEN and AMPK double null 
lymphomas were largely confined to the thymus (p<0.001).  Before the onset of 
tumours, the PTEN AMPK double null T cells were larger and had greatly increased 
phospho-S6 levels compared to wild type and PTEN null T cells. These results suggest 
xxi 
 
that AMPK delays tumour onset in cells with an overactive PI3K pathway by down-
regulating the mTOR pathway. 
Recent studies have also suggested a role for AMPK in the response to DNA 
damage, produced by treatments such as ionising radiation and the anti-cancer drug 
etoposide. However, the molecular mechanism underlying this activation was unclear. 
This thesis shows that etoposide activates AMPK in a CaMKKβ-dependent manner in 
HeLa cells and G361 cells, both of which lack LKB1. Activation is restricted to the 
AMPK-α1 isoform within the nucleus, and this is associated with increased nuclear 
calcium flux. Taken together the results suggest that release of intra-nuclear calcium 
activates CaMKK-β, which in turn activates AMPK-α1. In addition, activation of 
AMPK by the calcium ionophore A23187 increased the survival of mouse embryonic 
fibroblasts treated with etoposide in an AMPK-dependent manner. 
This thesis also investigates the role of C-terminal phosphorylation of LKB1 on 
Ser-325 and Ser-431. The results presented in this thesis show that mutation of these 
sites to alanine, did not affect activation of AMPK by LKB1. It also shows that ERK2 
does not phosphorylate LKB1 on Ser-325 efficiently, and that phosphorylation of Ser-
431 by p90RSK does not affect activation of AMPK. These results do not support the 
view that phosphorylation of these two residues in the C-terminal tail of LKB1 inhibits 
AMPK activation. 
Overall, the studies performed in this thesis demonstrate that AMPK can be both 
a “friend” and a “foe” in cancer; On the one hand, it functions as a tumour suppressor 
delaying the onset of cancer, while on the other hand, it increases the survival of cancer 
cells treated with the anti-cancer drug etoposide. These distinct effects of AMPK might 
be exploited therapeutically, both in the prevention and in the treatment of cancer. 
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CHAPTER 1: INTRODUCTION 
 
1.1 Protein phosphorylation 
 
The molecular process involving the conversion of an extracellular signal to a functional 
change within the cell is termed signal transduction. Protein phosphorylation, a type of 
post-translational modification of proteins, mediated by enzymes termed protein kinases 
is an integral part of this process. Protein phosphorylation is a reversible process by 
which, a covalently bound phosphate group is transferred from ATP to a serine, 
threonine or tyrosine residue on a protein by an upstream kinase, generating ADP as the 
other product. This process is reversed by the removal of the phosphate group by a 
protein phosphatase that catalyses a hydrolysis reaction (Figure 1.1). Phosphorylation 
and de-phosphorylation of cellular proteins can modify their function in many ways: it 
can lead to an increase or decrease in the catalytic activity of the protein, stabilise its 
structure, target it for degradation, alter its sub-cellular localisation, or affect its 
interaction with other proteins. Nearly 30% of the proteins encoded by the human 
genome are thought to be regulated  by phosphorylation and abnormal phosphorylation 
is linked either causally, or as a consequence of many human diseases (Cohen, 2002). 
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Figure 1.1: Protein phosphorylation 
This is a schematic representation of reversible phosphorylation of proteins. Phosphorylation 
is catalysed by a protein kinase with the phosphate group derived from ATP. Reversal of this 
process is mediated by protein phosphatases, which dephosphorylate the protein.  
 
 
Reversible regulation of a protein by phosphorylation  was first described by Fischer 
and Krebs, who showed that phosphorylase kinase converted phosphorylase b to 
phosphorylase a in the presence of Mg-ATP (Fischer and Krebs, 1955). The reverse 
reaction was found to be catalysed by protein phosphatase-1 (Ingebritsen and Cohen, 
1983). It was then discovered that cyclic-AMP-dependent kinase or protein kinase A 
itself activated phosphorylase kinase by phosphorylation; thus the concept of a kinase 
cascade was born (Walsh et al., 1968). This was followed by the discovery of many 
more such kinases and phosphatases. The genes encoding all of these kinases in the 
human genome were eventually identified, arranged and depicted as the human kinome. 
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1.2 The human kinome 
 
The subset of the human genome which encodes protein kinases is termed the kinome 
(Figure 1.2). Most protein kinases in the human kinome belong to a large superfamily 
characterized by the presence of a eukaryotic protein kinase (ePK) catalytic domain. 
There are also 13 families of atypical protein kinases (aPKs) which have biochemical 
kinase activity but lack sequence similarity to the ePK domain. A total of 518 kinases, 
comprising 478 ePKs and 40 aPKs have been described (Manning et al., 2002). All 
kinases are classified into groups, families and subfamilies primarily on the basis of 
sequence similarity of the catalytic domain, domain structure outside of the catalytic 
domains and known biological functions. Similar classifications of the yeast and worm 
kinomes have also been described (Plowman et al., 1999, Breitkreutz et al., 2010). Forty 
eight (≈ 10%) proteins in the human kinome are considered to be catalytically inactive, 
as they lack conserved residues required for kinase activity. These ‘pseudokinases’ have 
been reported to regulate the activity of other functional kinases, and they also function 
as scaffolding proteins in multi-protein complexes (Boudeau et al., 2006). One example 
of a pseudokinase is STRAD (Ste-20 related adapter protein), which is required for the 
stable assembly and activation of the LKB1 complex. Binding of STRAD and another 
protein MO25 (mouse protein 25) to LKB1, alters the  subcellular localisation of the 
LKB1 complex from the nucleus to the cytoplasm (Boudeau et al., 2006). 
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Figure 1.2: The human kinome 
Image downloaded from kinase.com (based on the paper by Manning et al 2002) showing the 
human protein kinome which is classified into groups, mainly based on sequences of the 
kinase domain. AMPK and the AMPK- related kinase family (ARKs) are shown shaded in green 
and yellow respectively. LKB1 is shaded in purple and CaMKK1 and 2 are shaded in blue. 
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1.3 AMP-activated protein kinase 
 
1.3.1 Introduction and historical background 
 
This thesis will focus on the 5’-AMP activated protein kinase (AMPK). AMPK was 
first described as activities present in rat liver extracts that inhibited the activity of either 
acetyl- CoA carboxylase (Carlson and Kim, 1973, Lee and Kim, 1977) (Lee and Kim, 
1977) or microsomal HMG- CoA reductase activity (Beg et al., 1973) in the presence of 
Mg-ATP. The HMG-CoA reductase kinase was initially reported to require both ADP 
and ATP for its activity (Brown et al., 1975), but  AMP was confirmed to be the 
nucleotide required to activate the kinase (Ferrer et al., 1985). The earlier observation 
by Brown et al was likely due to the presence of adenylate kinase in their extracts which 
converted ADP to AMP.  It was then shown that the acetyl-CoA carboxylase (ACC) 
kinase and HMG-CoA reductase kinase activities were both functions of a single 
protein kinase (Carling et al., 1987). This kinase, previously referred to as acetyl-CoA 
carboxylase kinase-3 was renamed AMP-activated protein kinase (AMPK), as it was 
known to be allosterically activated by AMP (Munday et al., 1988, Carling et al., 1989).  
The first subunit of AMPK to be identified was the α subunit. AMPK  was 
purified from rat liver and the catalytic subunit was identified (using a reactive ATP 
analogue that labelled the catalytic site) to be a 63 KDa protein, initially termed p63 
(Carling et al., 1989). Purification of AMPK to homogeneity using ATP-γ-sepharose 
affinity chromatography led to the identification of two other subunits of molecular 
mass 38 and 35 KDa, in addition to p63 (Davies et al., 1994). Purification of AMPK 
from porcine liver using peptide substrate affinity chromatography also confirmed the 
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existence of three AMPK subunits with estimated molecular masses of 63, 40 and 38 
KDa (Mitchelhill et al., 1994). The three distinct subunits p63, p38 and p35, are now 
referred to as the α, β and γ subunits of the AMPK complex (Figure 1.3). 
 
1.3.2 The catalytic α subunit 
 
The catalytic subunit of mammalian (rat) AMPK was first cloned and sequenced in 
1994 (Carling et al., 1994). The amino acid sequence was used to identify the AMPK 
orthologue in yeast, Sucrose non- fermenting (Snf1) protein. The mammalian AMPK α 
subunit has a 59% sequence identity to Snf1.  A Snf1 preparation purified from yeast 
efficiently phosphorylated the SAMS peptide, a rather specific peptide substrate for 
AMPK (Woods et al., 1994). A second, more abundant isoform of the mammalian 
catalytic subunit termed α1 was then identified, with the isoform originally  identified 
by Carling et al being  termed α2 (Stapleton et al., 1996). Despite being encoded by 
different genes, namely PRKAA1 and PRKAA2, α1 and α2 share 90% sequence 
identity in the catalytic domain and ≈60% sequence identity outside the catalytic 
domain (Stapleton et al., 1996). Both isoforms contain a threonine residue at position 
172, which was shown to be the site at which AMPK is phosphorylated by the upstream 
kinase, AMPKK (Hawley et al., 1996). Both isoforms had similar substrate specificity 
(Michell et al., 1996). Also, α1 was found to be evenly distributed in most tissues, while 
α2 was found to be mainly present in skeletal muscle, liver, heart, brain and kidneys 
(Stapleton et al., 1996). The α2, but not the α1 isoform was also enriched in the nucleus, 
suggesting a role in the regulation of gene expression (Salt et al., 1998).  
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The C-terminus of the α subunit (residues 392-548) is required for its interaction 
with the β subunit. Truncation of α1 at residues 312 or 392 abolished the interaction 
between the α subunit and the β and γ subunits (Crute et al., 1998). α1 (1-392) had 
greatly reduced AMPK activity compared to the full length α subunit when co-
expressed with β and γ subunits. When expressed as a single subunit, α1(1-312) had 30- 
fold increased activity compared to α1(1-392) indicating the presence of an auto-
inhibitory domain between residues 312 and 392 (Crute et al., 1998). This auto-
inhibitory domain was subsequently mapped to residues 313-335 in α1, which 
corresponds to residues 311-333 in α2. Deletion of residues 313-335 from α1 (1-394) 
and residues 311-313 from α2 (1-398) was sufficient to restore kinase activity (Pang et 
al., 2007). Analysis of the crystal structure of the unphosphorylated fragment of the α 
subunit containing the kinase domain and the auto-inhibitory domain (KD-AID) from S. 
pombe, revealed multiple interaction sites between the N and C lobes of the kinase 
domain and the auto-inhibitory domain. The authors propose that this binding of the 
AID may constrain the mobility of the kinase domain helix αC, causing it to remain in 
an open, inactive conformation (Chen et al., 2009).  
The C-terminal tail of the α subunit has recently been shown to contain a nuclear 
export sequence (Kazgan et al., 2010). Deletion of the last 14 amino acids in the C-
terminal tail led to nuclear sequestration of the α subunit. Moreover, cytoplasmic 
localisation of AMPK could be restored by other known nuclear export sequences when 
fused to the truncated AMPK-α subunit missing the last 14 residues (Kazgan et al., 
2010). 
 
  
8 
 
 
 
1.3.3 The β subunit 
 
The β subunit has 2 isoforms termed β1 and β2, encoded by the distinct genes PRKAB1 
and PRKAB2 (Hardie, 2007b). The two isoforms share 71% amino acid sequence 
identity. The original β subunit, now termed β1, was purified as a 38 KDa protein from 
rat liver with DNA encoding the β2 isoform being subsequently cloned from a skeletal 
muscle cDNA library (Thornton et al., 1998). The β subunit is related to the Sip1/Sip2/ 
Gal83p family of proteins found in the budding yeast (Woods et al., 1996b, Gao et al., 
1995). The β subunit was shown to interact with both the α and γ subunits, thus 
functioning as a scaffold. Co-expression of α and β or β and γ subunits in rabbit 
reticulocytes and subsequent immunoprecipitation of the cell lysates using anti-β 
antibody revealed  the presence of α or γ subunits in the precipitate, thus suggesting that 
AMPK assembles into a heterotrimeric complex with the β subunit at the core (Woods 
et al., 1996b). A conserved region within the C-terminus of the AMPK β subunit 
(residues 180-276) is 90% identical between β1 and β2. This region is homologous to 
the ASC domain in the Sip1/Sip2/Gal83 complex, and has been shown to be required 
for the binding of α and γ subunits and the formation of the active AMPK heterotrimeric 
complex (Iseli et al., 2005, Xiao et al., 2007).  
The β subunit also contains another highly conserved domain, originally called 
the Kinase Interacting Sequence (KIS) domain, which is conserved in Gal83 and is now 
known to mediate the interaction of AMPK with glycogen (Hudson et al., 2003, 
Polekhina et al., 2003). Co-expression of the full-length β subunit with α and γ subunits 
caused accumulation of AMPK in large cytoplasmic inclusions, which also stained 
positive for glycogen and glycogen synthase. These inclusions were lost when the 
truncated β subunit lacking this domain was expressed with α and γ subunits, although 
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the kinase activity was unaffected (Hudson et al., 2003). This domain is now termed the 
glycogen-binding domain (GBD) or carbohydrate-binding module (CBM), and it is 
related to CBMs found in glycogen-binding proteins in animals and bacteria, and starch 
binding proteins in plants. The crystal structure of the CBM of β1 has been determined 
in complex with β-cyclodextrin and is similar to those of several starch-binding 
enzymes (Polekhina et al., 2005). A high level of glycogen in muscle negatively 
regulates AMPK activation in response to exercise and AICA riboside, while glycogen 
and oligosaccharides have been found to inhibit purified AMPK (Wojtaszewski et al., 
2002, Mcbride et al., 2009). This has led to proposals that AMPK can act as a cellular 
glycogen sensor.  
Using mass spectrometry, several phosphorylation sites have been mapped on 
the β subunit, including Ser-24/25, Ser-108 and Ser-182 (Mitchelhill et al., 1997). 
Mutation of the Ser-24/25 and Ser-182 sites to alanine  had  no effect on the regulation 
of kinase activity, but caused a redistribution of the subunit to the nucleus (Warden et 
al., 2001). Mutation of Ser-108 to alanine reduced the activity of the kinase by 60%.  
The Ser-108 residue is also required for activation of AMPK by the drugs A-769662 
and salicylate (Scott et al., 2008, Hawley et al., 2012). The N-terminus of the β subunits 
also have glycine residues at position 2, which  undergo myristoylation (Mitchelhill et 
al., 1997). Mutation of this glycine to alanine (G2A) leads to a four-fold increase in 
AMPK activity (Warden et al., 2001), similar to the effect observed by N-terminal 
truncation of the β subunit (Hudson et al., 2003). Myristoylation is known to target 
proteins to cell membranes, and the G2A mutation also alters subcellular localisation of 
AMPK from a particulate extra-nuclear distribution to a more homogenous cell 
distribution (Warden et al., 2001). It has also been recently shown that myristoylation of 
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the β subunit is required for stimulation of phosphorylation of Thr-172 on AMPK by 
AMP and ADP (Oakhill et al., 2010, Oakhill et al., 2011). 
 
1.3.4 The γ subunit 
 
The γ subunit has three isoforms, i.e. γ1, γ2 and γ3, encoded by three distinct genes 
PRKAG1, PRKAG2 AND PRKAG3 (Woods et al., 1996a, Cheung et al., 2000). The γ1 
and γ2 isoforms are expressed ubiquitously, while γ3 is mainly expressed in skeletal 
muscle. The γ2 and γ3 isoforms have extended N-terminal regions that do not share 
sequence identity to one another (Cheung et al., 2000); the exact role of these extended 
regions is not fully understood. Shorter variants of γ2 and γ3, probably due to alternate 
transcriptional start sites, have also been identified. The C-terminal region of all three γ 
isoforms show significant sequence identity. Photoaffinity labelling of partially purified 
AMPK using the AMP analogue, 8-azido [
32P] AMP, resulted in labelling of the γ1 
subunit, which was abolished in the presence of AMP (Cheung et al., 2000). This was 
the first evidence that the γ subunit was involved in AMP binding.   
The C-terminal region of the γ subunit contain four tandem repeats of a 60 
amino acid sequence motif known as a cystathione β synthase (CBS) motif  (Bateman, 
1997). These motifs associate in pairs to form two Bateman domains, each of which 
binds one molecule of AMP (Scott et al., 2004). The two Bateman domains appear to 
bind AMP with positive cooperativity, with the second site binding AMP with higher 
affinity after the first site has bound AMP (Scott et al., 2004). The crystal structure of 
AMPK confirmed the presence of these two sites (site 1, in the cleft between CBS1 and 
CBS2 and site 3, in the cleft between CBS3 and CBS4) that bind AMP or ATP, but also 
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identified a third site that has a tightly bound, non-exchangeable molecule of AMP 
located in site 4 between CBS3 and CBS4 (each nucleotide contacts residues from 
different CBS motifs, but the sites are numbered according to the CBS motif that bears 
an aspartate residue containing the 2’- and 3’- hydroxyls of the ribose rings; CBS 2 
lacks this aspartate, so there is no site 2). The two exchangeable sites, sites1 and 3, have 
been recently shown to bind ADP as well as ATP and AMP (Xiao et al., 2011). As ATP 
is more abundant than ADP or AMP in unstressed cells, under basal conditions, these 
sites are most likely occupied by ATP and the complex is inactive (Xiao et al., 2007). 
Binding of AMP (Davies et al., 1995) or ADP at the lower affinity site (site 3) has been 
shown to protect AMPK against dephosphorylation by protein phosphatases (Xiao et al., 
2011). Because ADP is usually present at higher concentrations than AMP, a rise in 
ADP may be the critical signal that induces that effect. However, binding of AMP (but 
not ADP) at the higher affinity site, site 1, causes a further allosteric activation (see 
below). 
 Mutations with dominant inheritance within the CBS motifs of the γ2 subunit 
that affect AMP binding have been shown to cause hypertrophic cardiomyopathy and 
Wolff-Parkinson White syndrome (Gollob et al., 2001). These mutations (e.g. R302Q, 
H383R and R531G) are associated with reduced AMPK activation by AMP (Daniel and 
Carling, 2002) and reduced binding of AMP to the γ subunit (Scott et al., 2004) . The 
R531G mutation also increases the basal activity of the kinase, most likely because it 
affects binding of the inhibitor, ATP, as well as the activator, AMP (Daniel and Carling, 
2002, Hawley et al., 2010). This increase in basal activity was particularly evident with 
two mutations, R531Q (Burwinkel et al., 2005) and R384T (Akman et al., 2007) that 
cause severe hypertrophic cardiomyopathy and death within weeks or months of birth. 
These were new mutations that were not inherited from parents (Akman et al., 2007). 
12 
 
 
 
Because the R531G mutation causes insensitivity to changes in adenine nucleotide 
concentration, cells expressing this variant have been used to identify the mechanism of 
action of various agents that activate AMPK (Hawley et al., 2010). The region 
immediately N-terminal to the CBS motifs of the γ subunit contains a conserved 
sequence of residues required for its binding with the β subunit (Viana et al., 2007), a 
finding confirmed following crystallisation of a partial heterotrimeric AMPK complex 
(Xiao et al., 2007). 
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Figure 1.3: AMPK subunit isoforms and splice variants 
Schematic diagram adapted from (Towler and Hardie, 2007) showing the AMPK subunit 
isoforms and splice variants of the γ subunit isoforms.                                                      
 AID- Auto inhibitory domain, CBM- Carbohydrate binding module, CBS- Cystathione-β-
synthase 
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1.3.5 Phosphorylation by upstream kinases 
 
1.4.5.1 Identification of LKB1 as the main AMPKK 
AMPK was shown to be phosphorylated on Thr-172 within the activation loop 
of the α subunit by an upstream kinase, termed AMPKK, whose identity was at that 
time unknown (Hawley et al., 1996). Its identity remained elusive for some time, 
despite the efforts of several research groups. However, in budding yeast, the AMPK 
orthologue Snf1 was eventually shown to be activated by phosphorylation on Thr-210, 
the site equivalent to Thr-172 site in rat AMPK by three kinases (Elm1, Pak1p and 
Tos3), which acted in a partially redundant manner (Sutherland et al., 2003, Hong et al., 
2003). Deletion of all three kinases abolishes Snf1 activity and causes the same 
phenotype as deletion of SNF1 gene in budding yeast. Yeast showing the snf1 
phenotype fail to grow on fermentable carbon sources other than glucose (e.g. sucrose 
or raffinose), as well as non-fermentable carbon sources like glycerol. The kinases 
within the human kinome with closest sequence similarity to these three kinases were 
calmodulin-dependent kinase kinases-α and -β, and LKB1 (Hawley et al., 2003, Hong et 
al., 2003). Three groups independently identified that LKB1 was the major upstream 
kinase that phosphorylated the recombinant α subunit of  AMPK in cell free assays as 
well as endogenous AMPK in cells (Woods et al., 2003, Hawley et al., 2003, Shaw et 
al., 2004b). The ability of LKB1 to phosphorylate AMPK was greatly increased when 
co-expressed with its accessory proteins STRAD and MO25 (Hawley et al., 2003). Cell-
free assays demonstrated that the LKB1: STRAD:MO25 complex activated AMPK 
about a hundred fold. LKB1-deficient cells, such as the HeLa tumour cell line had very 
low basal AMPK activity, which was increased by expression of recombinant LKB1 
(Hawley et al., 2003). In addition,  LKB1-null mouse embryonic fibroblasts had low 
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basal AMPK activity and were not activated by treatment with AICAR or phenformin, 
unless LKB1 was re-expressed (Hawley et al., 2003).  
These results showed that LKB1 was both necessary and sufficient for AMPK 
activation in response to energy stress. However, since multiple kinases acted upstream 
of the SNF1 complex in budding yeast, it seemed likely that AMPK was also likely to 
be activated by more than one kinase. This was supported by the finding that in mouse 
heart, under conditions of mild myocardial ischaemia, an AMPKK other than LKB1 
was responsible for increase in AMPK activity in heart muscle (Altarejos et al., 2005).  
 
1.4.5.2 CaMKK-β is the alternate upstream kinase for AMPK 
Calmodulin-dependent kinase kinase (CaMKK)  purified from pig brain had 
previously been shown to activate AMPK in cell-free assays (Hawley et al., 1995), 
although the major AMPKK purified from rat liver ( which was later identified to be 
LKB1) did not appear to be calmodulin-dependent and was therefore not thought to be a 
CaMKK. However, several LKB1-deficient cell lines including HeLa cells, had a 
detectable level of Thr-172 phosphorylation and activity of AMPK, and exhibited 
increased Thr-172 phosphorylation and AMPK activation in response to calcium 
ionophores. These findings suggested that an alternative, calcium-dependent AMPKK 
was involved. CaMKKβ was identified as the major alternative upstream kinase for 
AMPK in cells, although CaMKKα does activate AMPK in cell-free assays (Hawley et 
al., 2005, Hurley et al., 2005, Woods et al., 2005). These studies showed that AMPK 
was activated by treatment with the calcium ionophore A23187 or ionomycin, and that 
overexpression of CaMKKβ increased AMPK activity in HeLa cells. The CaMKK 
inhibitor STO-609 abolished calcium ionophore-mediated AMPK activity. Knockdown 
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of endogenous CaMKKβ using RNA interference also significantly reduced calcium 
ionophore-mediated AMPK activation (Hawley et al., 2005, Hurley et al., 2005, Woods 
et al., 2005). Therefore, it was proposed that CaMKKβ activated AMPK in response to 
increased Ca
2+
 levels, while LKB1 is normally required for activation of AMPK 
following an increase in the AMP:ATP ratio (Hawley et al., 2005). However, as 
CaMKK is not widely distributed in tissues and not abundant in the heart, it is unlikely 
to be the kinase that Altarejos and colleagues described. 
Transforming growth factor-β- activated kinase (TAK1) has been proposed as a 
third upstream kinase that activates AMPK. Expression of mammalian TAK1 in yeast 
lacking all the three SNF1 kinases (ΔElm1ΔPak1ΔTos3) rescues the snf1 phenotype. 
TAK1 has been shown to activate the SNF1 complex and phosphorylate SAMS peptide 
in cell-free assays (Momcilovic et al., 2006). Expression of dominant negative TAK1 in 
cardiac myocytes was associated with inhibition of Thr-172 phosphorylation and 
AMPK activity (Xie et al., 2006). TAK1 was also shown to be activated by agents such 
as oligomycin, AICAR and metformin that are known to activate AMPK (Xie et al., 
2006). Also, treatment of breast epithelial cells with tumour necrosis factor- related 
apoptosis-inducing ligand (TRAIL) activates AMPK and induces autophagy in these 
cells, in an AMPK-dependent manner. This AMPK activation was attenuated when 
TAK1 levels were reduced by siRNA- mediated silencing (Herrero-Martin et al., 2009). 
However, clear evidence of AMPK activation by endogenous TAK1 in intact cells is 
lacking. 
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1.3.6 Regulation by nucleotides: AMP, ADP and ATP 
 
AMPK is activated by an increase in the AMP:ATP or  ADP:ATP ratios due to 
increases in ATP consumption caused by processes such as exercise or cell growth, or 
caused by treatments that decrease ATP production, such as hypoxia or glucose 
deprivation (Hardie, 2007a). ATP is converted to ADP (or in a few synthetase reactions, 
to AMP plus pyrophosphate) by energy-requiring reactions that are driven by ATP 
hydrolysis. When ADP is produced, the enzyme adenylate kinase then converts two 
molecules of ADP into one ATP and one AMP molecule, a reaction that is maintained 
close to equilibrium in eukaryotic cells and is thought to be the major source of cellular 
AMP. Because of the adenylate kinase reaction, the cellular AMP: ATP ratio varies 
approximately as the square of the ADP:ATP ratio (Hardie and Hawley, 2001). In 
unstressed cells, the concentration of ATP is thought to be 10-fold higher than ADP, 
and 100-fold higher than AMP. However, studies have shown that the lower affinity site 
on the γ1 subunit (site 3) binds Mg-ATP with 5-10 fold lower affinity than free ATP, 
ADP or AMP (Xiao et al., 2011). Since free ATP is present at a 20-fold lower 
concentration  than Mg-ATP in cells, ADP (which does not bind Mg
2+
), would be able 
to compete with ATP for binding at site 3 even during mild stress, while AMP may be 
able to compete with ATP and ADP at site 1 when its concentration rises during a more 
severe stress (Xiao et al., 2011) .  
AMP allosterically activates AMPK as confirmed by several studies (Ferrer et 
al., 1985, Carling et al., 1989). ATP antagonizes this action of AMP but does not inhibit 
the kinase on its own (Hardie et al., 2011). When AMP binds to the high affinity site on 
the γ subunit (site 1), it can increases the activity of AMPK via the allosteric effect by as 
much as 10-fold (Hardie et al., 2011). AMP also increases the net phosphorylation of 
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AMPK by upstream kinases. By phosphorylating Thr-172, upstream kinases can 
increase the AMPK activity by >100-fold, which is then enhanced a further 10-fold by 
AMP resulting in a maximum of >1000-fold increase in AMPK kinase activity overall 
(Carling et al., 1987, Carling et al., 1989, Suter et al., 2006, Hawley et al., 1996). 
Mutations in the γ subunit that decrease its ability to bind AMP have shown to reduce 
the allosteric activation of AMPK (Scott et al., 2004, Sanders et al., 2007). Recently it 
has been shown that ADP can also bind to site 1 and 3 on the γ subunit and this causes a 
conformational change that promotes Thr-172 phosphorylation, although ADP does not 
allosterically activate AMPK (Oakhill et al., 2011). The effects of ADP and AMP to 
promote phosphorylation require N-terminal myristoylation of the β subunit (Oakhill et 
al., 2011). 
AMP also protects the kinase from dephosphorylation by protein phosphatases 
(Davies et al., 1995, Suter et al., 2006). When the AMP-binding sites of the γ subunit 
were mutated in bacterially expressed heterotrimers, the complex showed a reduction in 
the protection against dephosphorylation of Thr-172 by protein phosphatase 2Cα in cell-
free assays (Sanders et al., 2007). The same mutations also prevented allosteric 
activation of the kinase by AMP. These results suggest that AMP promotes allosteric 
activation and inhibits dephosphorylation by binding to the same sites on the γ subunit. 
This effect has been shown to be independent of the upstream kinase. In cells lacking 
LKB1, increasing AMP levels using phenformin did not affect AMPK activity on its 
own, but it further increased AMPK activation caused by treatment with a calcium 
ionophore (Fogarty et al., 2010).  
Recent studies of a partial heterotrimeric complex which included the kinase 
domain has confirmed that ADP can also inhibit dephosphorylation of AMPK (Xiao et 
al., 2011). This study provided new insights into the conformational change in the 
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structure of the heterotrimer whereby, binding of AMP or ADP binding to site 3 is 
proposed to stabilize the close association of the activation loop containing Thr-172 
with the C-terminal domains of the α and β subunit. This is thought to shield Thr-172 
from the protein phosphatase so that the latter is less able to de-phosphorylate the 
residue (Xiao et al., 2011).  
Previous reports suggested that AMP had an additional third regulatory effect. 
AMP binding was thought to make AMPK a better substrate for phosphorylation by 
upstream kinases (Hawley et al., 1995). However, it was subsequently proposed that 
this may have been an artefact caused by the fact that the kinase preparations might 
have been contaminated by PP2C (Sanders et al., 2007). AMP did not stimulate the 
phosphorylation of AMPK by either LKB1 or CaMKKβ using bacterially expressed 
AMPK heterotrimers (Sanders et al., 2007, Suter et al., 2006). However, it was later 
shown that AMP did promote phosphorylation of Thr-172 as long as the β subunits 
were myristoylated, a modification that does not occur in bacteria, unless a mammalian 
N-myristoyl transferase is co-expressed (Oakhill et al., 2010). 
To summarise this section, the current model suggests that AMP and ADP 
increase Thr-172 phosphorylation both by promoting phosphorylation and by inhibiting 
dephosphorylation, both effects being antagonized by ATP. AMP also allosterically 
activates AMPK, an effect that is antagonized by ATP and ADP.  
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Figure 1.4: Regulation of AMPK by reversible phosphorylation and 
adenine nucleotides 
AMPK is activated ≥100-fold by phosphorylation by upstream kinase in cell-free assays. 
CaMKKβ is the alternative upstream kinase which activates AMPK following a rise in cytosolic 
Ca2+.  TAK1 has been proposed as the third upstream kinase, although its ability to 
phosphorylate AMPK in vivo has not been fully established. Adenine nucleotides regulate the 
kinase in three ways: 
1) allosteric activation: AMP activates the kinase allosterically, causing a 10-fold increase 
in activity. ADP and ATP inhibit AMP-mediated allosteric activation of AMPK; 
2) both AMP and ADP cause a conformational change that promotes Thr-172 by 
upstream kinases- this effect, which is opposed by ATP, is dependent on N- terminal 
myristoylation of the β subunit; 
3) preventing dephosphorylation: AMP and ADP binding to site 3 causes a conformational 
change in the kinase, protecting it from dephosphorylation by protein phosphatases 
(PP). ATP antagonises this effect of AMP and ADP. 
 
Adapted from (Hardie, 2011a) 
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1.3.7. Activators of AMPK 
  
In general, AMPK is activated by metabolic stress. AMPK activation was initially 
reported during severe pathological metabolic stress such as hypoxia (Marsin et al., 
2000) or following addition of mitochondrial inhibitors such as arsenite (Corton et al., 
1994). AMPK is activated in cultured cells by glucose deprivation, although total 
removal of glucose would not be a normal event in vivo. AMPK may however be 
regulated by glucose in specialised tissues such as pancreatic beta cells and 
hypothalamic neurons, where, due to the expression of high Km isoforms of glucose 
transporter (GLUT2) and/or hexokinase (HKIV or glucokinase), the rate of glucose 
metabolism (and hence ATP production) is affected by physiological variations in blood 
glucose (Salt et al., 1998, Sun et al., 2010, Mccrimmon et al., 2008). Type I cells of the 
carotid body also sense physiological variations in blood oxygen levels, and trigger 
appropriate alterations in breathing, due to activation of AMPK and AMPK-mediated 
phosphorylation and inhibition of voltage gated BKCa  potassium channels (Ross et al., 
2011). AMPK is also activated by muscle contraction during exercise (Winder and 
Hardie, 1996, Wojtaszewski et al., 2000), most likely due to increase in ATP 
consumption. In exercise involving rapid, powerful contractions (e.g. sprinting or 
weightlifting), glycogen is the major fuel and AMPK may not be important. Activation 
of AMPK in response to muscle contraction becomes more relevant during prolonged 
endurance exercise, where AMPK mediates increased uptake of glucose from the 
bloodstream, as well as adaptive responses to regular endurance training. Mice that have 
had LKB1 conditionally deleted in skeletal muscle, have lower basal AMPK α2 activity 
in skeletal muscle that is not increased by phenformin, AICAR or muscle contraction 
(Sakamoto et al., 2005). These mice also showed greatly reduced glucose uptake in 
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response to muscle contraction or AICAR treatment (Sakamoto et al., 2005). AMPK 
activation may account for several other beneficial effects of exercise such as increased 
fatty acid oxidation (Merrill et al., 1997, Aschenbach et al., 2004) and increased 
mitochondrial biogenesis (Zong et al., 2002). 
 In addition to regulating cellular energy, AMPK is also activated by cytokines 
and hormones that regulate energy status at the whole body level (Hardie, 2011b). 
Leptin, which is released from adipocytes to signal the presence of adequate fat stores, 
activates AMPK in skeletal muscle leading to fatty acid oxidation (Minokoshi et al., 
2002). The hormone adiponectin, which is released from adipocytes with low fat stores, 
has also been shown to activate AMPK in liver and skeletal muscle, inhibiting 
gluconeogenesis in the liver and stimulating fatty acid oxidation in both organs 
(Yamauchi et al., 2002). In contrast to its effects in muscle, leptin acting on neurons in 
the hypothalamus inhibits AMPK, possibly by binding to leptin receptors on pro-
opiomelanocortin-expressing neurons that inhibit food intake, triggering release of 
opioids onto other neurons where AMPK is inhibited (Hardie, 2011b). Fasting is known 
to increase AMPK activity in the hypothalamus, while refeeding suppresses it 
(Minokoshi et al., 2004), suggesting a role for AMPK in the regulation of food intake 
and appetite (Kahn et al., 2005). Treatments that increase food intake such as ghrelin, 
cannabinoids and  hypoglycaemia all activate AMPK in the hypothalamus, possibly by 
acting on presynaptic neurons upstream of agouti- related protein (AGRP) -expressing 
neurons that promote food intake (Hardie, 2011b).  
 A number of drugs and xenobiotics also activate AMPK. The first agent 
identified to activate AMPK was AICAR, which is taken up into cells and converted to 
5-aminoimidazole-4-carboxamide ribonucleoside monophosphate (ZMP), an AMP 
analogue that mimics both activating effects of AMP on AMPK (Corton et al., 1995). 
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The widely used antidiabetic drug metformin, which is prescribed to over 100 million 
people worldwide, also activates AMPK. Activation of hepatic AMPK was shown to be 
required for the anti-hyperglycaemic effects of metformin (Zhou et al., 2001, Shaw et 
al., 2005), although it appears not to be required for the acute effects of metformin on 
gluconeogenesis (Foretz et al., 2010). Another class of anti-diabetic drugs, the 
thiazolidinediones, have also been shown to activate AMPK (Fryer et al., 2002). Several 
xenobiotics or nutraceuticals derived from plants, such as resveratrol in red wine, 
epigallocatechin 3-gallate from green tea, berberine used in Chinese medicine and 
quercetin activate AMPK by diverse mechanisms (Hardie, 2011b). Many of these 
agents including  metformin, thiazolidinediones, oligomycin, resveratrol and berberine 
inhibit mitochondrial respiration and increase cellular AMP:ATP and ADP:ATP ratios, 
thus activating cells expressing wild type AMPK but not cells expressing the 
AMP/ADP-insensitive R531G mutant γ subunit (Hawley et al., 2010). Agents such as 
hydrogen peroxide also appear to activate AMPK indirectly by damaging the respiratory 
chain  (Hawley et al., 2010). Agents such as A23187 and ionomycin increase 
intracellular calcium and thus activate AMPK by activating the alternative upstream 
kinase CaMKKβ, whereas A-769662 and salicylate directly bind to AMPK, causing 
both allosteric activation and inhibition of Thr-172 dephosphorylation. These agents 
thus activate the R531G mutant as well as wild type AMPK (Hawley et al., 2010, 
Hawley et al., 2012).  
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1.3.8 Processes regulated by AMPK 
 
AMPK activation switches on catabolic ATP-generating pathways while switching off 
ATP-consuming anabolic pathways (Hardie, 2007a). The optimum AMPK substrate 
motif is Ф (X,β)XXS/TXXX Ф where Ф is a hydrophobic residue (M, L, I, V or F) and 
β is a basic residue (R, K or H) (Weekes et al., 1993, Dale et al., 1995). Additional 
determinants upstream of this motif that promote binding but are not essential have also 
been studied (Scott et al., 2002). AMPK regulates several important cellular processes 
by phosphorylation-mediated activation or inhibition of numerous downstream targets. 
Some of these processes and the AMPK target substrates that regulate them are 
discussed in the next section. 
 
1.3.8.1 Lipid metabolism 
 Acetyl-CoA carboxylase was the first AMPK substrate to be identified (Carlson 
and Kim, 1973). ACC catalyses the conversion of acetyl-CoA to malonyl-CoA, which is 
the first step committed to fatty acid synthesis. AMPK phosphorylates ACC on Ser-79, 
thus inhibiting the enzyme and consequently inhibiting fatty acid synthesis (Davies et 
al., 1992). ACC2, another  isoform of acetyl-CoA carboxylase mainly expressed in 
muscle cells, is also phosphorylated and inhibited  by AMPK (Winder et al., 1997). 
Unlike ACC1, ACC2 is associated with mitochondria and it is believed to increase 
levels of malonyl-CoA at the mitochondrial surface. Malonyl-CoA inhibits carnitine 
palmitoyl transferase-1 (CPT-1), an enzyme required for fatty acid uptake across the 
inner mitochondrial membrane and subsequent oxidation in mitochondria (Abu-Elheiga 
et al., 2000). AMPK activation inhibits ACC2, reducing malonyl-CoA levels and thus 
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increasing CPT-1-mediated fatty acid oxidation (Merrill et al., 1997). Consistent with 
the above findings, mice lacking ACC2 have been shown to have a greatly increased 
rate of fatty acid oxidation (Abu-Elheiga et al., 2001). AMPK also phosphorylates and 
inhibits HMG-CoA reductase, which is a key enzyme in cholesterol synthesis, thereby 
inhibiting this process (Beg et al., 1973, Towler and Hardie, 2007, Carling et al., 1987). 
AMPK also negatively regulates hormone-sensitive lipase and thus inhibits hydrolysis 
of triglyceride in adipocytes and in muscle (Smith et al., 2005, Corton et al., 1995). 
 
1.3.8.2 Carbohydrate metabolism 
During exercise, skeletal muscle cells actively take up glucose, mainly through 
glucose transporter GLUT4. Translocation of GLUT4 to the cell membrane is the rate-
limiting step in this process (Steinberg and Kemp, 2009). Activation of AMPK, 
particularly α2 in muscle in response to contraction or AICAR treatment, increases 
glucose uptake by increasing translocation of the glucose transporter GLUT4 from 
intracellular GLUT4 vesicles to the cell membrane (Jørgensen et al., 2004). AMPK 
phosphorylates TBC1D1 on Ser-237, which enhances 14-3-3 binding; this causes 
dissociation of this protein (which contains a Rab-GAP domain) from GLUT4 vesicles, 
promoting exchange of GTP for GDP on Rab proteins that trigger fusion of the vesicles 
with the plasma membrane (Chen et al., 2008). AMPK has also been shown to 
phosphorylate and activate the PFKFB2 and PFKFB3 isoforms of 6-phosphofructo-2- 
kinase (PFK2). PFK2 regulates the formation and degradation of fructose 2,6 bis-
phosphate, which in turn activates the glycolytic enzyme PFK1, increasing glycolysis in 
heart muscle where PFKFB2 is expressed (Marsin et al., 2000), and in monocytes and 
macrophages where expression of PFKFB3 is induced by pro-inflammatory stimuli 
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(Marsin et al., 2002). Interestingly the latter isoform is also expressed in some tumour 
cells, and this mechanism may in part explain their high glycolytic rate. AMPK also 
regulates hepatic glucose production. Mice that lack LKB1 in the liver or are deficient 
in α2 exhibit fasting hyperglycaemia and increased hepatic glucose production (Shaw et 
al., 2005, Viollet et al., 2003). AMPK is also involved in glucose sensing in specialised 
cells in the pancreas and hypothalamus (Mccrimmon et al., 2008, Sun et al., 2010).  
 
1.3.8.3 Mitochondrial Biogenesis, Autophagy and Mitophagy 
A role for AMPK in mitochondrial biogenesis was suggested by reports that 
AICAR treatment in mice increased mitochondrial enzymes levels in skeletal muscle 
(Winder et al., 2000). Mice expressing wildtype AMPK also showed increased 
mitochondrial biogenesis in muscle on treatment with AICAR or β-guanidinopropionic 
acid (a creatine analogue that depletes cellular ATP and thus increases the AMP:ATP 
ratio) (Zong et al., 2002, Thomson et al., 2007). This effect was lost in mice that lacked 
α2 or expressed a dominant negative AMPK mutant (Thomson et al., 2007, Zong et al., 
2002). Expression of Nuclear Respiratory factor (NRF1), which is a key transcriptional 
factor controlling mitochondrial biogenesis is increased following AMPK activation 
(Bergeron et al., 2001). AMPK has also been reported to phosphorylate the “master 
regulator” of mitochondrial biogenesis, the transcriptional coactivator PGC-1α, which 
co-activates at genes with binding sites for NRF1 and other transcription factors.  
Deacetylation of PGC-1α is then proposed to cause activation of its own transcription 
(Jäger et al., 2007). AMPK also regulates the process of mitophagy, whereby 
dysfunctional mitochondria are engulfed by autophagic vacuoles which then fuse to 
lysosomes to be broken down and their contents recycled (Hardie, 2011a). Initiation of 
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autophagy involves activation of ULK1 and ULK2, proteins that are orthologues of 
Atg1 in yeast (Hardie, 2011a). AMPK has been shown to phosphorylate ULK1 at 
multiple sites (Egan et al., 2011, Kim et al., 2011). Hepatocytes lacking either AMPK or 
ULK1 show increased accumulation of mitochondria with aberrant morphology. Cells 
expressing mutant ULK1, where four serine residues phosphorylated by AMPK were 
mutated to non-phosphorylatable alanine residues, also showed functional impairment 
in the ability to maintain mitochondrial membrane potential (Egan et al., 2011).  
 
1.3.8.4 Regulation of transcription factors 
In addition to modulating the effects of target enzymes and proteins by direct 
phosphorylation, AMPK also affects the transcription of proteins that regulate the same 
cellular processes. Activation of AMPK by metformin suppresses expression of 
SREBP-1, a key lipogenic transcription factor (Zhou et al., 2001). AMPK has also been 
shown to directly phosphorylate SREBP-1c and SREBP-2 and AMPK activation has 
also been shown to decrease the nuclear accumulation of SREBP-1c and SREBP-2 (Li 
et al., 2011). AMPK represses transcription of mRNAs encoding enzymes regulating 
gluconeogenesis in part by phosphorylating CRTC2, a transcriptional co-activator of 
CREB (cyclic AMP response element binding protein), causing binding of 14-3-3 
proteins and its exclusion from the nucleus (Koo et al., 2005).  AMPK also 
phosphorylates Class II HDACs (a family of histone deacetylases comprising HDAC-4, 
-5 and -7). Treatment of cells with A-769662, a direct AMPK activator, increases 
phosphorylation of Class II HDACs and this causes their nuclear exclusion  (Mihaylova 
et al., 2011). When present in the nucleus, Class II HDACs acetylate and activate 
FOXO transcription factors. AMPK activation by AICAR has also been shown to 
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decrease the levels of Hepatocyte Nuclear Factor 4α (HNF-4α) , another transcription 
factor and decreases the expression of HNF-4α target genes (Leclerc et al., 2001). 
AMPK inhibits the transcriptional co-activator p300 by direct phosphorylation , 
preventing its interaction with transcriptional factors such as peroxisome proliferator-
activated receptor-γ (PPAR-γ), thyroid hormone receptor and retinoic acid receptor 
(Yang et al., 2001). 
 
1.3.8.5 Protein synthesis and cell growth 
Cell growth and protein synthesis are energy-consuming processes. The 
mammalian target-of-rapamycin (mTOR) controls cell growth and proliferation in 
response to growth factors and nutrients (Laplante and Sabatini, 2012). The Rheb-GAP 
(GTP-ase activating protein) heterodimer TSC1/TSC2 (Tuberous sclerosis protein 1 and 
2) is a negative upstream regulator of mTOR, converting Rheb into the inactive GDP 
bound form, thus disrupting its interaction with mTORC1 (Inoki et al., 2003). AMPK 
directly phosphorylates TSC2, increasing its GAP activity, thus inhibiting mTOR (Inoki 
et al., 2003). AMPK has also been shown to directly phosphorylate Raptor (Regulatory 
associated protein of TOR), causing 14-3-3 binding to Raptor and subsequent inhibition 
of mTORC1 (Gwinn et al., 2008).  
 
1.3.8.6 Regulation of membrane excitability 
AMPK has been shown to phosphorylate voltage gated potassium channels in 
neuronal cells. Activation of AMPK by A-769662 in HEK-293 cells expressing a 
voltage-gated potassium channel Kv2.1, has been shown to cause the channels to open 
at more negative membrane potential, thus sensitizing them to depolarization (Ikematsu 
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et al., 2011). AMPK phosphorylates Kv2.1 on two sites, Ser-440 and Ser-537, although 
mutation of Ser-440 to alanine was sufficient to abolish the effect on voltage gating 
(Ikematsu et al., 2011). Kv2.1 is a major delayed rectifier K
+
 channel in central neurons, 
where it regulates the frequency of firing of action potentials. As expected, activation of 
AMPK in cultured primary neurons from rat brain reduced the firing of action potentials 
(Ikematsu et al., 2011). Since firing of action potentials is a major energy-consuming 
process in the brain, AMPK would conserve energy by reducing their frequency. 
Interestingly, AMPK has an opposite, inhibitory effect, when it phosphorylates another 
voltage-gated K
+
 channel, BKCa, which is expressed in Type I cells in the carotid body 
(Ross et al., 2011). These cells are believed to be the primary oxygen-sensing cells that 
control breathing. It is proposed that AMPK is activated by hypoxia in the carotid 
arteries that supply the brain, causing phosphorylation and inactivation of BKCa 
channels. This triggers depolarization of Type I cells, causing release of 
neurotransmitter onto the carotid sinus nerve, that communicates with the brain to elicit 
corrective changes in breathing patterns (Ross et al., 2011). 
 
1.3.8.7 Regulation of the cell cycle 
Cell division, not unlike cell growth is also an energy consuming process and 
AMPK activation has been shown to cause a cell cycle arrest at the G1 phase of the cell 
cycle (Imamura et al., 2001). Treatment of HepG2 cells with AICAR caused G1 cell 
cycle arrest which was associated with phosphorylation of the p53 tumour suppressor 
on Ser-15. However, it is still not clear whether p53 is a direct AMPK substrate. AMPK 
has been shown to phosphorylate the cyclin- dependent kinase inhibitor p27, thereby 
increasing its stability and inhibiting cell cycle progression (Liang et al., 2007). 
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Phosphorylation of Raptor by AMPK causes a reduction in the percentage of cells 
progressing to G2/M (Gwinn et al., 2008). Activation of CaMKKβ by A23187 in G361 
cells (which lack LKB1) also causes a G1 cell cycle arrest (Fogarty S PhD thesis 2008).  
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 Figure 1.5: Processes regulated by AMPK  
This figure shows the effect of AMPK activation on its various downstream targets. Catabolic 
pathways shown above namely, glucose uptake via glucose transporter type 4 (GLUT4) and 
GLUT1 glycolysis, fatty acid oxidation, mitochondrial biogenesis and autophagy, are activated 
by AMPK. Anabolic pathways such as fatty acid synthesis, cholesterol, glycogen and protein 
synthesis, and transcription of lipogenic and gluconeogenic enzymes are inhibited by AMPK. 
Adapted from (Hardie et al., 2012) 
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1.4 AMPK and cancer 
 
The role of AMPK as a master regulator of cell metabolism is well established. Cell 
proliferation is an energy consuming process and is therefore likely to stress cells and 
thereby activate AMPK. The link between cellular metabolism and tumourigenesis has 
been known for decades (Warburg, 1956). However, in recent years, there has been a 
growing body of evidence linking the AMPK pathway to the regulation of cell growth 
and proliferation. This has led to interest in AMPK as a potential therapeutic target in 
cancer. The main reasons for this have been detailed in this section. 
 
1.4.1. LKB1 and Peutz Jeghers syndrome 
 
The discovery that LKB1, a tumour suppressor, was the main upstream kinase for 
AMPK (Hawley et al., 2003, Woods et al., 2003, Shaw et al., 2004b), was a major 
finding which prompted interest in the role of the AMPK in cancer. Loss of LKB1 
causes Peutz -Jeghers syndrome (PJS), a rare, autosomal dominant inherited cancer 
syndrome, characterised by the development of benign, hamartomatous polyps and 
marked pigmentation of mucous membranes (Alessi et al., 2006). Patients with PJS also 
have a markedly increased risk of cancer especially colon, stomach, small intestinal and 
pancreatic cancer (Hemminki, 1999). In addition to germ line mutations that cause PJS, 
somatic mutations of LKB1 have been reported in 30% of non-small cell lung cancers 
(Matsumoto et al., 2007, Sanchez-Cespedes et al., 2002) and around 20% of cervical 
tumours (Wingo et al., 2009). 144 different mutations in LKB1 have been identified in 
patients with PJS and from sporadic tumours, with a substantial proportion being 
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truncating mutations in the catalytic domain resulting in loss of function (Alessi et al., 
2006). PJS has similar clinical features to Cowden syndrome, another inherited 
syndrome which causes hamartomas and a predisposition to cancer, which is caused by 
inactivating mutations of the tumour suppressor, phosphatase and tensin homolog 
(PTEN). PTEN negatively regulates the PI3-kinase/Akt pathway. The overlap of 
clinical features between PJS and Cowden’s suggests a common downstream pathway 
which may be altered in both these syndromes.  The mTOR pathway which regulates 
cell growth and proliferation has been identified as the common downstream pathway 
regulated by activating signals from the PI3-kinase/Akt pathway in response to nutrients 
and growth factors, and  inhibitory signals from the LKB1-AMPK pathway, which 
responds to energy stress and down-regulates mTOR (Shackelford and Shaw, 2009). 
 LKB1 is a master upstream kinase, and in addition to AMPK-α1 and 
AMPK-α2,  LKB1 is known to phosphorylate 12 other protein kinases (BRSK1, 
BRSK2, NUAK1, NUAK2, QIK, QSK, SIK, MARK1, MARK2, MARK3, MARK4, 
and SNRK) that are located next to AMPK in the human kineome dendrogram and 
share significant sequence homology with AMPK (Alessi et al., 2006). However, 
evidence suggests that some of the tumour suppressor effects of LKB1 may be mediated 
through AMPK. LKB1-deficient mouse embryonic fibroblasts and HeLa cells (which 
lack LKB1) show activation of mammalian target of rapamycin complex 1 (mTORC1), 
without increase in PI3-kinase signalling (Corradetti et al., 2004, Shaw et al., 2004a). 
Treatment of wild type MEFs with AICAR, which activates AMPK, reduced mTOR 
signalling whereas, this reduction in mTOR signalling was not observed in LKB1- 
deficient MEFs (Shaw et al., 2004a). Also, lung cancer cells deficient in LKB1 fail to 
inactivate mTOR when deprived of glucose, whereas cell lines containing LKB1 show 
reduction in mTOR activity which is also associated with increased levels of pACC, 
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suggesting that activation of AMPK is associated with inhibition of mTOR activity 
(Carretero et al., 2006). This suggests that AMPK, acting downstream of LKB1, 
modulates targets downstream of the PI3-kinase/Akt pathway, under conditions of 
energy stress. 
 
1.4.2 AMPK negatively regulates the mTOR pathway 
 
AMPK has been shown to negatively regulate the mTOR pathway by two ways. Firstly, 
AMPK phosphorylates TSC2 (Inoki et al., 2003), a Rheb GTPase activating protein 
(GAP). Rheb increases phosphorylation of mTOR on Ser-2448 and activates the 
mTORC1 complex. Phosphorylation of TSC2 inhibits its GAP activity towards Rheb, 
thereby inhibiting mTORC1. Secondly, AMPK directly phosphorylates Raptor, one of 
the binding partners of mTOR, on two residues Ser-722 and Ser-792, leading to 14-3-3 
binding and subsequent suppression of mTORC1 (Gwinn et al., 2008).Phosphorylation 
of these two residues is required for suppression of mTOR, as cells stably expressing 
the non-phosphorylatable mutant Raptor, where both phosphorylation sites were 
mutated to alanine, failed to suppress mTOR signalling when treated with AICAR, 
while cells stably expressing wildtype Raptor down-regulated mTOR signalling in 
response to AICAR treatment (Gwinn et al., 2008). 
 
1.4.3 Evidence for the role of AMPK in cancer  
 
There is strong epidemiological data showing that diabetics on metformin have a 30% 
reduced overall risk of cancer compared to diabetics on other treatments such as insulin 
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or sulphonylureas (Evans, 2005, Bowker et al., 2006b). Also, in mouse tumour models, 
metformin and phenformin have been shown to delay the onset of tumours in mice that 
are heterozygous for PTEN and LKB1 (Huang et al., 2008). This effect of delaying 
tumour onset was also observed in mice treated with A-769662, a direct activator of 
AMPK, suggesting that AMPK activation mediated the tumour suppressive action of 
metformin and phenformin. Moreover, murine ES cells lacking LKB1 not only failed to 
activate AMPK in response to treatment with AICAR, phenformin or metformin, but 
they also did not supress mTOR signalling, further supporting the view that AMPK was 
acting to suppress mTOR signalling and delay tumours in this model (Huang et al., 
2008). 
 
1.4.4 Tumour cells down- regulate AMPK 
 
There is a growing body of evidence that tumour cells down-regulate AMPK. 
Melanoma cells expressing the B-RAF-V600E mutation have been shown to down-
regulate AMPK. The authors propose that the c-terminal tail of LKB1 is phosphorylated 
on Ser-325 and Ser-428 (equivalent to Ser-431 on murine LKB1)  by ERK and p90RSK 
respectively, which are downstream of the constitutively active B-RAF (Zheng et al., 
2009). LKB1 when phosphorylated on these two residues fails to activate AMPK 
(Zheng et al., 2009). Inhibition of the MEK- ERK pathway using the MEK inhibitor 
U0126 reduced phosphorylation of Ser-428 and restored AICAR induced activation of 
AMPK in a melanoma cell lines carrying the oncogenic B-RAF mutation (Esteve-Puig 
et al., 2009). Also, immunostaining for phospho-AMPK in breast tissues taken from 
patients with breast cancer showed that tumour cells demonstrated less staining for 
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phospho-AMPK when compared to normal breast tissue contained in the same tissue 
block from individual patients (Hadad et al., 2009). 
Taken together, the evidence suggests that AMPK activation in response to 
energy stress, downstream of LKB1, leads to suppression of the mTOR pathway, 
antagonising the PI3-kinase/Akt pathway (Figure 1.6). Dysregulation of the LKB1- 
AMPK axis is observed in different tumours and AMPK activators may be useful in 
cancer prevention. 
 
1.5 Experimental aims and objectives 
 
The main aim of this thesis was to investigate the role of AMPK in cancer and in the 
DNA damage response. A mouse tumour model was utilised to examine the role of 
AMPK as a tumour suppressor. This thesis also explores mechanisms underlying 
AMPK activation in response to genotoxic stress caused by anti-cancer drugs, such as 
etoposide. Finally, the regulatory role of C-terminal phosphorylation of LKB1 on Ser-
325 and Ser-431 on AMPK activation was examined. 
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Figure 1.6: The AMPK signalling pathway in cancer 
AMPK antagonises the PI3-kinase /Akt pathway and inhibits mTOR in 2 ways: 
1) Firstly, AMPK phosphorylates TSC2 (Inoki et al., 2003), a Rheb GTPase activating 
protein (GAP). Rheb increases phosphorylation of mTOR on Ser-2448 and activates the 
mTORC1 complex. Phosphorylation of TSC2 inhibits its GAP activity towards Rheb, 
thereby inhibiting mTORC1  
2) Secondly, AMPK directly phosphorylates Raptor, one of the binding partners of mTOR, 
on two residues Ser-722 and Ser-792, leading to 14-3-3 binding and subsequent 
suppression of mTORC1.  
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CHAPTER TWO: MATERIALS AND METHODS 
2.1 MATERIALS 
2.1.1 Chemicals 
 
Hepes, Tris (hydroxymethyl) methylamine(Tris), Triton X-100, Tween-20, 
phenylmethylsulphonylfluoride (PMSF), Soya bean trypsin inhibitor, 
dimethylsulphoxide (DMSO), magnesium chloride, Serva blue G, Brij-35, benzamidine, 
Propidium iodide, Dithiothreitol, ethidium bromide and A23187 were from Sigma 
(Poole, UK). Sodium chloride, sodium fluoride, sodium pyrophosphate, glycine, 
hydrochloric acid, sodium azide, acetic acid, sodium ethylenediaminetetraacetate 
(EDTA), sodium ethylenebis (oxyethylenenitrilo)-tetraacetate (EGTA) and glycerol 
were obtained from BDH (Lutterworth UK). Ethanol, methanol, orthophosphoric acid 
were from VWR, UK. ‘Complete’ EDTA free protease cocktail inhibitor, Adenosine 
triphosphate (ATP) and adenosine monophosphate (AMP) was from Roche (Lewisham, 
UK). Glutathione Sepharose and Optisafe HiSafe II liquid scintillant and [γ-32P] were 
from Perkin Elmer (Bucks, UK). Effectene transfection reagent and RNAse A were 
from QIAGEN (Crawley, UK). siPORT transfection reagent was from Ambion, Life 
Technologies, UK. PEI was from Polysciences Inc (Warrington, PA). Dulbecco’s 
Modified Eagle’s Medium (DMEM), McCoy’s 5A medium, Fetal Bovine serum (FBS), 
Optimem reduced serum medium, Dulbecco’s PBS, Trypsin EDTA, L-Glutamine and 
Penicillin/ streptomycin antibiotic solution were from Life Technologies, UK. 75cm
3
 
and 175 cm
3
 tissue culture flasks and 6 well plates were from Invitrogen and 60 and 
100mm tissue culture dishes were from Nunc (Lutterworth, UK). 
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2.1.2 Molecular Biology reagents 
 
Restriction enzymes KpnI, SpeI, 1kb and 100bp DNA ladder and 100X buffer were 
from NEB (Herts, UK). T4 DNA ligase and Blue Orange 6X loading dye were from 
Promega (Southampton, UK). Top 10F competent E. Coli, XL gold super competent E. 
Coli, Molecular biology grade agarose and SOC medium were from Invitrogen. QIA 
prep® Spin Miniprep kit, QIA Quick Gel extraction kit and HiSpeed plasma Maxi kit 
were from QIAGEN. QuikChange XLII site directed mutagenesis kit and cloned Pfu 
DNA polymerase were from Stratagene (La Jolla, CA). dNTPs were from Fermentas 
and DMSO from Sigma. Liquid LB medium and agar plates supplemented with 100µg/ 
ml ampicillin and 50X TAE buffer (1X contains 40mM Tris acetate pH 8.0 with 1mM 
EDTA) were supplied by Media Services, College of Life Sciences, University of 
Dundee. Oligonucleotides were from Sigma. siRNA constructs against CaMKK-β and 
ATM were from Ambion, Life Technologies, UK. 
2.1.3 Plasmids 
 
Plasmids encoding Wild type and Kinase-dead rat LKB1in the pcDNA3.1 Zeo vector 
were gifts from Dr. Sarah Fogarty, formerly of University of Dundee. Wild type and 
Kinase-dead human LKB1 were kind gifts from Prof. Dario Alessi, University of 
Dundee. Site-directed mutagenesis of LKB1 is described in section and sub-cloning 
constructs into the pEBG2T vector is described in section. The pEBG2T vector was a 
gift from Dr. Andrew McBride, formerly of the University of Dundee. 
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2.1.4 Peptides and Proteins 
 
The AMARA peptide was synthesised by Dr. G. Bloomberg, University of Bristol and 
was derived from rat acetyl-CoA carboxylase (Dale et al 1995) and has the sequence 
AMARAASAAALARRR.  GST-ERK was provided by the Division of Signal 
Transduction Therapy (DSTT), University of Dundee. 
2.1.5 Protein Biochemistry Reagents 
 
NuPage 
® 
LDS sample buffer (4X), NuPage 
® 
MOPS Running Buffer (20X), Tris 
acetate Running Buffer (20X), NuPage 
® 
Transfer buffer (20X), SeeBlue Plus 2 
Prestained Standard, NuPage 
® 
Antioxidant, precast NuPage 
® 
Novex
 
4-12% Bis-Tris 
gels and 3-8% Tris acetate gels, Xcell Sure Lock™ Mini-Cell, Xcell Blot Module ™ 
were from Life Technologies, UK. Bovine Serum Albumin (BSA) and Protein G 
conjugated to horse radish peroxidase were from Sigma, ECL reagent was from 
Millipore, UK and Hyperfilm™ was from GE Healthcare (Bucks, UK). Li-Cor Odyssey 
Blocking Buffer was from Li-Cor. IRDye 680 secondary antibodies were from 
Molecular Probes, Life Technologies, UK. IRDye 800 secondary antibodies were from 
Rockland Immunochemicals Inc (Gilbertsville, PA). 
2.1.6 Antibodies 
 
The source and catalogue number of all antibodies used in the experiments detailed in 
the thesis are described in Table 1. All non-commercial antibodies used are described in 
Table 2. 
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Table 2: In-house antibodies used in this thesis 
 
Antibody       Species  Recognises     
AMPK α1  Sheep   344-358 rat AMPK α1 (immunogen)  
AMPK α2  Sheep   352-366 rat AMPK α2 (immunogen)  
GST   Sheep    GST-LKB1 (produced as a by-product 
       of GST-LKB1 antibody) 
pACC (S79-P)  Sheep   ACC1phosphorylated at S79   
LKB1 total  Sheep   1-31 LKB1 (rat)    
CaMKKβ  Sheep   Total CAMKK-β   
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2.1.7 Buffers 
 
Lysis Buffer :  50mM Tris- HCl, pH 7.2, 50mM NaF, 1mM NaPPi, 1mM 
EDTA, 1mM EGTA, 1mM DTT, 0.1mM Benzamidine, 0.1mM 
PMSF, 5μg/ml soybean trypsin inhibitor, 1%(v/v) Triton X-100 
IP Buffer:  50mM Tris- HCl, pH 7.25, 150mM NaCl, 50mM NaF, 1mM 
NaPPi, 1mM EDTA, 1mM EGTA, 1Mm DTT, 0.1mM 
Benzamidine, 0.1mM PMSF, 5μg/ml soybean trypsin inhibitor, 
1% (v/v) Triton X-100 
High Salt IP buffer: 50mM Tris- HCl, pH 7.25, 0.5 M NaCl, 50mM NaF, 1mM 
NaPPi, 1mM EDTA, 1mM EGTA, 1Mm DTT, 0.1mM 
Benzamidine, 0.1mM PMSF, 5μg/ml soybean trypsin inhibitor, 
1% (v/v) Triton X-100 
Assay Buffer:  50mM Hepes pH7.4, 1mM DTT, 0.02% (v/v) Brij-35. 
Affinity purification   
Buffer 1: 50mM Tris- HCl, pH 7.25, 150mM NaCl 
Buffer 2: 50mM Tris- HCl, pH 7.25, 150mM NaCl, 1mM DTT, 0.5% (v/v) Triton 
X-100 
Buffer 3: 50mM Tris- HCl, pH 7.25, 150mM NaCl, 1mM DTT, 0.27M sucrose,  
0.5% (v/v) Triton X-100 
Elution Buffer: 50mM Tris- HCl, pH 7.25, 150mM NaCl, 1mM DTT, 0.27M sucrose, 
20mM glutathione. 
PBS:  137mM NaCl, 2.7mM KCl, 8.1mM Na2HPO4 
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2.1.8 Microscopy Reagents and Equipment 
 
Glass slides and coverslips were from VWR, UK. Paraformaldehyde and Fish skin 
gelatin and fluorescent secondary antibodies were from Sigma, UK. Vectashield was 
from Vector Laboratories, Burlingame, CA. Willco Wells were from Intracel, Herts, 
UK. Fluo-4 AM was from Invitrogen. The Deltavision wide field deconvolution 
microscope and the Zeiss LSM 710 confocal microscope were based at the College of 
Life Sciences, University of Dundee. 
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2.2 METHODS 
2.2.1 Site-directed mutagenesis  
 
Synthetic complimentary oligonucleotides (shown in Table 3) were designed to give 
specific mutations by making base changes at the appropriate codon. Site-directed 
mutagenesis was performed using QuikChange
®
II site directed mutagenesis kit 
according to manufacturer’s instructions. Briefly, the mutagenesis reactions were set up 
in sterile 0.2 ml PCR tubes; each containing 1x reaction buffer, 15ng dsDNA template, 
125 ng of each mutagenic oligonucleotide, 1mM dNTPs, 2.5U Pfu turbo DNA 
polymerase made upto a final volume of 50µl with sterile de-ionised water. The 
reactions were incubated in a Hybrid PCR Express thermal cycler using the following 
parameters- 1cycle 95ºc for 30sec, 18 cycles 95ºc for 30 sec, 55 ºc for 1 min, and 68 º c 
for 8mins. After cycling, the tube was cooled to below 37ºc after which 10U DpnI 
restriction endonuclease was added. DpnI digests methylated and hemi-methylated 
DNA, but leaves non-methylated mutant DNA. The reaction was incubated for 1hour at 
37ºc. 2 µl of the reaction mixture was used to transform competent E.coli cells as 
described in section 2.2.3. pcDNA3.1 Zeo plasmids encoding LKB1 were used as 
template DNA for all mutagenesis reactions. 
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Table 3: List of primers used for site-directed mutagenesis of LKB1 
LKB1 S325A:  5’- GTGCCCATCCCACCGGCCCCAGACACCAAGGAC 
3’- GTCCTTGGTGTCTGGCGCCGGTGGGATGGGCAC 
LKB1 S431A:    5’- CTGCTGCTTGCAGGCCGCCAGCCGGCGGATCTT 
   3’- GTCCTTGGTGTCTGGGGCCGGTGGGATGGGCAC 
 
2.2.2 Sub cloning of GST-LKB1 constructs 
 
pcDNA3.1 Zeo plasmids encoding wild-type and mutant LKB1 constructs were used as 
DNA templates and were amplified by PCR using the primers and ligated into pEBG-
2T plasmid using the SpeI/KpnI restriction sites. The PCR reaction contained 1x Pfu 
reaction buffer, 100ng dsDNA template, 1mM dNTPs 1pmol forward primer, 1pmol 
reverse primer, 5% (v/v) DMSO, 4mM MgCl2 and 2.5U Pfu DNA polymerase made up 
to a final volume of 50µl with sterile de-ionised water. The reactions were incubated in 
a Hybrid PCR Express thermal cycler using the following parameters- 1 cycle at 95ºC 
for 10 minutes, 36 cycles at 95ºC for 1min, 50ºC for 1 min, 72ºC for 2 minutes, 
followed by a final extension at 72ºC for 10 minutes. The PCR reactions were analysed 
on 1% agarose gel (as described in section 2.2.6) and the appropriate bands were 
excised using a sterile scalpel. The PCR products were purified (as described in section 
2.2.5). 10 µl of purified PCR product and 1 µg of pEBG-2T vector were digested with 
SpeI and KpnI at 37ºC for 2 hours. The restriction digest reactions were analysed on 1% 
agarose gel and linearised plasmids were purified (as described in section 2.2.5). The 
purified digest products were incubated overnight at 4ºC with 1 µl T4 DNA ligase and 
1x ligase buffer at a vector: insert ratio of 1:7 in a final volume of 10 µl. TOP10F E.Coli 
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were transformed with 2 µl of thee ligation reactions (as described in the next section). 
Positive clones were screened by DNA sequencing. 
2.2.3 Transformation of competent E.Coli cells 
 
An aliquot of TOP10F E. Coli was allowed to thaw on ice. Ligation reaction (2 µl) or 
plasmid (0.5-1 µg) was added to cells and incubated on ice for 30 minutes before being 
subjected to ‘heat shock’ at 42ºC for 1 min. The cells were placed back on ice for a 
further 2 minutes and 500 µl of SOCS medium was then added. The samples were 
incubated at 37ºC for 1 hour on a shaking platform set at 220rpm. 20-100 µl of cells 
were streaked onto LB-kan or LB-amp plates and incubated overnight at 37ºC. 
2.2.4 Purification of plasmid DNA from E.Coli 
2.2.4.1 Small-scale purification 
Transformed E.Coli cells were grown overnight at 37ºC in 2ml LB-amp. 
Centrifugation at 2300g (5000rpm) for 2 minutes was used to pellet the cells and 
plasmid DNA was purified using the QIAGEN QIA prep Spin Miniprep kit, according 
to manufacturer’s instructions. Briefly, the cells were resuspended and lysed in 250 µl 
of buffers P1 and P2, which contain sodium hydroxide, SDS and RNase A. The SDS 
solubilises the phospholipid and protein components of the cell membrane leading to 
cell lysis, while the alkaline conditions denature chromosomal and plasmid DNA. The 
samples were neutralized by 350 µl buffer N3, which is a high salt buffer that causes 
denatured proteins, chromosomal DNA and SDS to precipitate. The precipitate was 
separated from the soluble fraction by centrifugation at 16000g for 10 minutes. The 
supernatant was applied to a silica membrane column, which selectively binds plasmid 
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DNA under high salt conditions, and centrifuged at 16000g for 1min. The membrane 
was washed with 750 µl of the ethanol-based PE buffer to remove any contaminating 
salts. The plasmid DNA was eluted from the column with 30 µl of sterile de-ionised 
water. This DNA was used for sub-cloning and DNA sequencing. 
 
 2.2.4.2 Large- scale purification 
To prepare larger quantities of DNA for transfection into mammalian cells, 
transformed E.Coli cells were grown overnight at 37 ºC in 200ml LB-amp or LB-kan as 
required. The cells were pelleted at 6000g for 15 minutes at 4 ºC. Plasmid DNA was 
purified using the QIAGEN Hispeed plasmid Maxi kit according to manufacturer’s 
instructions. Briefly, the cells were resuspended and lysed in 10mls each of buffers P1 
and P2. The suspension was neutralized by the addition of 10mls of buffer P3. The 
lysate was cleared by filtration and applied to a silica column. The column was washed 
with 60mls of buffer QC and plasmid DNA was eluted with buffer QF. DNA was 
precipitated by the addition of 10.5 ml isopropanol and was collected using the QIA 
precipitator before final elution in 750 µl sterile de-ionised water. 
2.2.5 Purification of DNA from agarose gels 
 
DNA was purified from agarose gels using the QIAGEN QIAquick Gel Extraction kit 
following manufacturer’s instructions. Briefly, the desired band was excised from the 
agarose gel using a sterile scalpel. The band was dissolved in 3 volumes of buffer QG at 
50ºC for 10 minutes. After the gel slice was completely dissolved, 1 volume of 
isopropanol was added and the sample was gently mixed. The mixture was applied to a 
silica membrane column by centrifugation at 16000g for 1min. the column was washed 
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with 750 µl of the ethanol based PE buffer. The DNA was eluted in a final volume of 30 
µl sterile de-ionised water. 
2.2.6 Analysis of DNA by agarose gel electrophoresis 
 
Agarose gel electrophoresis was performed using a horizontal gel electrophoresis 
system. 1% (w/v) agarose gels containing 0.5 µg/ml ethidium bromide or SyBr green 
were cast and run in TAE buffer. Samples were loaded in 6X DNA loading buffer and 
were resolved alongside 1Kb DNA ladder markers at 110 volts for 30 minutes. DNA 
was visualized using an ultraviolet light transilluminator.  
2.2.7 Determination of DNA concentration 
 
Plasmid DNA was diluted in sterile de-ionised water to a final volume of 500 µl and 
transferred to a quartz cuvette. The absorbance was measured at 260 nm against water 
blank. A 50 µg/ml solution of double stranded DNA has an absorbance of 1 at 260nm. 
The quality of DNA (contamination with RNA and protein) was assessed by measuring 
the absorbance at 280 nm. A 260/280 nm ratio of greater than 1.6 was indicative of 
highly purified DNA. 
2.2.8 DNA Sequencing 
 
DNA Sequencing was performed by the DNA Sequencing Service, College of Life 
Sciences, University of Dundee; using Applied Biosystems Big-Dye Ver 3.1 chemistry 
on an Applied Biosystems model 3730 automated capillary DNA Sequencer. 
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2.2.9 Glycerol Stocks of transformed E.coli 
 
200 µl of sterile glycerol was added to 800 µl from an overnight culture of transformed 
E.coli and vortexed thoroughly. The mixture was snap frozen in liquid nitrogen and 
stored at -80ºC. 
2.2.10 Tissue culture 
 
All media and buffers used for tissue culture were warmed in a water bath to 37ºC prior 
to use. Cells were maintained in 75 cm
3
 or 175 cm
3 
flasks at 37ºC in an incubator with 
an atmosphere containing 5% CO2. The cells were grown until 80-90% confluent before 
splitting for routine maintenance. For passaging of cells, the culture medium was 
aspirated, 5-10 mls of trypsin-EDTA was added and the cells were returned to the 37ºC 
incubator for 3-5 minutes. After the cells detached from the surface of the flask, 1 ml of 
the cell suspension was used to seed a fresh 75 cm
3
 or 175 cm
3 
flask containing 15 ml or 
25 ml of complete culture medium. 
 
2.2.10.1 HeLa cells 
HeLa cells were obtained from the Department of Health and were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) Foetal 
bovine serum and 1% (v/v) antibiotic/ antimycotic solution. 
 
2.2.10. 2 Trex-HeLa stable cell lines 
Trex-HeLa parental cells as well as Trex-HeLa cells expressing wild type and 
kinase-dead (KD) LKB1 were kind gifts from Professor Dario Alessi, University of 
51 
 
 
 
Dundee (described by Sapkota et al 2002). These were cultured in Earle’s Modified 
Eagle’s Medium (EMEM) supplemented with 10% (v/v) Foetal bovine serum, 5 µg/ml 
blasticidin and 100 µg/ml zeocin. 
 
2.2.10.3 HEK 293 cell line 
HEK 293 cells obtained from the Department of Health were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) Foetal 
bovine serum and 1% (v/v) antibiotic/antimycotic solution. 
 
2.2.10.4 G361 melanoma cell line 
The human G361 melanoma cell line was cultured in McCoy’s 5A medium 
supplemented with 2mM glutamine, 5% (v/v) Foetal bovine serum and 1% (v/v) 
antibiotic/antimycotic solution. 
 
2.2.10.5 Mouse embryonic fibroblasts 
Both wild type and AMPK-α1, -α2 knock out (KO) mouse embryonic cells were 
kind gifts from Dr. Benoit Viollet, Universit´e Paris. The fibroblasts were cultured in 
Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% (v/v) Foetal 
bovine serum and 1% (v/v) antibiotic/antimycotic solution. These MEFs were passaged 
no more than 10 times before being discarded and a fresh batch of MEFs thawed for 
use. 
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2.2.11 Transfection 
 
Cells were transfected with wild type and mutant LKB1 DNA, along with STRAD and 
MO25 or GST-ERK2, by one of the two methods listed below. 
 
2.2.11.1 PEI Transfection 
Cells were transfected using polyethylimine (PEI) which has been described 
previously (Durocher et al 2002). PEI is a cationic polymer in which every third atom is 
an amine nitrogen that can be protonated giving it a substantial buffering capacity at 
physiological pH. PEI can assemble DNA into compact structures, which allows 
efficient entry into cells, while its pH buffering properties protects DNA from 
lysosomal degradation. For a 100 mm diameter dish, 1 ml of serum-free media was 
incubated with 5-10 µg DNA and 20-30 µl of 1mg/ml PEI at room temperature for 20 
minutes. The solution was then added drop wise to each dish and the cells were 
incubated at 37ºC in an incubator with an atmosphere containing 5% CO2. 
 
2.2.11.2 Transfection of HeLa and G361 cells using Effectene 
HeLa and G361 cells were transfected using Effectene transfection reagent 
according to manufacturer’s instructions. Effectene is a non-liposomal lipid formulation 
used with an enhancer and DNA condensation buffer (buffer EC). DNA is condensed 
by its interaction with the enhancer in a defined buffer system. Addition of Effectene 
leads to the formation of condensed Effectene-DNA complexes, which allow efficient 
entry of DNA into cells with the Effectene reagent providing a cationic lipid coating . 
For a 100mm dish, 2µg of DNA was incubated with 300 µl buffer EC and 16 µl 
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Enhancer for 2 minutes at room temperature. 60 µl of Effectene was then added and the 
mixture was incubated at room temperature for 10 minutes. 3mls pre-warmed complete 
media was mixed with Effectene-DNA solution and added drop wise to each dish. The 
dishes were incubated for 48 hours at 37ºC and 5% CO2. 
2.2.12 Freezing and thawing cell lines 
 
Cells grown to confluence in 75cm
3
 culture flasks were trypsinised in 5ml trypsin-
EDTA solution as described previously. Tubes containing the trypsinised cells were 
centrifuged for 5mins at 230g. Trypsin was aspirated and the cells were resuspended in 
capped tubes containing 900 µl of pre-warmed culture medium and 100 µl DMSO. The 
tubes were transferred to a cell freezer and kept in a -80ºC freezer overnight, after which 
it was stored long term in liquid nitrogen. Frozen cell stocks were thawed in a water 
bath at 37ºC with gentle shaking and transferred into 10mls of media. Cells were re-
pelleted to remove DMSO and the supernatant discarded. The cells were re-suspended 
in fresh media and seeded immediately into 75cm
3
 flasks containing pre-warmed culture 
medium. 
2.2.13 Lysis of cells 
 
Cells were harvested using a rapid lysis method to minimize activation of AMPK during 
cell lysis. Dishes were placed on ice and the culture media was aspirated. The cells were 
washed twice with ice cold PBS, lysed in 250-500 µl ice-cold lysis buffer and scraped 
into pre-chilled 1.5ml eppendorf tubes. Cell lysate was clarified by centrifugation at 
17,600 g for 10mins at 4ºC. The clarified lysate was kept on ice for immediate use or 
snap frozen in liquid nitrogen and stored at -80ºC. Frozen lysates were thawed on ice 
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before use. Protein concentration of the lysates was determined by the Bradford method 
(section 2.2.15). 
2.2.14 Purification of GST-fusion proteins from the cells 
 
100mm dishes containing HEK 293 or HeLa cells were transiently transfected with 
plasmids encoding GST- tagged wild type and mutant LKB1. 36-48 hours post 
transfection, the cells were lysed in 0.5 mls of ice-cold lysis buffer as described 
previously and the clarified lysates were incubated for 2 hours on a rolling platform 
with glutathione-sepharose (25 µl/100mm dish) previously equilibrated in buffer 1. The 
beads were washed 3 times in buffer 1, twice in buffer 2 and twice in buffer 3 
containing 0.27M sucrose. The resin was incubated with 1-1.5 volumes buffer 4 
containing 0.27M sucrose and 20mM glutathione to elute the GST- fusion proteins. The 
eluate was snap frozen and stored at -80ºC. 
2.2.15 Determination of protein concentration 
 
Protein concentration was estimated using the Bradford dye-binding method (Bradford 
1976). Bradford reagent was prepared using 30mg Serva Blue G in 50ml of 95% (v/v) 
ethanol and 85% (w/v) orthophosphoric acid. The solution was made up to a final 
volume of 1 litre with de-ionised water and stored in a bottle protected from light, as the 
solution is light sensitive. A standard curve was generated for each preparation of 
Bradford reagent using a range of concentrations of Bovine serum albumin (1-10 
mg/ml). The concentration of BSA was confirmed by measuring absorbance at 280 nm 
(1mg/ml BSA has an absorbance of 0.68 at 280 nm). Protein concentrations were 
determined by adding 1ml of Bradford reagent to samples in a volume of 100 µl and 
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measuring the absorbance at 595nm against a reference containing 1 ml Bradford 
reagent and 100 µl de-ionised water. 
2.2.16 SDS-polyacrylamide gel electrophoresis 
 
SDS-PAGE is used to separate proteins based on their apparent molecular weight. The 
anionic detergents Sodium dodecyl sulphate (SDS) or lithium dodecyl sulphate (LDS), 
denature proteins and confer a negative charge in proportion to mass resulting in a 
constant charge to mass ratio for most proteins. The rate of migration through a 
polyacrylamide gel matrix is determined by the molecular weight (size) and the charge 
of the protein. Smaller proteins migrate faster than larger proteins and negatively 
charged proteins migrate slower than uncharged proteins. Purified proteins, cell lysates 
and immunoprecipitate prepared in NuPage® LDS sample buffer (4X) and 25mM DTT 
were heated to 70ºC for 15 minutes. The samples and 5 µl of SeeBlue®Plus Two 
Prestained molecular weight protein standards were loaded onto a pre-cast gradient gel 
in an XCell Sure Lock™ Mini-Cell. 4-12% Bis-Tris polyacrylamide gels were used 
with NuPage® MOPS running buffer. Proteins were resolved at 200V after which gels 
either stained or the proteins transferred to a nitrocellulose membrane for 
immunoblotting. For the analysis of acetyl CoA Carboxylase and ATM, 3-8% Tris-
acetate polyacrylamide gels were used with tris- acetate running buffer and the proteins 
were resolved at 150V for 75 minutes, after which the gels were transferred to a 
nitrocellulose membrane for immunoblotting. 
2.2.17 Coomasie staining of gels 
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Proteins separated by SDS-PAGE on agarose gel were visualized using Coomasie 
staining. Gels were fixed for 30 minutes in a solution containing 50 % (v/v) methanol, 
10% acetic acid (v/v) and 0.1% (w/v) Coomasie Blue on a shaking platform. The gels 
were then de- stained with a solution containing 10% (v/v) methanol and 10 %(v/v) 
acetic acid in de-ionised water overnight  to remove background staining. The gels were 
then washed in de-ionised water and visualized on the Li-Cor Odyssey Imaging system. 
2.2.18 Transfer of proteins to nitrocellulose membrane 
 
Proteins were transferred following SDS-PAGE onto nitrocellulose membrane using an 
Xcell II Blot Module™, according to the manufacturer’s instructions. Blotting pads, 
nitrocellulose membrane and 3MM filter paper were pre-soaked in 1X NuPage® 
transfer buffer containing 20% (v/v) methanol. The gel membrane sandwich was 
assembled from back to front as follows- blotting pad, filter paper, gel, nitrocellulose 
membrane, filter paper and blotting pads with the gel towards the cathode and the 
membrane towards the anode. The blotting module was placed in an Xcell Sure Lock™ 
Mini Cell and filled with the transfer buffer. Transfers were normally carried out at 34V 
for 90 minutes. In the case of high molecular weight proteins, transfer was carried out 
overnight at 12 V in the cold room (at 4°C). 
2.2.19 Immunoblotting 
 
Following transfer, nitrocellulose membranes were incubated either in Li-Cor Odyssey 
buffer or TBS buffer with 5% (w/v) non-fat milk for 1 hour to reduce non-specific 
antibody binding. Membranes were incubated overnight at 4°C with primary antibody 
(usually diluted 1:1000 for phospho antibodies and 1:5000 for total antibodies) in Li-
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Cor buffer for phospho antibodies and TBS containing 2% (w/v) non-fat milk for total 
antibodies. Following incubation, membranes were washed in TBS containing 0.1% 
(v/v) Tween-20 for atleast 30 minutes (3X10 min washes). IRDye680- or IRDye800-
conjugated secondary antibodies or Protein G-Sepharose coupled HRP (horse radish 
peroxidase) antibody were diluted 1:5000 in TBS containing 2% (w/v) non-fat milk. 
Membranes were washed in TBS containing 0.1% (v/v) Tween-20 for atleast 30 
minutes (3 X10 min washes) followed by a final wash in de-ionised water. The signal 
was detected either using the Li-Cor Odyssey™ system which detects Infra-red IRDye-
conjugated secondary antibody, or using enhanced chemiluminescence reagent for HRP 
conjugated secondary antibody. Briefly, equal volumes of luminol and peroxide were 
mixed and applied to the membrane for 2-5 minutes. The signal was then detected by 
placing the membrane with an X-ray film and developing the film after exposure. 
 
2.2.20 Non- covalent coupling of antibodies to protein G-
Sepharose  
 
Protein G –Sepharose is commercially available as 66% slurry in ethanol. The required 
volume of beads was washed in IP buffer 4 times to remove alcohol, centrifuged at 
16000g for 30 seconds and the supernatant removed. The beads were resuspended as a 
20% slurry in IP buffer. The required antibody was added to the beads at a 
concentration of 1 µg antibody per µl Protein G-Sepharose resin. The mixture was 
placed on a roller mixer overnight to allow non-covalent coupling of the antibody to the 
beads. The beads were then centrifuged at 16000g for 30 seconds and the supernatant 
aspirated. The beads were then washed 3 times with IP buffer containing 0.5M NaCl to 
remove unbound antibody. The beads were then washed with IP buffer containing 
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150mM NaCl twice and finally resuspended in IP buffer containing 0.02% sodium azide 
and stored at 4°C until required. 
2.2.21 AMPK immunoprecipitation assay  
 
AMPK activity was measured by its ability to phosphorylate the AMARA synthetic 
peptide. AMPK-α1 and -α2 antibodies coupled to protein G-Sepharose (15µg antibody 
with 15 µl beads) was incubated with 100 µg cell lysate to immunoprecipitate 
endogenous AMPK. This method has previously been described (Davies et al., 1989); 
the only change to the described protocol is the use of AMARA synthetic peptide 
instead of SAMS peptide. The beads were then washed to remove unbound proteins and 
then aliquoted into 3 eppendorf tubes in assay buffer (5 µl beads in 20 µl buffer). The 
reactions were started by the addition of 30 µl assay buffer containing 200 µM AMP, 
200 µM [γ32P]-ATP, 5 µM MgCl2 and 200 µM AMARA and the mixture was incubated 
in an orbital shaker at 30°C for 15 minutes. 30 µl of the reaction mixture was spotted 
onto p81 paper and the reaction was terminated by transfer of the paper to a beaker 
containing 1% orthophosphoric acid. Following further washes to remove 
unincorporated ATP, the papers were air-dried before being placed in scintillation vials 
and radioactivity was measured using an LKB- Wallace 1214 Rackbeta liquid 
scintillation counter. One unit of activity was defined as that which catalysed the 
incorporation of one nmole of γ32P into the synthetic peptide. 
2.2.22 Mice 
 
All mice were bred in the Wellcome Trust Biocentre Transgenic Unit at the University 
of Dundee in accordance with UK Home Office Animals (Scientific Procedures) Act 
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1986.  Mice with floxed PTEN alleles (129 ES cells implanted into FVB-N mice) were 
kindly donated by Hergen Spitz and mice with AMPK-α1 floxed alleles (129 ES cells 
implanted into C57Bl/6mice) were gifts from Dr. Benoit Viollet. Both mice were 
backcrossed onto the C57BL/6 background for atleast six generations.  These were then 
crossed onto C57Bl/6 mice with a Cre recombinase under the control of the Lck 
promoter.  This part of the project is co-supervised by Prof. Doreen Cantrell. 
2.2.23 Genotyping 
 
PCR reactions were used to amplify DNA extracted from ear clip samples from the 
mice. The primers listed below were used in the reactions 
 
Table 4: List of Genotyping primers used 
 
AMPKα 1  forward 5’ TAT-TGC-TGC-CAT-TAG-GCT-AC (20) 
reverse 3’ ACC-TGA-CAG-AAT-AGG-ATA-TGC-CCA-ACC-TC (29) 
 
PTEN    forward 5’ GCCTTACCTAGTAAAGCAAG (20) 
reverse 3’ GGCAAAGAATCTTGGTGTTAC (21) 
 
Cre-recombinase forward 5’ CGGTCGATGCAACGAGTGATGAGG (24) 
   reverse 3  CCAGAGACGGAAATCCATCGCTCG (24) 
 
PCR reactions for each were carried out in PCR buffer with MgCl2 with dNTP’s using 
RedTaq DNA polymerase. The PCR products were resolved on a 2% agarose gel 
containing 1:40,000 ethidium bromide and visualised with an Infra-red imaging system. 
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2.2.24 siRNA knockdown of CaMKK-β 
  
Reverse transfection of siRNA constructs against CaMKK-β were carried out according 
to protocols detailed in the Ambion™ siRNA starter kit. Briefly, transfection reagent 
(siPORT) was diluted 1 in 20 in Opti-MEM medium and allowed to incubate for 10 
minutes. Meanwhile, cells were trypsinised for 5 minutes and the trypsin quenched with 
complete media. siRNA (obtained from Ambion, Life Technologies) was diluted in 
Opti-MEM to a final concentration of 5nM. siRNA and diluted transfection reagent 
were then mixed and incubated for 10 minutes. The siRNA- siPORT mixture was added 
to 6 well plates and cells were seeded into the 6-well plates. The plates were returned to 
the incubator for 24 hours, following which treatment with vehicle or drugs was carried 
out for 18 hours. Knockdown was confirmed by Western blotting. 
2.2.25 Cell Cycle Analysis 
 
Cells were seeded in 6 cm dishes until 40-80% confluence and treated for 16-18 hours. 
Cells were trypsinised until detached from the base of the dish and the trypsin was then 
quenched with media. The cells were pelleted, transferred into 5 ml falcon tubes and 
washed with PBS containing 1% FCS and 0.1mM EDTA. The cells were then fixed 
with ice cold 70% ethanol for atleast 2 hours. The cells were then washed twice in the 
PBS buffer and then stained with PBS containing propidium iodide (diluted 1 in 20 in 
the PBS buffer) and RNAse to digest RNA. The cell cycle analysis was performed on 
the Calibur flowcytometer and analysis performed using Flow Jo software. 
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2.2.26 Cell Survival Assay 
 
Cells were seeded into 25cm
3
 flasks at equal density and treated at 40-80% confluence 
with control and different concentrations of drug for 24 hours. Cells were trypsinised in 
3 mls of trypsin EDTA for 5 minutes and then quenched with 5 mls complete media. 
The cells in the control flask were counted using a haemocytometer under a microscope 
and 2000-5000 cells seeded in triplicate into 10 cm dishes containing 10 mls of media. 
The same volume of media containing cells was aspirated from the treated flasks and 
seeded in triplicate into 10 cm dishes also containing 10 mls of media. The dishes were 
placed at 37ºC in an incubator with an atmosphere containing 5% CO2 for 7-10 days. 
The media was changed once during this period. At the end of the incubation period, the 
media was aspirated; the cells were fixed in ice-cold methanol for 10 minutes and 
stained with 0.4% (w/v) Giemsa in methanol for 10 minutes. The dishes were washed 
with de-ionised water and the number of colonies was counted manually. 
2.2.27 Immunofluorescence Microscopy 
 
Cells were grown on glass coverslips in 6-well dishes until 40-80% confluence. They 
were then treated with control or different concentrations of various drugs for a set 
period of time. The coverslips were then washed in PBS thrice, fixed in 4% 
Paraformaldehyde made up in PBS for 20 minutes and washed again with PBS three 
times. The cells were then permeabilised in 0.2% Triton in PBS for 5 minutes. The 
coverslips were again washed in PBS. The coverslips were then placed in blocking 
buffer (PBS containing 0.2% Fish skin gelatin) for 1 hour to block non-specific 
antibody binding. Coverslips were then stained with primary antibody (1:300- 1:1000 
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dilution in blocking buffer) for 30 minutes. After the coverslips were washed in 
blocking buffer, the coverslips were again stained with fluorescent secondary antibody 
(1:200 dilution in blocking buffer) for 30 minutes. The coverslips were then washed in 
PBS twice, mounted onto slides using Vectashield and then sealed with nail varnish. 
The slides were imaged on the Deltavision deconvolution microscope and images 
acquired and deconvolved using the SoftWorx program. 
 
 2.2.28 Live Cell Imaging 
 
Cells were grown on glass bottom dishes (Willco Wells) until 40-80% confluence. Cells 
were then loaded with 1 μM Fluo4-AM dye for 20-30 minutes. The cells were then 
washed with PBS and fresh media added to the dish. The Willco dish was mounted onto 
a stage pre-heated to 37 degrees and enclosed with a lid to deliver 5% CO2 to the cells. 
Calcium flux was measured using the Zeiss LSM-710 confocal system with 
fluorescence measured at 488nm using 63X magnification objective. Image analysis and 
quantification was done using Volocity 5.5.1 software.  
2.2.29 Real-time PCR 
 
Real time PCR was used to analyse and compare the mRNA expression of genes in 
mice thymocytes which lacked PTEN ± AMPK to that of wild type thymocytes. First, 
RNA was extracted from the thymocytes using the QIAGEN RNeasy Kit, according to 
the manufacturer’s instructions. Cell pellets of thymocytes, previously frozen at -80°C 
were resuspended and lysed in RLT buffer (QIAGEN) before being passed through QIA 
shredders. Nucleic acids were precipitated by adding 70% ethanol. The mixture was 
passed through RNeasy spin columns, which bound nucleic acids. Genomic DNA was 
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then digested on the column with DNase I. Following a series of wash steps, RNA was 
eluted in RNase-free water. The RNA was quantitated using the nanodrop.  
 cDNA was then synthesised using the Quanta cDNA synthesis kit, according to 
the manufacturer’s instructions. Briefly 500ng of RNA was added to qScript reaction 
mix, which contained primers and nucleotides, before the addition of qScript reverse 
transcriptase. The final volume of this reaction was 20 μls. The cDNA was synthesised 
by placing this mixture in a thermal cycler programmed as follows: 1 cycle at 22°C for 
5 minutes, 1 cycle at 42°C for 30 minutes and 1 cycle at 85°C for 5 minutes, before 
being cooled to 4°C. 80 μls of DEPC water was then added to the PCR product. 
 PCR reactions were then performed in triplicate with the cDNA as a template 
along with specific primers for various genes (See Table 5), along with the reaction 
mixes containing nucleotides and SyBr green which stained double stranded DNA. The 
PCR reactions were performed in a real-time PCR machine, according to a standardized 
programme, which measured the intensity of SyBr green signal as a measure of the 
amount of DNA synthesised. The number of cycles to achieve a defined intensity of 
SyBr green by the different cDNA constructs was noted and normalized to the number 
of cycles required by a   housekeeping gene to achieve the same intensity of SyBr green. 
 
Table 5: List of primers used for RT-PCR 
 
1) S1P1  forward   5’-GTG TAG ACC CAG AGT CCT GCG-3’ 
S1P1  reverse   5’-AGC TTT TCC TTG GCT GGA GAG-3’ 
2) HPRT  forward 5’-TGA TCA GTC AAC GGG GGA CA-3’ 
HPRT  reverse   5’-TTC GAG AGG TCC TTT TCA CCA-3’ 
3) CD62L forward  5’- CCT GTA GCC GTC ATG GTC AC-3’ 
CD62L  reverse   5’- GAA TCA GTA TGG ATC ATC CAT C -3’ 
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4) CCR7  forward 5’- CAG CCT TCC TGT GTG ATT TCT ACA-3’ 
CCR7  reverse  5’- ACC ACC AGC ACG TTT TTC CT-3’ 
5) CD69  forward  5’- AAC TGA CTG CTA ATC ACA TCA AGG-3’ 
CD69  reverse  5’- GTC ATT CGG CAA TAA ATA GTA ACT CTA G-3’ 
 
2.2.30 Statistical Analysis 
 
Statistical analysis was carried out using GraphPad Prism software version 5. Student t-
test was used to compare 2 groups and ANOVA used to compare three or more groups. 
Where applicable, the Newman-Keuls post-test was used, which assumes equal 
variance. In cases where a large number of samples were compared, then a Bonferroni 
test was used.  Statistical significance was determined by calculating p values and 
represented as follows- p <0.05 (represented in some figures as *), p<0.01(represented 
in some figures as **) and p<0.001(represented in some figures as ***).
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CHAPTER THREE:  ACTIVATION OF AMPK BY AGENTS 
THAT CAUSE DOUBLE STRANDED DNA BREAKS 
 
3.1 INTRODUCTION 
3.1.1 DNA Damage response pathways 
 
Endogenous DNA damage occurs at high frequency in normal cells. For example, base 
loss due to spontaneous hydrolysis of DNA glycosyl bonds occurs at a frequency of 10
4
 
events per mammalian cell per day (Lindahl and Nyberg, 1972). These defects need to 
be detected and repaired rapidly to allow the cell to divide and pass on the correct 
complement of genomic material (Rouse and Jackson, 2002). Different types of DNA 
damage occur on exposure to different agents, for instance, exposure to ultraviolet 
radiation causes single strand DNA breaks (Reynolds and Friedberg, 1981), while 
ionising radiation, reactive oxygen species and exposure to topoisomerase inhibitors 
(e.g. etoposide) cause double strand DNA breaks (Povirk, 2006, Heisig, 2009). Of all 
the various genotoxic stresses the cell undergoes, double stranded DNA breaks are the 
most deleterious. To counter DNA damage, cells have evolved complex responses, with 
a network of distinct, but  interacting pathways that are defined by the type of DNA 
damage (Lord and Ashworth, 2012). The different pathways involved with specific 
types of DNA damage are summarised in Figure 3.1. The rest of this introductory 
section deals with double strand breaks caused by etoposide and focusses on activation 
of the Ataxia-Telangiectasia Mutated (ATM) kinase. 
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3.1.2. The PIKK family of proteins  
 
The phosphatidyl inositol 3-kinase-like kinases (PIKKs) are a family of six kinases of 
unusually large molecular weight (300-500 KDa), which play an important role in 
dealing with cellular stress (Abraham, 2004b). They include three protein kinases, 
namely,  Ataxia-Telangiectasia Mutated (ATM), ATM and Rad-3 related kinase (ATR) 
and  DNA- dependent protein kinase (DNA- PK), which share sequence identity and  
are involved in the DNA damage response (Durocher and Jackson, 2001). Two other 
kinases in this group include the mammalian Target-of-Rapamycin (mTOR), which 
regulates protein synthesis, cell growth and cell proliferation in response to the 
availability of nutrients and mitogenic growth factors, and Suppressor of Morphogenesis 
in Genitalia-1 (SMG-1), which may also be involved in genotoxic stress as well as in 
mRNA  surveillance pathways (Abraham, 2004a). The sixth and final member of this 
family, Transformation/Transcription domain associated protein (TRRAP) retains the PI 
3-kinase related catalytic domain, but possesses no intrinsic phospho-transferase 
activity (Mcmahon et al., 1998). 
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Figure 3.1: DNA Damage response pathways 
The type of genotoxic insult determines the type of DNA repair, and different components of 
the DNA damage response are activated or recruited to sites of DNA damage in each case. 
Adapted from (Lord and Ashworth, 2012). 
 NHEJ: Non-homologous end joining 
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3.1.3 ATM Kinase 
 
ATM kinase, encoded by the ATM gene is a 370 KD protein. ATM is activated by 
double stranded DNA breaks (DSBs). Mutations in or loss of  the ATM gene are 
associated with the Ataxia Telangiectasia, an autosomal recessive human disorder, 
characterised by gait abnormalities, mainly ataxia, dilated blood vessels (telangiectasia), 
immune deficiency and predisposition to cancer and diabetes mellitus (Lavin and 
Shiloh, 1997). Under basal conditions, ATM exists as an inactive dimer. In response to 
DNA damage, it undergoes  auto-phosphorylation on Ser-1981, forms monomers and is 
activated (Bakkenist and Kastan, 2003). It is then recruited to sites of DNA damage by 
the Mre11- Rad50- NBS1 (MRN) complex (Carson et al., 2003), and NBS1 activation 
by ATM-dependent phosphorylation further strengthens the association of ATM to 
these sites (Berkovich et al., 2007). Once activated, ATM phosphorylates several 
downstream targets involved in the repair of DSBs and regulation of the cell cycle. The 
optimal ATM substrate motif is a serine or threonine followed by glutamine (S/TQ) and 
large scale proteomics analysis reveals that ATM and ATR may phosphorylate as many 
as 900 sites on 700 different proteins (Matsuoka et al., 2007).  
One target for ATM is the checkpoint kinase Chk2, which is phosphorylated on 
Thr-68 (Ahn et al., 2000). Chk2, in turn, phosphorylates  and inactivates the protein 
phosphatases Cdc-25A and Cdc-25C, thereby causing a cell cycle arrest at the G2/M 
phase (Ahn et al., 2004). Another key protein that is phosphorylated by ATM is the p53 
tumour suppressor. The p53 protein regulates the cell cycle by causing a G1/S arrest and 
also promotes apoptosis. ATM phosphorylates p53 on Ser-15 (Canman et al., 1998, 
Banin et al., 1998). This phosphorylation promotes a second phosphorylation on p53 by 
ATM at Thr-18, which disrupts its interaction with Mdm2 and enhances its 
transcriptional activity (Schon et al., 2002). ATM also phosphorylates Mdm2 and 
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Mdmx and destabilises them, further enhancing p53 activity (Meulmeester et al., 2005). 
As the cell cycle needs to be stalled in order to repair DNA damage, the two distinct 
phases in which cell cycle arrest occurs also determine which type of DNA repair takes 
place. The error-prone Non-homologous end joining (NHEJ) repair occurs in the G0/G1 
phase when non-replication DSBs occur while homologous recombination can only 
occur in S/G2phase (Bekker-Jensen and Mailand, 2010).  
Two other well characterised ATM substrates are the histone family member X 
(H2AX), which is phosphorylated on Ser-139 (when it is termed 
 γ-H2AX) and Structural Maintainence of Chromosome-1 (SMC-1), which is 
phosphorylated on Ser-966 (Fernandez-Capetillo et al., 2004, Kitagawa et al., 2004). 
ATM phosphorylates SMC-1 on two sites, Ser-957 and Ser-966 and these 
phosphorylation events have been shown to be necessary for S phase arrest in cells 
(Kitagawa et al., 2004). Antibodies against these phosphorylated ATM substrates have 
been used in the experiments detailed in this chapter as markers of ATM activation. 
 
3.1.4 Etoposide causes double stranded DNA breaks 
 
Etoposide (VP-16) is a potent anti-cancer drug used as a chemotherapeutic agent in 
cancers of the lung (Mascaux et al., 2000), testes (Loehrer, 2006), ovaries (Bruzzone et 
al., 2011), lymphoma  (Bauer et al., 2011) and glioblastoma multiformae (Francesconi 
et al., 2010). It is a topoisomerase II (Top II) inhibitor derived from 40-
demethylepipodophyllin benzylidene glucoside, a naturally occurring compound found 
in the Podophyllum plant root. Topoisomerase II is an enzyme that mediates transient 
double strand breaks in DNA, which allows the helix to unwind before replication. The 
same enzyme is also involved in the re-ligation of the disrupted DNA double strand. 
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Etoposide binds to topoisomerase II and stabilises the Topoisomerase II-DNA complex, 
preventing re-ligation of the broken DNA strands and thus increases the steady state 
concentration of double stranded DNA breaks (Hande, 1998, Montecucco and 
Biamonti, 2007). Although etoposide has been in clinical use for over twenty years, and 
its action on topoisomerase II delineated over thirty years ago, the cellular responses to 
etoposide remain poorly understood.  
 
3.1.5 Activation of AMPK by DNA damage: Relationship between 
ATM and AMPK 
 
ATM and ATR have been shown to phosphorylate LKB1 on its C-terminal tail on Thr-
366 in cell free assay. Also, HeLa cells stably expressing wild type LKB1 and treated 
with ionising radiation, showed increased nuclear signal when stained with anti-
phosphoThr-366 antibody compared to untreated cells. This nuclear localisation  was 
lost in the cells expressing non-phosphorylatable alanine mutant (T366A) (Sapkota et 
al., 2002b). Etoposide has also been reported to activate AMPK, involving  
phosphorylation at Thr-172 within the activation loop (Fu, 2008). These authors 
reported that reduction in ATM levels by siRNA- mediated silencing reduced AMPK 
activation following etoposide treatment in HeLa cells, suggesting that the effect 
involves ATM. This is an interesting observation, as HeLa cells lack LKB1 and 
therefore this effect cannot have been mediated by phosphorylation of Thr-172 on 
AMPK by LKB1. Moreover the first paper (Sapkota et al., 2002b) was published before 
LKB1 had been identified as the main upstream kinase for AMPK and therefore the role 
of ATM-mediated LKB1 phosphorylation on activation of AMPK activity was not 
tested.  
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ATM is also activated by oxidative stress. ATM in the cytoplasm is activated by 
reactive oxygen species (ROS) and this leads to an LKB1-dependent activation of 
AMPK, and subsequent repression of the mTOR pathway via phosphorylation of TSC2 
(Alexander et al., 2010). This activation of ATM is distinct from that caused by ionising 
radiation-induced DSBs, which occur in the nucleus and where activated ATM forms 
monomers. Activation of ATM in the cytoplasm by oxidative stress involves the 
formation of disulphide-linked dimers (Guo et al., 2010). The catalytic α subunits of 
AMPK lack the S/Q or T/Q motif required for ATM phosphorylation (Matsuoka et al., 
2007), so the mechanism underlying etoposide induced AMPK activation remained 
unclear. The role of LKB1 in this process was also not defined. The role of AMPK 
activation in the overall cellular response to etoposide had also not been studied, apart 
from the observation that NRF-1 transcription in response to etoposide may be 
regulated by AMPK in an ATM-dependent manner (Fu, 2008). 
Finally, large scale genome wide association studies have linked ATM with 
AMPK. Single nucleotide polymorphisms in a region of linkage disequilibrium 
containing the ATM locus are associated with an enhanced response to metformin 
(Pearson, 2011).  
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3.2 AIMS 
  
The main aim of the chapter was to delineate the mechanism by which AMPK was 
activated following double strand breaks, clarify the relationship between ATM and 
AMPK and to examine if C-terminal phosphorylation of LKB1on Thr-366 by ATM was 
involved in regulating AMPK activity. Intact cells were treated with etoposide and 
endogenous AMPK was immunoprecipitated from the lysate and effects on its function 
examined. Western blotting was used to look for activation of ATM substrates as well 
as phosphorylation of Thr-172 on AMPK. Immunofluorescence microscopy was 
performed to detect subcellular localisation of activated ATM and AMPK. 
 The second aim of this chapter was to see if AMPK activation affected the 
cellular response to DNA damage. Clonogenic cell survival assays were utilised to 
examine whether activating AMPK using agents such as A-769662 and the calcium 
ionophore A23187 prior to DNA damage by etoposide, affected cell survival.  Changes 
in the cell cycle in response to these treatments were also examined. 
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3.3 RESULTS 
3.3.1 Etoposide activates AMPK in an LKB1-independent manner 
 
Recent evidence suggests that etoposide activates AMPK and this causes increased 
mitochondrial biogenesis (Fu, 2008). In order to assess the mechanism behind this 
activation, several cell lines, namely HEK 293, H4IIe, HeLa, Mouse embryonic 
fibroblasts and G361 melanoma cells were treated with control (DMSO) or increasing 
concentrations of etoposide for varying lengths of time from one hour to 24 hours. HEK 
293 cells and H4IIe cells failed to activate AMPK in response to etoposide (data not 
shown). However, HeLa cells (Figure 3.2 A) and G361 cells (Figure 3.3.B), both of 
which lack LKB1, showed a two- to three-fold increase in AMPK activity on 
immunoprecipitation kinase assays when treated with 30 µM etoposide for 18 hours, 
which is a concentration similar to that achieved by therapeutic oral or intravenous 
dosing in humans. This increase in AMPK activity was associated with an increase in 
phosphorylation of AMPK at Thr-172 detected by western blotting (Figure 3.2.B). It is 
important to note that these cells have very low basal AMPK activities as they lack 
LKB1, the main upstream kinase for AMPK. Interestingly, treatment of mouse 
embryonic fibroblasts, which have LKB1 with etoposide also resulted in a greater than 
two fold increase in AMPK (Figure 3.3 C and D).  
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         Figure 3.2: Etoposide activates AMPK  
(A) HeLa cells were treated with increasing concentrations of etoposide for 18 hours, 
Endogenous AMPK was immunoprecipitated from the cell lysate and AMPK activity 
measured using the AMARA peptide substrate. Results shown are mean ± SEM 
(n=3, each replicate was a mean of two individual values of duplicate assay 
samples) and are representative of three independent experiments. 
(B) Cell lysates from HeLa cells were subject to Western blotting with anti- AMPK-α1 
and -α2 and anti- pT172 antibodies. Anti- pSMC-1 and γ- H2AX antibodies were 
used as markers of ATM activation. . 
A. 
B. 
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Figure 3.3: Etoposide activates AMPK independently of LKB1 
Three different cell lines were treated with etoposide and endogenous AMPK was 
immunoprecipitated from the cell lysates and AMPK activity measured using the AMARA 
peptide substrate. The dose of etoposide and the duration of treatment used were different in 
different cell lines as some cell lines such as MEFs were very sensitive to the dose used and 
prolonged treatment caused cell death. Results shown are mean ± SEM (n=3) and are 
representative of three independent experiments. Student t-test was used to measure 
significance (p<0.01-**, p<.0001-***).  
(A) HeLa cells (which lack LKB1) were treated with 30 μM etoposide for 18 hours 
(B) G361 cells (which also lack LKB1) were treated with 30 μM etoposide for 18 hours 
(C) MEF cells (which have LKB1) were treated with 20 μM etoposide for 2 hours  
(D) Cell lysates from MEFs were subject to Western blotting with anti- AMPK-α1 and -α2 
and with anti-pT-172 antibodies. Actin was used as a loading control.  
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In order to determine if AMPK activation by etoposide was isoform-specific, lysates 
subjected to western blotting were immunoblotted with pT-172, followed by infra-red 
secondary antibody read at 680nM (shown in red in Figure 3.4) and either anti-α1 or 
anti-α2 antibodies, followed by infra-red secondary antibody read at 800nM (shown in 
green in Figure 3.4) on the Li-Cor Odyssey imaging system . When treated with 
etoposide, HeLa cells showed activation of the α1 isoform of AMPK, as evidenced by 
colocalisation of the red and green fluorescence, which appeared as a yellow signal in 
the blots stained with anti-pT-172 and anti-AMPK-α1. In contrast, two separate bands 
were seen in the blots stained with anti-pT-172 and anti-AMPK-α2. This result shows 
that the activated AMPK was entirely AMPK-α1, with no activation of AMPK-α2. 
 
Figure 3.4: Etoposide treatment activates AMPK-α1 but not -α2 
Cell lysates from HeLa cells treated with vehicle (DMSO) or etoposide were subject to Western 
blotting with anti- AMPK-α1 and -α2 and anti- pT172 antibodies. The Li-Cor Odyssey system 
was used for  dual immunoblotting , with anti-pT172 antibody coupled to a Infra-red secondary 
antibody (read at 680nM and seen in red) and the anti- AMPK-α1 and -α2 antibodies were 
coupled to a second Infra-red secondary antibody (read at 800nM and seen in green). The top 
panel shows colocalisation of the anti-pT172 signal with anti- AMPK-α1 (seen as a yellow 
signal) and increased phosphorylation in the etoposide treated lanes (seen as brighter bands), 
while the bottom panel shows two distinct non-overlapping red and green bands of anti-pT172 
and anti- AMPK-α2. This suggests that the α1 isoform of AMPK is selectively phosphorylated 
following etoposide treatment. 
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3.3.2. Etoposide activates AMPK in a CaMKK-β−dependent 
manner  
 
3.3.2.1 The CaMKK inhibitor STO-609 abolishes etoposide-induced AMPK 
activation 
 As LKB1 was not required for AMPK activation in response to etoposide, we 
examined whether CaMKKβ, the alternative upstream kinase for AMPK was involved. 
We used both STO-609, a pharmacological inhibitor of CaMKK-α and CaMKK-β and 
siRNA- mediated knock down of CaMKK-β before treatment with etoposide to see 
whether AMPK activation was affected when CaMKK activity was inhibited. 
Immunoprecipitate kinase assays for AMPK activity were performed on the cell lysates 
which showed that inhibition of CaMKK-β by STO-609 significantly reduced 
etoposide-induced AMPK activation in HeLa cells (Figure 3.5.A) suggesting that 
AMPK activation in response to etoposide is dependent on CaMKK. However, as the 
fold change between STO-609 treated cells and cells treated with STO-609 and 
etoposide was almost the same as cells treated with vehicle and etoposide, it may be 
possible that another kinase may also be involved. Western blotting was also performed 
on the lysates. Following etoposide treatment, phosphorylation of SMC-1 (structural 
maintainence of chromosome-1) on Ser -966, which is mediated by ATM was detected 
using a phospho-specific antibody with no change in total SMC-1 confirming that ATM 
was activated.   Western blotting also showed that phosphorylation of AMPK on Thr-
172 in response to etoposide treatment was abolished by pre-treatment with STO-609, 
despite increase in pSMC-1 following etoposide treatment in cells treated with both 
STO-609 and etoposide (Figure 3.5.B). Interestingly, etoposide treatment did not cause 
an increase in phosphorylation of ACC on Ser-79, a known downstream target of 
AMPK, despite the increase in activity and Thr-172 phosphorylation on AMPK. 
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Phosphorylation of ACC, which was not increased by AMPK activation with etoposide, 
was also not affected by treatment with STO-609.  
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Figure 3.5: Etoposide activates AMPK in a CaMKK– dependent manner 
HeLa Cells were treated with 30 μM etoposide for 18 hours with or without 1 hour pre-
treatment with 25 µM STO-609.  
(A) Endogenous AMPK was immunoprecipitated from the cell lysate and AMPK activity 
measured using the AMARA peptide substrate. Results shown are mean ± SEM (n=3) and 
are representative of three independent experiments done in triplicate. (p<0.01-**, 
p<.0001-***).  
(B) Cell lysates from HeLa cells were subject to Western blotting with anti- AMPK-α1 and -α2, 
anti-pT-172 antibodies, anti- pSMC-1and anti-SMC-1, Anti-pACC and biotinylated total ACC 
was detected with Streptavidin. 
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3.3.2.2 siRNA- mediated Knock down of CaMKK-β also abolishes 
etoposide- induced AMPK activation 
siRNA-mediated knockdown was carried out in HeLa cells as a second approach 
to see whether reducing levels of CaMKK-β resulted in a loss of AMPK activation by 
etoposide. Scrambled negative control siRNA and CaMKK-β-specific siRNAs were 
reverse transfected into HeLa cells 24 hours before treatment with vehicle or etoposide. 
The Ca
2+
 ionophore A23187 was used as a positive control in these experiments. A 70% 
knock-down of endogenous CaMKK-β was achieved by this process (Figure 3.6.B). As 
expected, knock down of CaMKK-β resulted in a marked decrease in Thr-172 
phosphorylation on AMPK on western blotting following treatment with A23187 
(Figure 3.6.A) and this was confirmed by a marked reduction in the AMPK in 
immunoprecipitate kinase assays (Figure 3.6.C). Also, the fold change difference 
between vehicle and A23187 treated cells in the scrambled and siRNA knock-down 
cells was different with a lower degree of fold-change in the siRNA treated cells. Knock 
down of CaMKK-β completely abolished etoposide-induced AMPK activation on 
immunoprecipitate kinase assays (Figure 3.7.A) and also abolished Thr-172 
phosphorylation on AMPK on western blotting (Figure 3.7.B), confirming that 
CaMKK-β was the main upstream kinase phosphorylating AMPK in response to 
etoposide-induced double strand breaks.  
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Figure 3.6: siRNA-mediated knock down of CaMKKβ reduces AMPK 
activation following treatment with A23187 
siRNA-mediated knock-down of CaMKKβ was performed in HeLa cells by reverse transfection 
24 hours before treatment with 10 μM A23187 for 1 hour 
(A) Cell lysates were subject to Western blotting with anti- CaMKKβ, anti-pT-172, anti- 
AMPK-α1, -α2 and anti- pACC. Total ACC is a biotin enzyme and was detected by 
streptavidin. GAPDH was used as a loading control.  
(B) The extent of knockdown of CaMKK is represented as the ratio of signal intensity of 
CaMKKβ to the signal intensity of GAPDH between the replicates treated with negative 
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control siRNA and the CaMKKβ- specific siRNA (n=4). 80% knockdown of CaMKKβ was 
achieved using this construct when measured against GAPDH signal intensity 
(C) Immunoprecipitate kinase assays were performed on the cell lysates and the data 
plotted as shown. Results shown are mean ± SEM (n=3) and are representative of two 
independent experiments. (p<.0001-***).   
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Figure 3.7: siRNA-mediated Knock down of CaMKKβ abolishes AMPK 
activation following treatment with etoposide 
siRNA-mediated knock-down of CaMKKβ was performed in HeLa cells by reverse transfection 
24 hours before treatment with 30 μM etoposide for 18 hrs 
(A) Immunoprecipitate kinase assays were performed on the cell lysates. Untransfected 
cells and cells transfected with negative control siRNA were used as controls. Results 
shown are mean ± SEM (n=3) and are representative of two independent experiments 
in triplicate (p<.0001-***). 
A. 
B. 
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(B) Cell lysates were immunoblotted with anti- CaMKKβ, anti-phospho Thr-172, anti- 
AMPK α1, α2, pSMC-1 and tSMC-1 to confirm knockdown of CaMKKβ and to confirm 
lack of AMPK activation. 
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3.3.3 ATM inhibition reduces but does not abolish AMPK 
activation 
 
The selective ATM inhibitor KU-55933 (Hickson et al., 2004)  was used to examine 
whether ATM was involved in etoposide- induced  AMPK activation. Whilst this 
inhibitor can inhibit other members of the PIKK family, at the doses that the treatments 
was carried out, it selectively inhibited only ATM (Hickson et al., 2004). Cells were 
pre-treated with 10 μM KU-55933 one hour before treatment with etoposide for 16 
hours. Pre-treatment with KU-55933 caused a 30% reduction in etoposide- induced 
AMPK activity (Fig 3.8A). Western blotting showed that although the KU-55933 
effectively inhibited ATM as evidenced by the marked reduction in phosphorylation of 
its substrate SMC-1 on Ser-966, there was only a very slight reduction in Thr-172 
phosphorylation in the KU-55933 pre-treated cells when compared to cells treated with 
etoposide alone (Fig 3.8 B). This suggests that ATM may not be involved in this 
process. siRNA- mediated knock-down of ATM expression also showed a similar 
effect, although only 50% reduction of ATM expression could be achieved by this 
process (data not shown). 
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Figure 3.8: The ATM inhibitor KU-55933 reduces but does not abolish 
etoposide–induced AMPK activation 
HeLa Cells were treated with 30 μM etoposide for 18 hours with or without 1hour pre-
treatment with 10 μM KU-55933. 
(A) Endogenous AMPK was immunoprecipitated from the cell lysate and AMPK activity 
measured using the AMARA peptide substrate. Results shown are mean ± SEM and are 
representative of three independent experiments done in triplicate (p<0.05-*, p<.001-
**).  
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(B) Cell lysates from HeLa cells were immunoblotted with anti- AMPK α1 and α2, 
anti-pT-172 antibodies, anti- phospho SMC-1 and anti-SMC-1. The ATM inhibitor 
abolishes pSMC-1 signal but does not affect the phosphorylation of AMPK.  
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3.3.4 Etoposide-induced AMPK activation occurs in the nucleus 
 
A surprising observation was that etoposide-induced activation of AMPK was not 
accompanied by a concomitant increase in its downstream substrate Acetyl CoA 
Carboxylase (ACC). ACC phosphorylation on Ser-79 is usually obvious when AMPK is 
activated and has been used as a marker for AMPK activation in several well published 
studies.  ACC is a cytoplasmic protein. This led us to consider whether AMPK was 
being selectively activated in the nucleus, which is the primary site of DNA damage. To 
examine this, immunofluorescence microscopy was used to localise the site of AMPK 
activation. HeLa cells were grown on coverslips in 6 well dishes, treated with etoposide, 
fixed and stained with phospho-specific antibodies against Thr-172 on AMPK and Ser-
1981 on ATM, the auto-phosphorylation site on ATM, which becomes phosphorylated 
in response to double strand DNA breaks. These were then probed with fluorescent 
secondary antibody and imaged. DAPI was used to stain the nucleus.  
 The specificity of the commercially available anti-pT-172 AMPK antibody for 
immunohistochemistry was tested using Wild type (WT) and AMPK-α1, -α2 Knock-out 
MEFs. The cells were treated with control or various AMPK activators such as A-
769662 (direct activator of AMPK), berberine and A23187 (Figure 3.9). WT MEFs 
showed increased signal following treatment with AMPK activators compared to the 
control (Figure 3.9), while the KO cells did not show any signal either in the control 
cells or the cells treated with AMPK activators (Figure 3.10). Thus the specificity of the 
antibody was validated. It was also interesting to note that A23187 caused an increase in 
nuclear signal for AMPK phosphorylated on Thr-172 in the WT MEFs compared to 
A-769662 which caused a diffuse, less intense increase in fluorescence. 
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 Once the anti-phosphoThr-172 AMPK antibody had been validated, we then 
performed the same staining on HeLa cells treated with control (DMSO) or etoposide. 
Cells were also stained for anti-phosphoSer-1981 on ATM to see whether AMPK was 
activated in the nucleus and if so, whether the pT-172 signal co-localised to sites of 
ATM activation.  Robust nuclear activation of AMPK was seen following etoposide 
treatment in G361 cells (Figure 3.11 A and B) and Hela cells (Figure 3.11 C and D) 
when stained with the anti pT-172 phospho antibody alone.  
 Double staining with anti-pT-172 AMPK antibody and anti-pS-1981 ATM 
antibody showed that while both kinases were activated in the nucleus, they co-localised 
only partially (Figure 3.12). Nuclear and cytoplasmic fractionation was performed to try 
and further confirm this observation by two different methods. As most of the protocols 
involve osmotic stress followed by disruption of cell membranes, the basal activity 
levels of AMPK were greatly elevated following fractionation and meaningful 
comparison could not be made between the nuclear and cytoplasmic pools of AMPK 
between the control and etoposide treated cells (data not shown). 
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Figure 3.11: Etoposide activates AMPK in the nucleus 
G361 cells and HeLa cells were grown on glass slides in 6 well dishes and treated with DMSO 
(control) or etoposide 30 µM for 18 hours. The slides were then fixed with 4% 
paraformaldehyde, non-specific antibody binding blocked with fish skin gelatine and immuno-
stained using the anti-pT-172 antibody and a FITC secondary antibody.  
(A) G361 cells treated with DMSO  
(B) G361 cells treated with etoposide  
(C) HeLa cells treated with DMSO  
(D) HeLa cells treated with etoposide.  
The slides are representative and the experiment with G361 cells was performed twice in 
triplicate while the experiment in HeLa cells was repeated four times in triplicate. 
A. 
D. C. 
B. 
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Figure 3.12: Activated AMPK partially co-localises with activated ATM in 
the nucleus 
HeLa cells were grown on glass slides in 6 well dishes and treated with DMSO (control) or 
etoposide 30 µM for 18 hours. The slides were then fixed with 4% paraformaldehyde, non-
specific antibody binding blocked with fish skin gelatine and immunostained using the anti-pT-
172 antibody and a FITC secondary antibody and also the anti-pS-1981 ATM antibody and a 
fluorescent red secondary antibody. DAPI was used as the nuclear control. The first 3 rows 
show cells stained with DAPI, pT172 and pATM respectively. The bottom left panel shows a 
merged picture) with all three channels while the bottom   right panel shows the green and red 
fluorescence merged.  
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3.3.5 Etoposide treatment leads to an increase in intra-nuclear 
calcium in HeLa cells 
  
The selective nuclear activation of AMPKα1 in response to etoposide was a new 
observation not reported previously with other agents. In order to explain the 
mechanism underlying this effect, nuclear calcium flux was measured using a pseudo 
ratiometric dye, Fluo-4AM. This dye binds calcium and increase in fluorescence 
intensity is used to measure increase in calcium within the cell (Gee et al., 2000). We 
observed an increase in nuclear calcium levels which was started around 3 hours and 
was maximal around 6-8 hours (Figure 3.13 A). This corresponds to when AMPK 
activation is first detected by immunoprecipitate kinase assays (Figure 3.13 B). This 
suggests that etoposide increases calcium ion concentration in the nucleus which then 
causes AMPK activation through activation of CaMKK-β. 
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Figure 3.13: Etoposide treatment causes an increase in calcium flux which 
correlates with AMPK activation. 
(A) HeLa cells were loaded with the pseudo-ratiometric calcium-sensitive dye, Fluo-4 AM 
and the response to etoposide was measured in live cells using confocal microscopy. 
The nuclear fluorescence was expressed as a ratio of fluorescence intensity at a given 
time against the fluorescence intensity at time 0. One-way ANOVA was used to 
determine statistical significance (p< 0.001-***). 
(B) In parallel with the live imaging, HeLa cells treated with etoposide were harvested at 
different time points and immunoprecipitate kinase assays were performed on the 
lysates. 
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3.3.6 Activation of AMPK by A23187 affects cell survival in 
response to etoposide 
  
In order to study the role of AMPK in genotoxic stress, clonogenic cell survival assays 
were carried out in MEF cells which were either WT for AMPK or lacked both AMPK 
α1 and α2. Cells grown in flasks were pre-treated with 300 nM calcium ionophore 
A23187. A lower concentration of A23187 was used as the total treatment duration was 
24 hours. Two hours after pre-treatment, increasing concentrations of etoposide was 
added to the flasks in duplicate and incubated the cells for 24 hours.  All flasks were 
trypsinised in the same volume of trypsin, the cells in the control flasks were counted 
and 5000 cells were seeded in triplicate into 10cm dishes. On the assumption that the 
agents had no effect, the other flasks would have the same number of cells. So the same 
volume of cells seeded in the control plates was aspirated from the trypsinised flasks 
and seeded into 10 cm dishes in triplicate. The assay was then performed as detailed in 
the methods section (2.2.25) and the results shown in Figure 3.14. WT MEFS had an 
IC50 of 39 nM etoposide while AMPK KO MEFs had an IC50 of 104nM (Figure 3.14 
B). When pre-treated with A23187, survival in WT MEFs showed a five- fold increase 
(Figure 3.14 C), while AMPK KO MEFs did not show any increase in cell survival 
(Figure 3.14 D). This effect of AMPK activation on cell survival was not observed 
when other AMPK activators such as A-769662 were used (data not shown). 
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Figure 3.14: A23187 increases cell survival following etoposide treatment 
by activation of AMPK 
Clonogenic cell survival assays were performed using wildtype (WT) and AMPKα1, α2 KO 
MEFS. The results were shown as a percentage of the number of colonies in the untreated 
controls. These results are representative of three experiments performed.   
(A) WT and AMPKα1, α2 KO MEFS were treated with increasing concentrations of 
etoposide ± 300nM A23187.     
(B) WT and AMPKα1, α2 KO MEFS were treated with increasing concentrations of 
etoposide.  
(C) WT MEFs show increased survival when pre-treated with A23187 (re-plotted from 
Figure A).                                      
(D) AMPKα1, α2 KO MEFS do not show increased survival when pre-treated with A23187 
(re-plotted from Figure A).  
A
. 
B. C. 
D. 
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3.3.7 A23187 increases cell survival by causing a cell cycle arrest 
  
The selective increase in cell survival in cells pre-treated with A23187 before etoposide 
treatment suggests that the Ca
2+/ CaMKKβ- AMPK pathway activation protects against 
genotoxic stress. We know that cells are most vulnerable to genotoxic agents in the S 
phase and that DSB repair requires the cell to undergo cell cycle arrest. Previous data 
from our lab has shown that overexpression of constitutively active CaMKK-β or 
treatment of HeLa and G361 cells with A23187 causes a G1 arrest (Fogarty 2008 PhD 
thesis). The possibility that AMPK activation modulates the cell cycle in order to favour 
cell survival was therefore tested in G361 cells. These cells were first synchronised in 
G0/G1 by starving the cells of serum and L-glutamine overnight and then released into 
complete media with either control, etoposide, A23187 or both agents. The results are 
summarised in Figure 3.15 A. Serum and L-glutamine starvation led to nearly 80% of 
cells being synchronised to G0/G1 phase. Cells released into complete media rapidly 
progressed through the cell cycle. Treatment with A23187 leads to arrest of the cell 
cycle in G0/G1. Etoposide caused S-phase cell cycle arrest, while by pre-treatment with 
A23187 prevented this, with the cells arresting in the G0/G1 phase. These cells also 
showed increase in survival following etoposide treatment when pre-treated with 
A23187 (Figure 3.15 B). Thus A23187 may protect cells from irreversible S phase 
arrest leading to cell death, and in turn leads to increased cell survival.  
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Figure3.15: A23187 causes a G1 cell cycle arrest and increases cell 
survival in G361 cells 
(A) G361 cells were synchronised in G0/G1 by serum and L-glutamine deprivation before 
being released into DMSO (control), A23187, etoposide or both. Cells were treated for 
18 hours. Cell cycle analysis was performed in triplicate and the results shown are 
representative of three different experiments. 
(B) G361 cells were pre-treated with DMSO (control) or 300 nM A23187 2 hours before 
treatment with increasing concentrations of etoposide. Clonogenic cell survival assays 
were performed in triplicate. The results are representative of three individual 
experiments  
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3.4 DISCUSSION  
 
Activation of AMPK in HeLa cells and G361 cells, which lack LKB1, demonstrates that 
etoposide-induced AMPK activation in these cells is an LKB1-independent process. 
This is consistent with the observations made by Fu et al that in HeLa cells, etoposide 
increases Thr-172 phosphorylation (Fu, 2008). Hela cells and G361 cells have very low 
basal AMPK activity as they lack the main upstream kinase LKB1.This may be the 
reason why a relatively modest increase in AMPK activation by etoposide was seen as a 
greater-fold change in HeLa cells and G361 cells. Also, HEK 293 cells and H4IIe cells 
have twenty times higher basal AMPK activity than HeLa cells and it is possible that 
this small increase in LKB1-independent AMPK activity caused by etoposide might 
have been missed in these cell lines . Interestingly, etoposide causes an increase in 
AMPK activity in mouse embryonic fibroblasts which have basal AMPK activity which 
is higher than that of HeLa cells, but is much lower than that of HEK 293 cells. Also the 
MEFs showed increased AMPK activity at a lower dose (20 µM) of etoposide than that 
required in HeLa cells (30 μM) and AMPK activation was apparent two hours after 
treatment compared to HeLa cells where the AMPK activation was measurable from 
around 6 hours after treatment. 
 CaMKK-β is the upstream kinase activating AMPK in HeLa cells (Hawley et 
al., 2005) and the requirement for CaMKK-β in increasing AMPK activity in response 
to etoposide was tested by two approaches, one involved pre-treatment of cells with the 
CaMKK inhibitor STO-609 and the second, silencing CaMKK-β expression using 
siRNA . Pharmacological inhibition of CaMKK-β by STO-609 causes a significant 
reduction in etoposide- induced AMPK activation. Knock-down of CaMKK-β by 
siRNA-mediated silencing completely abolishes AMPK-activation in response to 
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etoposide treatment. These results confirm that etoposide-induced AMPK activation is 
CaMKK-β-dependent.  
 The finding that phospho-ACC levels were not increased despite a two-three 
fold increase in AMPK activity was very interesting. ACC is a known substrate of 
AMPK, often used as a marker of AMPK activation. It is largely cytosolic in its 
localisation. DNA damage occurs in the nucleus and the mitochondria. 
Immunofluorescence microscopy was used to examine the subcellular localisation of 
AMPK. The anti-pT-172 antibody was first validated for immunocytochemistry using 
mouse embryonic fibroblasts expressing wild type AMPK and MEFs that lack 
AMPK-α1and -α2. Agents such as A-769662, a direct activator of AMPK caused a 
diffuse less intense fluorescence throughout the cytoplasm. The Ca
2+
 ionophore A23187 
caused a more intense nuclear staining in addition to cytoplasmic staining. Following 
etoposide treatment in Hela and G361 cells, AMPK appeared to be activated mainly in 
the nucleus. Attempts to fractionate nuclear AMPK from cells has so far proven 
difficult as these methods rely on osmotic stress, which in itself activates AMPK, 
making it hard to meaningfully compare cytosolic and nuclear activity of AMPK, 
especially with the modest increases seen in AMPK activation in the whole cell lysates 
of cells treated with etoposide.  
Fu et al have previously reported that etoposide-induced mitochondria 
biogenesis involved AMPK activation and that this process was ATM-dependent. 
However, the authors used siRNA mediated knock-down of ATM in HeLa cells to 
demonstrate loss of etoposide–induced AMPK activity. It is possible, that there might 
have been an off- target effect of the siRNA on either AMPK or CaMKK-β which may 
have caused this effect. While the authors of this paper had employed ATM+ and ATM- 
cells to look at mitochondrial biogenesis, AMPK activation in response to etoposide 
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was only seen in ATM+ cells. However, ATM- cells seemed to have several higher fold 
basal pT-172 signal on western blotting, which was not further increased by etoposide. 
Moreover, in the same paper, the authors have used AICAR and hydrogen peroxide to 
activate AMPK to demonstrate increased mitochondrial biogenesis and compound C, a 
rather non-specific inhibitor, which also inhibits AMPK, to show a reduction in ATM-
dependent mitochondrial biogenesis. AICAR is converted to ZMP, which is an AMP 
analogue within cells and activates AMPK. The results detailed in this chapter clearly 
show that etoposide-induced AMPK activation is CaMKK-β-dependent and 
accompanied by change in intra-nuclear calcium levels. 
Also, nuclear and cytoplasmic ATM activation may have different effects. The paper by 
Alexander et al suggests that ATM activation following oxidative stress induced by 
hydrogen peroxide, activates AMPK via an LKB1-dependent mechanism which is 
confined to the cytosol and is accompanied by increase in phospho-ACC (Alexander et 
al., 2010). The paper by Fu et al also showed that hydrogen peroxide treatment activated 
ATM and AMPK in HeLa cells and this was accompanied by increase in pACC levels. 
The immunohistochemistry data in this chapter clearly shows that etoposide-induced 
AMPK activation is limited to the nucleus and western blotting supports the nuclear 
localisation of activated AMPK by the lack of concomitant ACC phosphorylation. 
Moreover, activated AMPK did not co-localise completely with activated ATM. It has 
previously been shown that AMPK-α2 is the main nuclear isoform of AMPK (Salt et 
al., 1998). However, the data shows that only AMPK-α1 is activated by etoposide 
treatment. Western blotting shows no activation of AMPK-α2, although there is no 
detectable basal phosphorylation, either in the vehicle or etoposide treated cells. This 
was a very interesting result and is consistent with previous observations obtained with 
muscle-specific knockout (LKB1
fl/fl 
Cre
+/-
) mice, in which AMPK-α1activity in muscle 
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under basal and AICAR stimulated conditions was undiminished compared to the 
LKB1
fl/fl 
Cre
-/-
 controls (Sakamoto et al., 2005). In contrast, basal and AICAR-
stimulated AMPK-α2 activity was markedly reduced in muscle-specific LKB1 knockout 
compared to the LKB1
fl/fl
 Cre
-/-
 controls (Sakamoto et al., 2005).  
Also in HeLa cells, the selective ATM inhibitor KU-55933 inhibited ATM 
activation, as evidenced by a reduction in phosphoSMC-1 on Western blotting but did 
not significantly reduce etoposide-induced AMPK activation. Conversely, treatment 
with etoposide following CaMKK-β inhibition with STO-609 or reduction in CaMKK-β 
levels by siRNA-mediated silencing caused loss of AMPK phosphorylation despite 
increase in pSMC-1 levels. Thus, the data from this chapter suggests that DSB-induced 
nuclear AMPK activation is not dependent on ATM activation. This is further supported 
by the fact that neither CaMKK-β nor the catalytic α1 and α2 subunits of AMPK 
contain the SQ/TQ motif which is an absolute requirement for phosphorylation by ATM 
(Matsuoka et al., 2007). 
The results from this chapter show that activation of AMPK by the calcium 
ionophore A23187 increases cell survival in response to etoposide treatment. This effect 
of increased cell survival is AMPK-dependent as it is not seen in AMPK-KO MEFs.  It 
has previously been reported that activation of the CaMKKβ-AMPK pathway by the 
calcium ionophore A23187 causes a G1 cell cycle arrest in G361 cells (Fogarty 2008 
PhD thesis). In these cells, etoposide causes an S phase arrest. A23187 may therefore, 
protect cells from S phase arrest caused by etoposide. Moreover, arrest in G1 may allow 
for DNA repair by non-homologous end-joining to occur, thereby increasing cell 
survival. This mechanism of increased cell survival in response to DNA damaging 
drugs has been reported with pre-treatment with other cell cycle inhibitors, particularly 
CDK inhibitors such as flavopiridol, roscovitine and olomoucine (Cernak et al., 2005). 
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Flavopiridol and roscovitine cause a G1 arrest and increase cell survival in response to 
etoposide and doxorubicin (Di Giovanni et al., 2005, Crescenzi et al., 2005). The 
findings with A23187 suggest that activation of the CaMKKβ-AMPK pathway may 
enhance survival in tumour cells treated with etoposide. Conversely, it may be possible 
to selectively target tumour cells that have lost AMPK using drugs like etoposide and 
protect normal cells by using an AMPK activator. Given that metformin is now widely 
used in combination with chemotherapy which may involve DNA damaging drugs, 
further work in this area is warranted to ensure that beneficial effects alone are 
conferred to patients treated with these drugs.
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CHAPTER FOUR: AMPK IS A TUMOUR SUPPRESSOR IN A T 
CELL-SPECIFIC PTEN KNOCKOUT TUMOUR MODEL 
 
4.1 INTRODUCTION 
4.1.1 The adaptive immune system 
 
The immune system is composed of two main systems- the innate (or non-specific) and 
the adaptive (or specific) immune system. The adaptive immune system functions to 
prevent or eliminate growth of pathogens, including bacteria, viruses, fungi and 
parasites (Cooper and Alder, 2006). Elements of adaptive immunity are conserved 
throughout evolution; however, in jawed vertebrates and higher organisms, adaptive 
immunity is the cornerstone of the immune response (Danilova, 2012). The effectors of 
the adaptive immune response are highly specialised cells called lymphocytes, which 
have the ability to recognise and remember specific pathogens and to mount a stronger 
defence each time the pathogen is encountered. The two main types of lymphocyte are 
the T lymphocytes (T for thymus derived) and B lymphocytes (B for bursa or bone 
marrow derived), which effect cell-mediated and humoral immunity respectively. This 
introductory section focusses on the development, maturation and functions of T cells. 
 
4.1.2 The thymus and its organogenesis in mice 
 
The thymus is a bi-lobed organ located in the centre of the thoracic cavity in front of the 
heart and is the site of development of T cells(Osoba, 1966). The thymic anlage 
develops from the third pharyngeal pouch endoderm and surrounding neural crest cells 
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and lies adjacent to the developing parathyroid (Rodewald, 2008). At embryonic day 
11.5, the pouch endoderm separates into the parathyroid and thymus-fated domains by 
the mutually exclusive expression of two transcription factors, glial missing cells 
homolog 2 (gcm2) and forkhead box N1 (foxn1) (Ma et al., 2011 (epub ahead of print)). 
Around embryonic day 12, the thymus then undergoes differentiation, further separation 
from the parathyroid, it changes in morphology and migrates caudally into the thorax 
(Gordon et al., 2010). Along with the morphological changes of the whole organ, the 
cells within the thymus also undergo a series of developmental stages. 
 
4.1.3 T cell development 
 
T cells develop from haematopoetic stem cells which undergo a process of maturation 
and differentiation within the thymus. The hallmark of the T cell is the expression of the 
T cell receptor (TCR) (Hernandez et al., 2010). In order for a thymocyte to mature into 
a T lymphocyte, it has to undergo a series of maturational steps that have been 
summarised in the next section (Figure 4.1).  
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Figure 4.1: T cell development and differentiation 
This schematic shows the development of T cells within the thymus from the double negative 
to the single positive stage. The immature thymocyte undergoes commitment to the T cell 
lineage, TCR rearrangement, and proliferation, positive and negative selection to form a single 
positive thymocyte. Adapted from  (Engel and Murre, 2001).  
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4.1.3.1 T cell lineage commitment 
Developing T cells in the thymus can be sub-divided into three main groups 
namely, double negative, double positive and single positive cells. T cell development 
begins with early thymocytes (also called thymic settling precursors), which enter the 
thymus from the bone marrow at the double negative (DN) stage (the term double 
negative indicates that the cells lack CD4 or CD8 receptors). The DN cells can be 
further sub-divided into 4 subsets, namely DN1, DN2, DN3 and DN4, based on the 
expression of CD117 (c-kit), CD44 and CD25 receptors (Godfrey et al., 1993). DN1 
cells (CD117
+
, CD44
+
 and CD25
-
) are not committed T cell precursors and can develop 
into other types of thymus-derived cells, such as B, T, dendritic and natural killer cells 
(Carlyle et al., 1997). Transition to DN2 occurs when cells start to express CD25 (DN2 
cells are CD117
+
, CD44
+
 and CD25
+
). The DN2 cells can give rise to T, dendritic and 
NK cells but lose the ability to give rise to B cells. Notch signalling is required for 
commitment of progenitor cells to the T cell lineage. Deletion of Notch1 leads to failure 
of T cell development with an accumulation of B cells (Radtke et al., 1999). Transition 
from the DN1 to DN2 stage is also accompanied by a series of events leading to a 
diverse TCR repertoire by V(D)J recombination of the four TCR receptor genes Tcra, 
Tcrb, Tcrg and Tcrd (Hernandez et al., 2010).  
 
4.1.3.2. TCR rearrangement 
V(D)J recombination is directed by RAG1 and RAG2 (recombination activating 
genes-1 and -2), which are lymphoid-specific recombinases that create double strand 
breaks at recombinant signal sequences (RSs) flanking the variable (V), diversity (D) 
and joining (J) segments of the TCR gene. These breaks are then repaired by non-
109 
 
 
 
homologous end joining during which, the coding ends undergo nucleotide insertion or 
deletion and the joining segments sometimes undergo inversion (Bassing et al., 2002).  
This process leads to a large number of different TCR chains with the ability to 
recognise a huge variety of antigens. Recombination of Tcrb, Tcrg and Tcrd occur in 
the DN2 and DN3 (CD44
- 
CD25
+
)  stages (Krangel, 2009). Recombination of Tcrg and 
Tcrd results in expression of γδ TCR. Recombination of Tcrb with pre-Tα leads to 
assembly of pre-TCR; this recombination is a pre-requisite for progression to the DN4 
stage (CD44
- 
CD25
-). When the β-chain is unable to pair with a pre-Tα chain, the cells 
die; this process termed β-selection. Following β-selection, pre-TCR and Notch signals 
cause down-regulation of recombinase expression followed by proliferation and 
differentiation of thymocytes to the CD4
+
CD8
+
 double positive (DP) stage (Maillard et 
al., 2006, Ciofani and Zúñiga-Pflücker, 2007). Signalling via the pre-TCR requires γ, ε, 
and ζ chains of the CD3 complex and the Lck kinase (Von Boehmer et al., 1999). 
 
4.1.3.3 Positive selection 
Positive selection is initiated by TCR α-chain re-arrangement. This process 
generates unique α-chains that pair up with the rearranged β-chain expressed on the cell 
surface of a developing double positive cell. The re-arrangement of TCR-α chains 
continues even after formation of an αβ heterodimer, thus ensuring that the same cell 
expresses different α chains bound to the same β-chain, causing the expression of a 
variety of αβ heterodimers on its surface (Borgulya et al., 1992). Formation of an 
effective αβ heterodimer requires both the formation of a cell surface complex of the 
two chains and the ability to recognise MHC-self antigen complexes presented by the 
thymic epithelial cells, a process termed positive selection. The vast majority of 
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thymocytes that do not undergo positive selection die by neglect (almost 95%), while 
those that do, stop further TCR α-chain re-arrangement by down-regulation of RAG-1 
and RAG-2, developing into single positive (SP) cells (Borgulya et al., 1992). Two 
models have been proposed for the development of single positive cells. The stochastic 
model proposes that DP cells randomly commit to either CD4 or CD8 lineage, whereas, 
the instructive model proposes that cells that express TCR with specificity for the Class 
I MHC are biased towards developing into CD8
+ 
T cells while those with specificity for 
the Class II MHC are biased towards developing into CD4
+
 cells (Boehmer, 1986).  
 
4.1.3.4 Negative selection 
While positive selection ensures that the TCR is likely to recognise antigens 
presented on MHC, negative selection (also known as clonal deletion) is essential to 
prevent autoimmunity and eliminate self-reactive cells (Sant'angelo and Janeway, 
2002). During negative selection, thymocytes migrate to the medulla where they come 
into contact with medullary dendritic cells. Cells which express high avidity self- 
reacting TCR against self- antigen interact with the self-antigen−self-MHC complex on 
the dendritic cells (Sant'angelo and Janeway, 2002). This slows their migration, 
allowing them to make prolonged contact with the DCs, after which they undergo 
apoptosis (Le Borgne et al., 2009). Some self-reactive T cells escape negative selection 
and undergo peripheral functional inactivation, a process also termed anergy 
(Pacholczyk and Kern, 2008). Single positive cells that have survived negative selection 
exit the thymus and await activation. Emigration requires recognition of the lipid 
molecule sphingosine-1-phosphate (S1P) by the G-protein coupled receptor SIP1, which 
is expressed by the thymocytes in the final maturational stage. Blood and lymph have 
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high levels of SIP, drawing the lymphocytes expressing SIP1 away from the thymus 
(Murphy, 2012). Mature thymocytes also express CD62L (L-selectin), a lymph node 
homing receptor that facilitates movement of mature naïve T cells to lymphoid organs 
(Murphy, 2012).  These recent thymic emigrants (RTEs) are still immature compared to 
their more mature, yet naïve peripheral counterparts and further  maturation of T cells 
occurs in the peripheral tissues (Fink and Hendricks, 2011).  
 
4.1.4 T cell activation 
 
T cells exit the thymus via the medullary vessels and circulate in the blood and 
lymphatics. In the spleen and lymph nodes, they come into contact with antigen 
presenting cells (APC) bearing processed foreign antigens as small peptides in the 
groove between the α1-α2 domains of the MHC Class I and α1-β1 domains of MHC 
Class II complexes (Greer John P et al., 2004). The αβ-TCR:CD3 complex recognises 
these short peptides on the MHC and this interaction of the TCR-MHC is accompanied 
by other interactions which strengthen adhesion, for example, the integrin LFA-1 
(leukocyte function antigen 1) binds ICAM-1 (intercellular adhesion molecule 1) on the 
APC. Co-stimulatory interactions occur between CD28 on T cells and B7 on APC. This 
interaction between the two cells, primarily the TCR:MHC, initiates signal transduction 
and transcription of genes encoding cytokines in CD4
+
 T cells and components of 
cellular lysis in CD8
+
 T cells (Guy and Vignali, 2009). 
Naïve T cells are small cells with scanty cytoplasm and synthesise little RNA or 
protein. On activation, they re-enter the cell cycle and divide rapidly into progeny that 
then differentiate into different subsets of effector cells. Activated T cells produce IL-2, 
which further stimulates their proliferation and differentiation (Murphy, 2012). T cells 
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are activated by three signals which lead to their clonal expansion and differentiation. 
The first signal is TCR:MHC binding, which activates the naïve T cell (Murphy, 2012). 
The second involves co-stimulatory signals, such as interaction of CD28 and CD80 and 
this promotes survival and clonal expansion of T cells (Jones and Thompson, 2007). 
The third signal is involved in directing T cell differentiation into subsets of effector T 
cells and involves the release of cytokines and growth factors by the APC.  
The TCR relies on accessory proteins, such as CD3-γ,-ε,-δ and TCRζ. TCR 
initiates signalling by recruiting and activating protein tyrosine kinases (PTKs) of the 
Src, Syk and Tec families (Cantrell, 2002). The Src family PTK, Lck, phosphorylates 
the immunoreceptor tyrosine-based activation motifs (ITAM) on CD3, allowing ZAP-
70 a Syk family PTK to bind to ITAMs via its SH2 (Src homology-2) domain. ITAM 
bound to ZAP-70 is then tyrosine phosphorylated by Lck, leading to its activation and 
subsequent phosphorylation of its downstream targets, SLP-76 (SH2 domain containing 
leukocyte protein of 76 KDa) and LAT (Linker for activation of T-cells). The tyrosine 
phosphatase CD45 antagonises TCR signalling (Cantrell, 2002). However, once TCR 
has bound to MHC, the large extracellular domain of CD45 excludes it from the 
proximity of the TCR:MHC complex. 
SLP-76 and LAT function as scaffolds that assist the recruitment of additional 
PTK and scaffold proteins (Figure 4.2). Tyrosine phosphorylated motifs in the C-
terminal tail of LAT bind to Grb2 (Growth factor receptor-bound protein 2) and its 
close relative Gads (Grb2-related adaptor downstream of SHc) (Zhang et al., 1998). 
This interaction recruits and localises Grb2-associated proteins such as SOS (named 
after Drosophila ‘son of sevenless’ protein) which functions as a guanine nucleotide 
exchange protein (GEF) for Ras. Tyrosine-phosphorylated LAT also interacts with the 
SH2 domain of phospholipase Cγ1 (PLCγ1), recruiting it to the plasma membrane 
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(Cantrell, 2002). TCR activation of PLCγ1 causes hydrolysis of phosphatidylinositol (4, 
5) -bisphosphate [PtdIns (4,5) P2] and the production of inositol 1, 4, 5- trisphosphate 
which leads to release of intracellular calcium. PtdIns (4,5) P2 breakdown generates the 
second messenger diacyl glycerol (DAG), which binds to specific domains of signalling 
proteins such as protein the kinase C family, protein kinase D and the Ras-GEF, GRP 
(Cantrell, 2002). 
SLP-76 also binds to LAT via adapters such as Gads and Grf40 (Liu et al., 
1999). SLP-76 has its own SH2 domain and helps recruit the protein Vav to the antigen-
receptor complex. Vav proteins serve as GEFs for Rac1, Rac2 and RhoG in T cells, and 
also function as scaffolding proteins which contain SH2 and SH3 domains and undergo 
tyrosine phosphorylation following TCR activation (Tybulewicz, 2005). Vav1, one of 
three Vav isoforms, is essential for T cell development. Peripheral CD8
+
 cells that lack 
Vav1 show no proliferation following antigen-receptor stimulation (Penninger et al., 
1999, Gulbranson-Judge et al., 1999). SLP-76-mediated recruitment of proteins such as 
WASp (Wiskott- Aldrich Syndrome protein) via the adaptor Nck helps drive actin 
cytoskeletal rearrangement following TCR activation, leading to polarisation of the T 
cell towards the APC following the formation of the immunological synapse 
(Tybulewicz, 2005).  
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Figure 4.2: Signalling pathways downstream of TCR 
This schematic shows the main downstream signalling events which occur following T cell 
activation. The αβTCR pairs with CD3 accessory chains and TCRζ which contain ITAM motifs. 
Lck phosphorylates the ITAM motifs which recruits ZAP-70. Once phosphorylated by Lck, ZAP-
70 phosphorylates LAT and the SLP-76 complex. SLP-76 and ZAP-70 recruit and activate 
signalling molecules, leading to the activation of several pathways, including MAPK signalling, 
PtdIns (3, 4, 5) P3 signalling, calcium signalling and actin reorganisation. Adapted from 
(Mustelin and Taskén, 2003) 
 
 
  
115 
 
 
 
4.1.5. T cell sub-populations 
 
Activation of the T cell response leads to the generation of effector and memory T cells. 
Several different subsets of effector T cells exist, each playing different roles in the 
immune system. Some of them are listed below. Apart from the γδ T cells, all other 
subsets express αβ TCR. 
 
4.1.5.1 CD8+ cytotoxic T cells 
Naïve CD8
+
 T cells differentiate into CD8 cytotoxic T lymphocytes which kill 
their target cells, especially those that have been infected by viruses. Virus-infected 
cells display viral peptide on MHC Class I complexes, which are recognised by the 
CD8
+ 
T cells, triggering their proliferation into cytotoxic T lymphocytes (CTLs). 
Perhaps due to their destructive nature, naïve CD8 T cells require more co-stimulation 
to drive them to become activated CTLs than naïve CD4 T cells (Murphy, 2012). In 
some viral infections, mature dendritic cells, which have high intrinsic co-stimulatory 
activity, become activated and are sufficient to induce CD8 T cells to produce IL-2. 
However, in most cases, CD8 T cell activation requires additional signals provided by 
CD4 effector T cells (Zhai et al., 2007). Apart from viral infections, CTLs also play an 
important role in the response to intracellular bacterial pathogens. Mice that do not 
express Class I MHC and are unable to develop functional CD8
+ 
T cells, die rapidly 
when infected with Mycobacterium tuberculosis (Flynn et al., 1992).  
 The main mechanism of cytotoxicity of CTLs is calcium-dependent release of 
cytotoxic granules. These granules contain cytotoxic proteins such as perforin, which 
creates pores in the target cell membrane, serine proteases called granzymes that 
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activate caspases and granulysin, which in turn, induces apoptosis of target cells 
(Murphy, 2012). 
 
4.1.5.2 CD4+ T helper cells 
CD4
+  
T cells differentiate into several different subsets of effector T cells with 
different functions. The main classes are TH1, TH2, TH17 and the regulatory T cells as 
well as TFH cells, which help B cells in lymphoid follicles. 
 TH1, TH2, TH17 T helper cells are defined on the basis of the cytokines they 
secrete. TH1 cells help macrophages kill intra-vesicular pathogens such as M. 
tuberculosis. TH1and TH2, as the names suggest, were the first two subsets to be 
identified. TH1 cells, when activated, secrete interferon-γ (IFN-γ), IL-2, TNF-α and 
TNF-β (Mosmann et al., 1986). TH2 cells help control infections by parasites, 
particularly helminths, and release IL-4, IL-5, IL-6, IL-13 and IL-25 following 
activation (Murphy, 2012). TH17 cells were the third subset to be identified; they act to 
boost fungal defences and produce IL-17 (Harrington et al., 2005). T cell differentiation 
towards individual subsets is driven by the cytokines released into the environment of 
the naïve CD4
+ 
T cells. IL-12 released from DCs or macrophages favours TH1formation. 
IL-4 induces TH2 formation (Murphy and Reiner, 2002). IL-6 and TGF-β promote TH17 
formation. IL-6 stimulation is required for TFH cells, although the conditions required 
for their in vitro production have not yet been defined.  
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4.1.5.3 CD4+ Treg cells 
Regulatory T cells (Tregs) are a subset of CD4
+
 T cells which are involved in 
immune suppression and the prevention of unwanted immune responses. Tregs are 
CD4
+
 cells that highly express the IL-2 receptor α-chain, CD25. When CD25+ cells 
were depleted from the CD4
+
 cells and injected into lymphopenic mice, they developed 
autoimmune disease (Sakaguchi et al., 1995). Further evidence that Tregs were an 
independent population came with the identification of FoxP3 (also known as scurfin), a 
transcription factor which was highly expressed specifically in Tregs, and which 
regulated Treg function (Khattri et al., 2003). Mice deficient in FoxP3 develop 
progressive CD4
+
- mediated autoimmunity. Tregs can be classified into two groups: 
natural Tregs (nTreg), which arise in the thymus and inducible Tregs (iTreg), which 
arise in the periphery.  
 
4.1.5.4 NK T cells 
NK T cells are characterised by the expression of an invariant T cell receptor α 
chain paired with one of three β chains. They share some markers expressed by NK 
cells such as CD161 (Godfrey and Kronenberg, 2004). They can recognise glycolipid 
antigens presented to them by the MHC-like molecule CD1 (Murphy, 2012). Following 
TCR stimulation they release IFN-γ, IL-4 and IL-13 and function as suppressors of the 
cell-mediated immune response (Godfrey and Kronenberg, 2004). 
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4.1.5.5 CD4- CB8- γδ T cells 
γδ T cells, as the name suggests, bear an alternate TCR made up of γ and δ 
chains. γδ-TCR do not appear to be restricted to classical MHC Class I or II molecules. 
They appear to bind free antigens, such as bacterial heat shock protein, as well as 
antigens presented by non-classical MHC-like molecules (Murphy, 2012). They have 
been shown to play a role in the response to microbial infections such as M. tuberculosis 
and M.avium and in co-infection with HIV (Chen and Letvin, 2003).  
 
4.1.6. PI3K and PTEN in T cells 
 
Phosphatidylinositol 3-kinase (PI3K) enzymes are lipid kinases that phosphorylate the 
3’ position of the inositol ring of phosphoinositides, resulting in the production of three 
lipid products, namely phosphatidylinositol (3)- monophosphate (PIP), 
phosphatidylinositol (3,4)-bisphosphate (PIP2) and phosphatidylinositol (3,4,5)- 
trisphosphate (PIP3) (Cantrell, 2001). Increases in PIP3 levels within cells lead to the 
recruitment and activation of several pleckstrin homology (PH) domain containing 
proteins such as Akt, Tec, Vav, phospholipase Cγ1 and PDK1 (phosphoinositide-
dependent kinase 1) (Buckler et al., 2008).  
PI3Ks can be grouped into three main classes based on in-vitro substrate 
specificity, structure and mode of regulation (Curnock et al., 2002). Class IA PI3Ks can 
phosphorylate phosphatidylinositol (PtdIns), PtdIns (4) P and PtdIns (4,5) P2. They are 
heterodimers consisting of a 110 KDa catalytic subunit (of which there are three 
isoforms, p110α, p110β and p110δ) and an 85 KDa regulatory subunit (p85α, p85β and 
p55γ).  Class IB PI3Ks associate with a unique p101 adaptor molecule, and are activated 
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by G protein βγ subunits. Class II PI3Ks (PI3K-C2α/β/γ) contain a C2 domain, and 
PtdIns and PtdIns(4)P are their main substrates (Curnock et al., 2002), while class III 
PI3Ks only phosphorylate PtdIns. Class IA and IB are the only classes that generate 
PIP3, and are the best studied class in immune cells (Buckler et al., 2008).  T cell 
activation is accompanied by a rapid increase in PIP3 levels in the region of the 
immunological synapse. PI3K may be coupled to the TCR signals through p85 and its 
interactions with adaptor molecules with the canonical YxxM motif , or signalling 
molecules containing non-canonical tyrosine phosphorylation motifs , such as ZAP-70 
and SLP-76 (Buckler et al., 2008). 
 PI3K is also activated downstream of CD28 co-stimulatory signals. CD28 has 
the YxxM motif on its cytoplasmic tail and when it is tyrosine-phosphorylated by Lck, 
provides a docking site for the SH2 domain of the p85 regulatory subunit of Class I 
PI3K, which then recruits the catalytic subunit to the membrane, leading to PI3K 
enzyme activity (Prasad et al., 1994).  
 Activation of PI3K pathways leads to activation of several downstream targets 
such as the Tec family of tyrosine kinases (comprising Itk, Tec and Btk), GTPases of 
the Rac and Rho families and serine/ threonine kinases of the AGC family (Ward and 
Cantrell, 2001). One of the key proteins of the AGC family that is activated by P13K is 
PDK1 (phosphoinositide dependent kinase-1), which binds to PIP3 via its PH domain. 
PDK1 phosphorylates and activates the downstream protein kinases PKB (Akt), p70 
S6kinase and p90RSK. PDK1 is required for normal T cell development (Kelly et al., 
2007); the PDK1-PKB signalling axis regulates protein synthesis, cell growth and cell 
cycle progression (Rathmell et al., 2003). 
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 The tumour suppressor PTEN is a 3’-PI phosphatase, which converts PIP3 to 
PtdIns (4,5) P2 and thus negatively regulates the PI3K signalling pathway. Cells lacking 
PTEN therefore have a constitutively active PI3K pathway. The importance of PTEN in 
T cell biology is demonstrated by studies showing that mice lacking PTEN in T cells 
develop lymphomas (Hagenbeek et al., 2004, Hagenbeek and Spits, 2007). These mice 
died at a median age of around 95 days (89-103 days)  (Hagenbeek et al., 2004). The 
tumours arose in the thymus, but most mice also had peripheral tissue (spleen and 
lymph node) involvement (Hagenbeek and Spits, 2007).  Most of the T cell-specific 
PTEN-null mice had larger thymi and contained significantly higher number of 
thymocytes compared to the control mice (Hagenbeek and Spits, 2007). These mice had 
similar distribution of cells expressing either CD4 or CD8 compared to wildtype 
controls, but had much larger populations of DP cells (Hagenbeek et al., 2004). The 
PI3K/PKB pathway was indeed constitutively active, as evidenced by increased PKB 
and FOXO phosphorylation in these mice. The PTEN-null T cells were resistant to 
apoptosis, which may account for the increase in proportion of DP cells. Some of these 
cells were deficient in the TCR-β receptor and would have normally been eliminated 
during β-selection, and are likely to have survived as a result of increased PI3K activity 
(Hagenbeek et al., 2004). Tumour formation in this model has been shown to be  to be 
PDK1-dependent, as PTEN-null mice fail to develop tumours if PDK1 is also deleted 
(Finlay et al., 2009). 
 
4.1.7. Role of AMPK in T cells 
 
T cells express only the α1 isoform of the AMPK α subunit (Tamás et al., 2006). As 
discussed previously (in section 4.1.4) TCR activation causes an increase in intracellular 
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calcium, which also activates CaMKK-β. It has been shown that stimulation of TCR 
signalling by treatment of cells with anti-CD3  antibody activates AMPK and causes 
phosphorylation of its downstream target  ACC (Tamás et al., 2006). This activation 
was abolished by pre-treatment with the CaMKK inhibitor, STO-609. Activation of 
AMPK in T cells can occur either in a LKB1-dependent manner as is seen in conditions 
of metabolic stress, or in a CaMKKβ-dependent manner downstream of TCR activation. 
The AMPK activation downstream of TCR is dependent on LAT and SLP-76 activation 
(Jurkat cells which do not express these two proteins fail to activate AMPK when 
treated with anti-CD3 antibody) and independently of PI3K signalling (since Jurkat 
cells also lack PTEN) (Tamás et al., 2006). 
 T cell-specific deletion of AMPKα1  increases the sensitivity of cells to 
metabolic stress, but does not affect development or differentiation of T cells or 
immune responses of both cytotoxic and helper T cells (Mayer et al., 2008). However, 
recent evidence suggests a role for AMPK in determining effector and memory cell fate 
of CD8
+
 T cells (Finlay and Cantrell, 2011).  
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4.2 AIMS AND METHODS 
 
The main aim of the chapter was to test whether AMPK functions as a tumour 
suppressor. This project was carried out in collaboration with Prof. Doreen Cantrell’s 
group. We utilised a previously described Cre/loxP system to delete PTEN, with or 
without deletion of AMPK in T cells of C57Bl/6 mice. We initially generated mice that 
were heterozygous for PTEN ± deletion of AMPK (PTEN
+/-
 AMPK
+/+
 and PTEN
+/-
 
AMPK
-/-
), but then subsequently generated mice that were homozygous for PTEN ± 
deletion of AMPK (PTEN 
-/-
 AMPK 
+/+
 and PTEN
-/-
 AMPK
-/-
). These mice were then 
monitored to observe the development of lymphomas.  
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4.3 RESULTS 
 
4.3.1 Generation of mice with T cell-specific deletion of AMPK and 
PTEN 
 
T cell-specific PTEN knockout (KO) mice were generated by crossing PTEN
fl/fl
 mice, 
where LoxP sequences were inserted in introns 4 and 5 flanking exon 5, with mice 
heterozygous for Cre recombinase driven by the Lck promoter (Lck-Cre). Expression of 
Cre recombinase from this promoter caused deletion of the floxed genes following 
TCRβ rearrangement in the DN stage. This model has been well established and used in 
previous studies (Marino et al., 2002, Hagenbeek et al., 2004, Hagenbeek and Spits, 
2007, Finlay et al., 2009). The PTEN
fl/fl
 mice were kind gifts from Prof. Hergen Spits. 
AMPKα1fl/fl mice were kind gifts from Dr. Benoit Viollet; the methods used to generate 
these mice have been previously described (Jørgensen et al., 2004) 
As mentioned earlier α1 is the only AMPK-α isoform expressed in T cells. All 
of the strains of mice used were already established in Prof. Cantrell’s group. Mice that 
had T cell-specific deletion of PTEN were bred with mice that had T cell-specific 
deletion of AMPK to generate mice that had reduced (heterozygous) expression of 
PTEN and with complete loss of AMPK-α1 (PTEN+/- AMPK+/+ and PTEN+/- AMPK -/-) 
(Figure 4.3). The frequency and onset of tumour formation were compared between the 
PTEN heterozygous mice that either expressed or lacked AMPK-α1. Mice with 
complete T cell-specific deletion of PTEN with or without complete T cell-specific 
deletion of AMPK-α1 (PTEN-/- AMPK+/+ and PTEN-/- AMPK -/-) were also generated 
(Figure 4.4). The frequency and onset of tumour formation was also compared between 
these two groups. 
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Figure 4.3: Schematic diagram showing generation of T cell-specific PTEN 
heterozygotes which lack or express AMPKα1 
Mice that had T cell-specific deletion of PTEN were bred with mice that had T cell-specific 
deletion of AMPK to generate mice that had reduced (heterozygous) expression of PTEN and 
with complete loss of AMPK-α1 (PTEN+/- AMPK+/+ and PTEN+/- AMPK -/-). Once breeders had 
been established, there was a one-in-four chance of obtaining the desired genotype. The 
genotypes were confirmed by PCR. 
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Figure 4.4 Schematic diagram showing generation of T cell-specific PTEN 
homozygotes which lack or express AMPKα1* 
Mice with complete T cell-specific deletion of PTEN with or without complete T cell-specific 
deletion of AMPK-α1 (PTEN-/- AMPK+/+ and PTEN-/- AMPK -/-) were also generated. Cases and 
controls from the scheme used in Figure 4.3 were used to generate these mice.  As PTEN fl/fl 
Lck-Cre+/- mice developed tumours early, they were not used as breeders. Instead PTEN fl/WT 
Lck-Cre+/- mice were crossed with PTEN fl/fl Lck-Cre-/- mice to obtain the desired cases and 
controls. 
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4.3.2 Phenotype of T cell-specific PTEN heterozygotes that lack or 
express AMPKα1 
 
Mice with T cell-specific heterozygous deletion of PTEN expressing wildtype AMPK-
α1 (PTEN +/- AMPK +/+) or lacking AMPK α1 (PTEN+/- AMPK-/-) were generated 
according to the schematic in Figure 4.3. Ear snips from three-week old mice were 
digested, genomic DNA was extracted and PCR was carried out as described in the 
Methods section to confirm the genotype. Despite reports that PTEN heterozygotes in 
mice develop lymphomas due to loss of heterozygosity in mice (Suzuki et al., 1998, 
Podsypanina et al., 1999) and observations in the T cell-specific PTEN heterozygotes of 
lymphomas (Finlay D, personal communication), we observed very few lymphomas in 
the PTEN heterozygotes we studied. Only 1 out of 12 mice developed lymphomas and 
even this low frequency of events took over a year to become apparent. There was a 
trend towards an increase in tumour incidence in the PTEN
+/-
 mice that also lacked 
AMPK-α1 (4 out of 12 mice). However, as the numbers were small, no meaningful 
comparison could be made. One likely reason for this apparent discrepancy with the 
literature may be the difference in mouse strains used. The ES cells used for the 
generation of both AMPK and PTEN floxed mice were derived from 129 mice. The 
PTEN floxed mice were initially generated in a FVB-N line and back-crossed on a 
C57Bl/6 background. Since obtaining breeders, further backcrosses onto C57Bl/6 
background had been carried out in the animal unit from 2008 onwards. C57Bl/6 mice 
are known to be relatively tumour-resistant and the low frequency of tumours in the 
PTEN heterozygous mice may be due to increasing influence of the C57Bl/6 
background on the phenotype in successive generations of mice. 
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Mice that have T cell-specific deletion of PTEN develop lymphomas at a 
median age of 13-14 weeks (6-23 weeks) (Hagenbeek et al., 2004). Therefore, mice 
with homozygous T cell-specific PTEN deletion, with or without deletion of AMPK-α1 
were generated and followed for formation of lymphomas.  
 
4.3.3 AMPK suppresses tumour formation in the T cell-specific 
PTEN Knock-out mice 
 
Mice with T cell specific homozygous deletion of PTEN expressing wildtype AMPK 
(hereafter termed PTEN KO mice) or lacking AMPK (hereafter termed PTEN AMPK 
double KO mice) were generated according to the breeding scheme in Figure 4.4. As T 
cells have been shown to express only the α1 isoform of AMPK-α, cohorts used for the 
earlier breeding scheme (PTEN 
+/-
 group) were used as breeders. Over the next 2-3 
generations of breeding, desired genotypes were obtained and followed up for tumour 
formation. Mice were culled when they showed any signs of distress such as difficulty 
feeding, limping or lack of normal movements and presence of palpable lumps. As 
expected, mice with T cell-specific deletion of PTEN developed lymphomas around 85 
days of age (12-13 weeks), around the same age as reported in previous studies 
(Hagenbeek et al., 2004, Finlay et al., 2009). Interestingly, mice that lacked PTEN and 
AMPK in the T cells, developed lymphomas at a median age of 65 days, much earlier 
than mice with T cell-specific deletion of PTEN alone (Figure 4.5). The difference in 
survival between the two groups was highly statistically significant (p<0.0001). This 
result strongly suggests that AMPK functions as a tumour suppressor in T cells when 
the PI3K pathway is overactive.  
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Figure 4.5: Survival analysis of T cell-specific PTEN homozygous KO mice 
which lack or express AMPK-α1  
Mice that have T cell-specific deletion of PTEN (in black) had a median survival of 85 days. Mice 
that have T cell-specific deletion of PTEN and AMPK had a significantly shorter median survival 
of 65 days (p<0.0001, Hazard ratio=6.3 n=25 in each group). 
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4.3.4. Site- specific differences in tumour formation between the 
PTEN KO and PTEN AMPK KO MICE 
 
PTEN KO mice developed T cell lymphomas that arise in the thymus. However, most 
of these mice also had peripheral lymphoid involvement as evidenced by enlargement of 
the lymph nodes and spleen (Figure 4.6). This was consistent with observations from 
previous studies (Hagenbeek et al., 2004, Hagenbeek and Spits, 2007). Strikingly, the 
PTEN AMPK double KO mice were often found dead, having shown no previous 
evidence of poor feeding or sickness. Examination of the PTEN AMPK double KO 
mice revealed the presence of massive thymomas in all mice, usually constricting the 
heart and adherent to the chest wall. Interestingly, very few PTEN AMPK double KO 
mice developed extra-thymic tumours. This difference in tumour location was 
statistically significant (p<0.0001). This suggests that AMPK deletion caused 
thymocytes or tumour cells to be confined to the thymus. This may also explain the 
reduction in lifespan in these mice as the massive thymomas would cause rapid 
deterioration in cardiac function while an enlarged spleen may not cause much 
discomfort until it outgrows its blood supply. 
 Thymocytes express several markers which facilitate emigration from the 
thymus (e.g. S1P1) or that drive them towards peripheral lymph organs (e.g., L-selectin) 
.The expression of L-selectin in single thymocytes (measured by using fluorescent 
labelled L-selectin antibody and the signal measured using a flowcytometer) did not 
differ significantly between the PTEN KO and the PTEN AMPK double KO 
thymocytes (data not shown). However, the expression of S1P1  mRNA (measured using 
real-time PCR) in the PTEN AMPK double KO thymocytes was significantly reduced 
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compared to wildtype thymocytes obtained from 4 week old mice (Fig 4.7A). mRNA 
levels of CCR7 (Chemokine receptor 7, which is expressed by naïve T cells and also 
facilitates entry into lymph nodes) were also significantly lower in the PTEN AMPK 
double KO thymocytes compared to wild type thymocytes (Figure 4.7B). CCR7 levels 
were also found to be lower in PTEN KO thymocytes and the PTEN AMPK double KO 
thymocytes had lower CCR7 levels than the PTEN KO thymocytes (Figure 4.7B). 
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Figure 4.6 Distribution of tumours in PTEN KO and PTEN AMPK double 
KO mice  
PTEN KO mice developed T cell lymphomas arising in the thymus. Most mice also had 
enlarged/infiltrated lymph nodes and spleen. Examination of the PTEN AMPK double KO mice 
revealed the presence of massive thymomas in all mice, while very few developed extra-
thymic tumours. This difference in tumour location was statistically significant (p<0.0001 
determined using Chi square and Fisher’s exact test),n=23 mice in each group.  
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Figure 4.7: mRNA expression levels of S1P1 and CCR7 in wild type, PTEN 
KO and PTEN AMPK double KO thymocytes 
mRNA levels of (A) Sphingosine-1-phosphate receptor 1 (S1P1 ) and (B) Chemokine receptor 7 
(CCR7) were measured by real-time quantitative PCR by calculating the number of cycles 
required to obtain a defined signal intensity of the DNA binding dye SyBr green and normalised 
to the housekeeping gene HPRT. The figure shows results obtained in triplicate from three 
individual mice from each genotype. One-way ANOVA was used to compare the different 
groups.  
A 
B 
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4.3.5 T cell development in PTEN KO and PTEN AMPK double KO 
mice 
 
Flowcytometric analysis of T cell development and differentiation showed no difference 
in the development of thymocytes obtained from four week old PTEN KO and PTEN 
AMPK double KO mice (data not shown). Both groups had cells expressing high levels 
of TCRβ and had similar distribution of DN, DP and SP cells (data not shown). 
Expression of cell surface receptors such as CD62L (L-selectin) and CD69 did not 
differ between PTEN KO and PTEN AMPK double KO mice. However, PTEN AMPK 
KO thymocytes had increased cell size compared to wildtype and PTEN KO 
thymocytes overall (Figure 4.8). The predominant cells in the thymus at 4 weeks are the 
double positive cells and these cells are likely to contribute to the increased cell size. 
We aim to measure this in future by sorting DPs and measuring cell size and 
quantifying total protein content of cells from each genotype. 
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Figure 4.8: Difference in cell size in thymocytes from mice expressing 
different genotypes 
Cell size (forward scatter or FSC-H) of wildtype (WT), PTEN KO and PTEN AMPK double KO 
thymocytes was measured and their distribution represented. The PTEN AMPK double KO cells 
were larger than the PTEN KO cells and the wildtype cells. This result is representative of four 
experiments performed. 
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4.3.6 AMPK antagonises the mTOR pathway in a subset of cells in 
this tumour model 
 
Lysates of thymocytes obtained from 4-5 week old wild type, PTEN KO and PTEN 
AMPK double KO mice were subjected to SDS-PAGE and blots probed for proteins 
downstream of the PI3K/PKB and the mTOR pathways. PTEN KO mice showed 
increased activation of PKB compared to wild type mice, as evidenced by 
phosphorylation of two of its key regulatory residues, namely Thr-308 and Ser-473, as 
well as increased phosphorylation of FOXO-1 and -3A, which are known to be 
downstream of PDK1 and PKB. This is consistent with previous studies (Hagenbeek 
and Spits, 2007, Finlay et al., 2009). PTEN AMPK double KO cells also showed an 
increase in phosphorylation of PKB and FOXO compared to wildtype controls and the 
levels were comparable to those observed in the PTEN KO thymocytes (Figure 4.9). 
However, PTEN AMPK double KO cells showed markedly increased levels of 
phosphorylated ribosomal protein S6 compared to both wildtype controls and PTEN KO 
cells (Figures 4.9 and 4.10). This suggests that loss of AMPK in conjunction with 
increased PI3K signalling in thymocytes causes activation of signalling pathways 
downstream of mTOR. But as discussed earlier, the cells within the thymus can be sub-
divided into several different sub-sets. At 4-5 weeks of age, the vast majority of 
thymocytes are the DPs, wherein S6 activity is down-regulated. It is likely that 
increased S6 phosphorylation is limited to a small sub-set of DPs that fail to down-
regulate pS6 levels. 
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Figure 4.9: Activation of signalling pathways in PTEN KO and PTEN AMPK 
double KO mice 
Wildtype thymocytes as well as thymocytes from PTEN KO and PTEN AMPK double KO mice 
were lysed and subjected to SDS-PAGE and immunoblotted with antibodies against 
phosphorylated PKB (anti-pT-308 and anti-pS-473), pFOXO-1, -3A and -4 and pS6 (Ser235/236). 
Deletion of PTEN and AMPK was also confirmed.  
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Figure 4.10: PTEN AMPK double KO cells have high pS6 levels when 
compared to wild type or PTEN KO cells 
(A) Thymocytes were harvested from three wildtype, PTEN KO and PTEN AMPK KO mice. 
The cells were lysed and subjected to SDS-PAGE electrophoresis and immunoblotted 
with antibodies against pS6 (Ser 235/236) and total S6.  
(B) The intensity of the bands was quantified using the Li-Cor Odyssey imager and the 
results plotted as ratio of pS6:S6 (relative to control). One way ANOVA was used to 
compare the groups (p<0.001-***). 
  
A. 
B. 
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To determine the sub-set of cells expressing high levels of pS6, staining of single 
cells using anti-pS6 antibodies as well as staining for CD4 and CD8 was carried out, 
followed by flow cytometric analysis. Staining for phospho-S6 using thymocytes treated 
with vehicle versus rapamycin (mTOR inhibitor) provided an estimate of mTOR-
dependent phosphorylation of S6. Phosphorylation of S6 by mTOR is lost following 
rapamycin treatment and any positive staining in this group is taken as background 
staining. Staining in cells treated with vehicle was corrected for the background staining 
to compare mTOR-dependent phospho-S6 levels in wild type, PTEN KO and PTEN 
AMPK double KO mice. PTEN KO cells showed an increase in the proportion of pS6 
staining cells, which was increased further in the PTEN AMPK KO cells (Figure 4.11). 
Both PTEN KO and PTEN AMPK double KO mice had higher percentages of DP cells 
in the thymus compared to the wild type mice and it is likely that a subset of DPs had 
up-regulation of mTOR leading to increased phospho-S6 staining.  
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Figure 4.11: Distribution of phospho-S6 positive cells in thymocytes 
obtained from wild type, PTEN KO and PTEN AMPK double KO mice 
Thymocytes obtained from wildtype, PTEN KO and PTEN AMPK double KO mice were treated 
with vehicle or rapamycin and then fixed in methanol and stained with anti-pS6 antibody 
followed by fluorescent-labelled secondary antibody. The proportion of phospho-S6 positive 
cells in each sample was measured and expressed as a percentage of total cells. The 
distribution of DN, DP and SP cells among the phospho-S6 positive cells was also determined. 
This experiment was carried out by Rosie Clarke, Flowcytometry Manager, College of Life 
Sciences, University of Dundee. 
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4.4 DISCUSSION 
 
In recent years, it has been found that AMPK is downstream of the tumour suppressor 
LKB1 (Hawley et al., 2003, Woods et al., 2003, Shaw et al., 2004b). This has led many 
research groups to suggest that, AMPK may, atleast in part, modulate some of the 
tumour suppressive actions of LKB1(Corradetti et al., 2004, Shaw et al., 2004a, 
Carretero et al., 2007). There is evidence that the AMPK signalling pathway is down-
regulated in some tumours (Hadad et al., 2009). Epidemiological studies also show that 
that treatment of diabetics with the AMPK-activating drug metformin is associated with 
a lower incidence of cancer (Evans, 2005, Bowker et al., 2006a). These results suggest 
that AMPK may itself be a tumour suppressor, although direct evidence has so far been 
lacking.  
This study provides the first genetic evidence that AMPK functions as a tumour 
suppressor in vivo. T cell-specific deletion of PTEN and AMPK in mice resulted in 
death from lymphoma formation significantly earlier than that observed in mice with T 
cell-specific deletion of PTEN alone. The time of initial onset of tumour formation in 
the PTEN AMPK double KO mice is similar to that of the PTEN KO mice, but the 
former had more aggressive tumour growth and died much sooner. The striking 
difference in tumour location between the PTEN KO and the PTEN AMPK double KO 
mice was an interesting and unexpected result. While it has been established in previous 
studies that PTEN-null lymphomas involve the thymus as well as the liver and spleen, 
lymphomas in PTEN AMPK double KO mice were almost always confined to the 
thymus. This suggests a role for AMPK in promoting the exit of tumour cells from the 
thymus. Measurement of thymocyte mRNA levels by RT-PCR showed a significant 
reduction in S1P1 mRNA in PTEN AMPK double KO mice, when normalised to 
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expression of a housekeeping gene. This decrease was not accompanied by up-
regulation of CD69, which is known to cause a down-regulation of S1P1 following 
activation of naïve T cells (data not shown). This suggests a role for AMPK in 
controlling the expression of S1P1, a receptor that is vital for the egress of thymocytes 
from the thymus into the peripheral lymph organs and blood.  
 PTEN AMPK double KO mice also have larger cells in the thymus compared to 
wild type or PTEN KO mice. . However, further analyses of the different T cell sub-sets 
is required to determine which cells are enlarge or indeed if there is any delay in 
transition from DN to DP stage which may explain this observed difference in cell size. 
As wildtype thymus has very few DN cells at 4 weeks, we would probably need to pool 
thymocytes from 5-10 mice of each genotype and sort the DN cells to achieve this. 
 Another interesting observation was the increase in phospho-S6 levels in the 
PTEN AMPK double KO thymocytes, before the onset of tumours. At 4 weeks of age, 
only around 2% of wild type thymocytes exhibit detectable phospho-S6. The PTEN KO 
thymus had a greater percentage of cells expressing detectable phospho-S6 and this is 
doubled in PTEN AMPK double KO mice. Moreover, the PTEN KO mice seemed to 
have higher S6 protein levels, so that when pS6: S6 ratios were estimated, the wildtype 
and PTEN KO thymocytes had similar ratios. However, the PTEN AMPK double KO 
thymocytes had a ten-fold higher pS6:S6 ratio compared to either of the other two 
groups. This suggests a role for AMPK in down-regulation of mTOR- dependent S6 
phosphorylation in a sub-set of thymocytes. This may also reflect  a difference in sub-
populations of thymocytes at 4 weeks between the different genotypes.  
 Further work is required to delineate the pathways activated in thymocytes 
following deletion of AMPK in this model and micro array analysis of thymocytes from 
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these mice would be useful. However, before that is done, we would need to identify the 
sub-set of thymocytes which have been transformed into tumour cells and try to dissect 
which signalling pathways have been altered in these cells.
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CHAPTER FIVE: THE ROLE OF PHOSPHORYLATION OF 
THE C-TERMINAL TAIL OF LKB1 ON AMPK ACTIVATION 
 
5.1 INTRODUCTION 
5.1.1 Identification of LKB1 and Peutz Jeghers syndrome 
 
LKB1 (Liver Kinase B1) was first identified as part of a screen for new kinases by 
researchers at Chugai Research Institute, the results of which were not published (Alessi 
et al., 2006). Genetic linkage studies then showed that mutations in the gene encoding 
LKB1  were responsible for 11 out of 12 cases of Peutz-Jeghers syndrome (PJS), a rare 
inherited cancer syndrome (Hemminki et al., 1998). Parallel studies by a different group 
also confirmed that PJS was caused by mutations in the same gene which they had 
termed serine threonine kinase 11(STK11) (Jenne et al., 1998).  
             Peutz-Jeghers syndrome is a rare, autosomal dominant, inherited cancer 
syndrome, characterised by the development of benign hamartomatous polyps and 
marked pigmentation of mucous membranes (Alessi et al., 2006). The syndrome is 
named after Peutz, who first described this condition in 1921 and Jegher, who 
characterised it as an autosomal dominant condition in 1949 (Hemminki, 1999). Patients 
with PJS have a markedly increased risk of cancer, especially colon, stomach, small 
intestinal and pancreatic cancer (Hemminki, 1999). In addition to germ line mutations 
that cause PJS, sporadic loss of LKB1 has also been reported in tumours of the lung and 
cervix (Vaahtomeri and Mäkelä, 2011). 144 different mutations in LKB1 have been 
identified in patients with PJS and from sporadic tumours, with a substantial proportion 
being truncating mutations in the catalytic domain resulting in loss of kinase function 
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(Alessi et al., 2006). However, some point mutations have been identified in the 
C-terminal tail of LKB1 in PJS patients and in sporadic tumours, suggesting a role for 
this region in regulating LKB1 activity (Alessi et al., 2006). 
 
5.1.2 LKB1 structure and post-translational modifications 
 
LKB1 is a 50 KDa protein that exists as two splice variants as described in Section 
5.1.6. The LKB1 gene is located on chromosome 19 at 19p13 locus in humans and 
chromosome 10 in mice and is composed of ten exons, nine of which encode the LKB1 
protein (Hemminki et al., 1998, Smith et al., 1999). Human LKB1 has 433 and murine 
LKB1 has 436 amino acids. LKB1 has unique N- and C-terminal regions that are 
unrelated to other proteins and possess no identifiable functional domains (Alessi et al., 
2006). The N-terminus has a nuclear localisation sequence and over-expression of 
LKB1 leads to nuclear localisation of the protein (Smith et al., 1999).  
LKB1 is phosphorylated on at least 8 residues (Figure 5.1) (Alessi et al., 2006). 
Four of these, namely Thr-185, Thr-189, Thr-336 and Ser-404 appear to be auto-
phosphorylation sites (Karuman et al., 2001, Baas et al., 2003, Sapkota et al., 2002a). 
Ser-31and Ser-325 are phosphorylated by an as yet unidentified upstream kinase, 
although, Ser-31 lies within an AMPK consensus motif, while Ser-325 lies in a proline-
rich region and is likely to be phosphorylated by a proline-directed kinase (Alessi et al., 
2006). Thr-366 phosphorylation on LKB1 was shown to be increased when cells were 
treated with ionising radiation. It was then shown that this site was phosphorylated by 
Ataxia-telangiectasia mutated (ATM) kinase (Sapkota et al., 2002b). Ser-431 is 
phosphorylated by p90 ribosomal S6 kinase (p90RSK) and cyclic-AMP-dependent 
protein kinase (also termed protein kinase A or PKA), in response to agents such as 
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forskolin and glucagon, that activate these kinases (Sapkota et al., 2001, Boudeau et al., 
2003, Collins et al., 2000).  
LKB1 terminates with the sequence Cys-Lys-Gln- Gln (-CKQQ), which is an 
optimal motif for protein prenylation, a type of post-translational modification. LKB1 
was shown to be prenylated on its C-terminus using 14-C mevalonic acid labelling 
(Collins et al., 2000). Mutation of the Cys residue abolished prenylation (Collins et al., 
2000). Mass spectrometry showed LKB1 was modified by farnesylation (a type of 
prenylation) on Cys-433 (Sapkota et al., 2001). The figure below (Figure 5.1) shows the 
domains contained in LKB1 and the sites that are modified by phosphorylation and 
farnesylation. 
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Figure 5.1: Schematic of the murine LKB1 sequence showing residues 
modified by post-translational modification 
Murine LKB1 has 436 amino acids. The protein has an N-terminal domain, a kinase domain and 
a regulatory C-terminal tail.  Multiple phosphorylation sites have been identified on the 
protein: four of these, namely, Thr-185, Thr-189, Thr-336 and Ser-404 are auto-
phosphorylation sites. Thr-366 is phosphorylated by ATM, Ser-431 by PKA and p90RSK. Ser-325 
lies in a proline-rich region and is likely to be phosphorylated by a proline- directed kinase. 
Ser-31 lies within an AMPK consensus recognition motif (Alessi et al., 2006). 
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5.1.3. The LKB1:STRAD:MO25 complex 
 
LKB1 exists in a complex with  two other proteins, the  pseudokinase STRAD (Ste-20 
related adapter protein) and the helical repeat protein MO25 (Mouse protein 25) (Alessi 
et al., 2006). Yeast two-hybrid screens using Kinase-dead LKB1 as bait, identified 
STRAD as an interacting protein (Baas et al., 2003). LKB1 was also detected in 
immunoprecipitates obtained from cell lysate using anti-STRAD monoclonal antibody 
(Baas et al., 2003). STRAD is classed as a pseudokinase, because although it bears 
similarity to the Ste-20 family of kinases, it lacks key residues required for catalytic 
activity. STRAD has two isoforms, namely, STRAD-α and STRAD-β. The STRAD-α 
gene is located on chromosome 17, while the STRAD-β gene is located on chromosome 
2  in humans and the protein has a molecular weight of ~50 KDa (Baas et al., 2003). 
Binding of STRAD to LKB1 greatly enhances auto-phosphorylation of LKB1. LKB1 
also phosphorylates STRAD at Thr-329 and Thr-419 (Baas et al., 2003). Binding of 
STRAD alters the sub-cellular localisation of LKB1. LKB1 alone, when expressed in 
cells localises to the nucleus, whilst co-expression of STRAD with LKB1 alters its 
localisation to the cytoplasm (Baas et al., 2003). 
 MO25 also has two isoforms, namely, MO25-α and MO25-β, which are highly 
similar, but lack homology to other proteins (Baas et al., 2003). MO25 was first 
identified as a gene that was expressed at the early cleavage stage in mouse 
embryogenesis (Miyamoto et al., 1993). When FLAG-tagged LKB1 was stably 
expressed in HeLa cells and  the tagged protein was immunoprecipitated  with anti-
FLAG antibodies, the immunoprecipitate also showed the presence of MO25, 
suggesting that MO25 formed part of the LKB1 complex (Boudeau et al., 2003). MO25 
is an armadillo-like, helical repeat protein with a concave protein binding surface. It 
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binds to STRAD by interacting with the WEF motif on its C-terminus, and this binding 
is abolished when the last 3 amino acids on STRAD are deleted (Boudeau et al., 2003, 
Milburn et al., 2004). However, binding of LKB1 to STRAD creates new binding sites 
for MO25, as it is able to bind to truncated STRAD mutants complexed with 
LKB1(Boudeau et al., 2003). Binding of MO25 stabilises the STRAD:LKB1 complex 
and further increases LKB1 activity (Boudeau et al., 2003). 
The structure of the LKB1:STRAD:MO25 complex reveals that STRAD-α, 
although catalytically inactive, binds ATP and adopts a closed conformation like that of 
active kinases (Zeqiraj et al., 2009b). Also, unlike other kinases that are usually 
activated by phosphorylation, LKB1 is allosterically activated by binding to STRAD. 
This interaction is further strengthened by MO25 binding to STRAD though multiple 
residues on its concave surface (Zeqiraj et al., 2009a, Zeqiraj et al., 2009b). Mutations 
in the ATP binding pocket of STRAD have been shown to reduce LKB1 activity. 
Several mutations in LKB1 seen in patients with PJS were shown to affect its ability to 
bind STRAD and MO25, impairing the assembly and stability of the LKB1 complex, 
thereby affecting its activity (Zeqiraj et al., 2009a). 
 
5.1.4 LKB1 is a master upstream kinase 
 
LKB1 is the main upstream kinase that activates AMPK (Woods et al., 2003, Hawley et 
al., 2003, Shaw et al., 2004b). Apart from AMPK-α1 and AMPK-α2,  LKB1 is known 
to phosphorylate 12 other protein kinases (BRSK1, BRSK2, NUAK1, NUAK2, QIK, 
QSK, SIK, MARK1, MARK2, MARK3, MARK4, and SNRK) that are located in the 
same branch of the human kineome dendrogram as AMPK, and share significant 
sequence homology with it within the kinase domain (Alessi et al., 2006). LKB1 
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phosphorylates key residues in the activation loop of these kinases, causing a 50-fold 
increase in their activity (Lizcano et al., 2004, Jaleel et al., 2005). These kinases are 
therefore much less active when expressed in LKB1-deficient cell lines. The 
microtubule-affinity regulating kinases MARK1, MARK2, MARK3 and MARK4, 
which are orthologues of Par-1 in C. elegans, regulate cell polarity (Böhm et al., 1997, 
Drewes et al., 1997). NUAK 2, which is induced by cellular stresses and TNF, interacts 
with and phosphorylates myosin phosphatase target subunit-1 (MYPT-1) (Yamamoto et 
al., 2008). NUAK1 (also called AMPK related kinase-5 or ARK5 ) also interacts with 
MYPT-1 and has been reported to regulate cell adhesion by interacting with  myosin 
phosphatases (Zagorska et al., 2010). The brain specific kinases BRSK1 and BRSK2, 
which (as their names suggest) are mainly expressed in the brain, regulate polarisation 
of neuronal cells (Kishi et al., 2005). Mice deficient in both these kinases (also called 
SAD-B  and SAD-A), die due to the inability to polarise neurons into axons and 
dendrites (Kishi et al., 2005). The salt inducible kinases SIK 1 and SIK 2, phosphorylate 
TORC2 (also called CRTC2) at Ser-171, a site that is also phosphorylated by AMPK 
(Katoh et al., 2004, Screaton et al., 2004). Phosphorylation of CRTC2 on this site leads 
to its cytoplasmic sequestration, thereby preventing CREB-dependent transcription 
(Screaton et al., 2004). SIK2 is present mainly in adipose tissue and has been shown to 
phosphorylate insulin receptor substrate-1 (IRS-1) on Ser-794 and may play a role in 
regulating adipocyte metabolism (Katoh et al., 2004, Horike et al., 2003). 
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5.1.5 LKB1 is a tumour suppressor 
 
LKB1 is critically important in embryonic development as deletion of both LKB1 
alleles leads to embryonic lethality at mid-gestation (embryonic day 8.5 to 11). The 
non-viable LKB1-null embryos had severe neural tube defects and vascular 
abnormalities (Ylikorkala et al., 2001, Jishage et al., 2002). LKB1
+/-
 embryos were 
viable, but showed polyp formation at around 10 months of age. These polyps, although 
found in the stomach, were histologically similar to intestinal polyps seen in patients 
with PJS (Jishage et al., 2002, Bardeesy et al., 2002). LKB1
+/-
 mice also developed 
spontaneous hepatocellular carcinoma (Miyoshi et al., 2009). These studies suggested 
that haplo-insufficiency was sufficient to cause polyp formation (Miyoshi et al., 2009, 
Jishage et al., 2002). However, another study showed complete loss of the LKB1 
protein in the polyps, suggesting epigenetic inactivation of the second allele (Bardeesy 
et al., 2002). LKB1
fl/fl
 hypomorphic mice expressing five to ten fold less LKB1 than 
wild type mice did not develop tumours spontaneously, also suggesting that complete 
loss of LKB1 was required for tumour formation (Huang et al., 2008). Moreover, over-
expression of wildtype LKB1 in LKB1-deficient cell lines such as HeLa and G361 
melanoma cells lines leads to a G1 cell cycle arrest (Tiainen et al., 1999). These 
findings, taken together, emphasise the role of LKB1 as a tumour suppressor. 
 
5.1.6 Splice variants of LKB1 
 
During purification from rat liver, two forms of the LKB1:STRAD:MO25 complex 
were resolved. The LKB1 polypeptide in the two forms showed differing mobilities on 
SDS-PAGE (Hawley et al., 2003). These two forms were identified by tryptic peptide 
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mass fingerprinting to be splice variants derived from the STK11 gene encoding LKB1, 
and were termed LKB1L (long) and LKB1S (short)  (Towler et al., 2008). Both LKB1L 
and LKB1S share the first 373 residues, which are encoded by exons 1-8. Due to 
alternative splicing, LKB1S, has a unique 39 residue sequence at its C-terminus, 
encoded by exon 9A, whereas, LKB1L has a distinct 63 residue sequence encoded by 
exon 9B. The LKB1L   protein has 436 amino acids, while LKB1S has 412 amino acid 
residues. Therefore LKB1S lacks two sites of post-translational modification, namely, 
Ser-431 and the farnesylation site on Cys-433. LKB1L was  the predominant isoform 
found in most tissues, although LKB1S could also be detected ubiquitously, albeit at 
lower levels (Towler et al., 2008). Interestingly, LKB1S  has been shown to be required 
for spermiogenesis, as male mice unable to generate LKB1S  are sterile with 98% 
reduction in the number of sperm found in the epididymis compared to wild type mice 
(Towler et al., 2008). GST-LKB1S expressed and purified from  HEK 293 cells, was 
able to phosphorylate a GST-fused kinase domain of AMPK α1 more rapidly than GST-
LKB1L  (Towler et al., 2008). However, both proteins had similar substrate specificity 
against AMPK and the ARKs (Towler et al., 2008).  
 
5.1.7 The C-terminal tail of LKB1 and its effect on AMPK activity 
 
Although LKB1 is required for activation of AMPK and ARKs in most cells, most 
evidence available suggests that it is constitutively active. However, there are now many 
indications that the C-terminal tail of LKB1 is a regulatory region whose 
phosphorylation affects AMPK activation. Mutations in the C-terminal region of LKB1 
in some cases of PJS and sporadic tumours have been shown to be associated with 
reduced AMPK phosphorylation as well as impaired polarisation of intestinal cells 
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(Forcet et al., 2005). Interestingly, two of these mutations, namely P324L and T367M, 
were adjacent to the Ser-325 and Thr-363 (equivalent to Thr-366 in mouse LKB1) 
phosphorylation sites. This suggested that these mutations might interfere with 
phosphorylation of these residues. These LKB1 mutants also activated AMPK to a 
lower extent than the wild type protein (Forcet et al., 2005). LKB1 is phosphorylated on 
Ser-431 by agonists  that activate p90RSK and PKA (Sapkota et al., 2001). 
Phosphorylation on this site was initially shown  to be required to inhibit cell growth , 
as wild type LKB1 expressed in G361 melanoma cells caused inhibition of cell growth, 
whereas, cells expressing an LKB1 mutant, where Ser-431 was mutated to alanine were 
unable suppress cell growth (Sapkota et al., 2001). Phosphorylation of Ser-431 by 
protein kinase Cζ was also reported to be required for phosphorylation of Thr-172 on 
AMPK in bovine aortic endothelial cells in response to metformin treatment (Xie et al., 
2008). However, our laboratory found that LKB1 truncated to residue 343 (which lacks 
most of the C-terminal tail), is still able to form a complex with STRAD and MO25. 
This mutant is able to activate AMPK in cell free assays as well as in intact cells ( 
Fogarty S 2008, PhD thesis). Moreover, expression of LKB1S ( the short splice variant 
of murine LKB1 containing residues 1-412 which also lacks the Ser-431 residue)  or 
LKB1L ( full length murine LKB1 containing 436 amino acid residues) or LKB1L where 
the Ser-431 site was mutated to alanine in HeLa cells, all caused a similar increase in 
AMPK activity compared to cells expressing the empty vector (Fogarty and Hardie, 
2009). Our laboratory also showed that Ser-431 phosphorylation was not required for 
cell cycle arrest, although the effect of this mutation on cell survival and growth was not 
tested (Fogarty and Hardie, 2008).  
 Zheng et al have reported that Ser-325 and Ser-431 on the C-terminal tail of 
LKB1 are phosphorylated in melanoma cells carrying the V600E mutation in B-RAF 
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(present in -50% of malignant melanomas) (Zheng et al., 2009). The authors of the 
paper proposed that Ser-325 was phosphorylated by ERK and Ser-431 by p90RSK 
respectively, downstream of the RAF-MEK-ERK pathway that is activated by the 
V600E mutation (Figure 5.2). The melanoma cells carrying the B-RAF V600E mutation 
also exhibited reduced AMPK activity and it was proposed that this was caused by 
phosphorylation of the C-terminal sites in LKB1. However, as the Ser-325 site is 
flanked by multiple proline residues, a proline-directed kinase has been proposed as the 
likely upstream kinase that phosphorylates this site (Alessi et al., 2006).  
  
154 
 
 
 
 
Figure 5.2: Schematic showing the proposed effect of C-terminal 
phosphorylation of LKB1 on AMPK activity 
This model proposes that Ser-325 is phosphorylated by ERK in melanoma cells expressing the 
B-RAF (V600E) mutation, which renders B-RAF constitutively active. This in turn activates MEK 
and ERK, leading to phosphorylation of both Ser-325 and Ser-431 on LKB1. LKB1, 
phosphorylated on both these sites is then less effective at activating AMPK compared to the 
wildtype protein in these cells (Zheng et al., 2009). 
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5.2 AIMS 
 
The main aim of the chapter was to test whether Ser-325 and Ser-431 phosphorylation 
on LKB1 affected AMPK activity. The requirement for Ser-325 and Ser-431 on LKB1 
was initially tested by mutating these to non-phosphorylatable alanine residues. These 
mutants were expressed in HeLa cells and purified and the ability of these mutants to 
activate bacterially expressed AMPK heterotrimer was measured using a cell-free assay 
system. 
 We also aimed to test whether ERK2 phosphorylated Ser-325 on LKB1 and 
to determine the stoichiometry of the phosphorylation in a cell free system. We then 
aimed to phosphorylate Ser-325 and Ser-431 in a recombinant LKB1 complex 
(expressed in HeLa cells) by ERK2 and p90RSK and test the ability of this LKB1 
complex to phosphorylate a bacterially expressed AMPK complex in a reconstituted cell 
free system.  
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5.3 RESULTS  
 
5.3.1 Cloning and expression of GST- tagged wild type and mutant 
LKB1 complexes 
 
Rat LKB1 fused to Glutathione-S-transferase (hereafter termed GST-LKB1WT) was a 
gift from Sarah Fogarty, a former PhD student in the lab. Site-specific, non-
phosphorylatable alanine mutants for the Ser-325 (GST-LKB1S325A) and Ser-431 (GST-
LKB1S431A) sites were generated by site-directed mutagenesis of the wild type DNA, as 
described in the Methods section (section 2.2.1). In addition a double-alanine mutant, 
where both the sites were mutated (GST-LKB1S325A/S431A or GST-LKB1AA) was also 
generated.  HeLa cells, which lack LKB1, were transfected with the wild type and 
mutant GST-LKB1, along with its accessory proteins, namely STRAD-α, which 
contained a FLAG tag and MO25-α, which contained a myc tag. The LKB1 complex 
was detected in the cell lysate obtained 36 hours after transfection by probing Western 
blots for the GST, FLAG and myc tags respectively (Figure 5.3). As expected, non-
transfected HeLa cells lacked all components of the LKB1 complex. GST-LKB1, 
FLAG-STRAD and myc-MO25 were detected in HeLa cells transfected with GST-
LKB1WT, GST-LKB1S325A, GST-LKB1S431A and GST-LKB1AA constructs. The S325A 
and S431A mutants were expressed to a similar extent as the wild type LKB1 protein. 
The expression of the GST-LKB1AA protein was, however, slightly lower than that of 
the wild type protein. 
 
 
 
157 
 
 
 
 
 
 
 
Figure 5.3: Expression of wild type and mutant LKB1 in HeLa cells 
GST-tagged wild type LKB1, as well as S325A, S431A and AA mutants were expressed along 
with FLAG-STRAD and myc-MO25 in HeLa cells. Non-transfected cells were used as negative 
controls.  LKB1 was detected by anti- GST, STRAD was detected by anti- FLAG and MO25 was 
detected by anti-myc antibodies respectively. 
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5.3.2 Affinity purification of LKB1 using glutathione- Sepharose 
 
Following expression of GST-LKB1WT, GST-LKB1S325A, GST-LKB1S431A and GST-
LKB1AA with STRAD and MO25 in HeLa cells, the LKB1 complexes were purified by 
incubating the cell lysates with glutathione-Sepharose beads, which bind GST. 
Following a number of washing steps to remove unbound proteins, GST-LKB1 protein 
was then eluted in buffer containing glutathione, which displaces the GST-tagged 
protein from the glutathione-Sepharose beads. GST-LKB1 was therefore, highly 
enriched in the eluate (Figure 5.4). As expected, STRAD and MO25 were also detected 
in the purified eluate. However, while most of the GST-LKB1 was bound to the beads 
and very little was detectable in the supernatant or wash, only a proportion of the 
STRAD and MO25 initially present in the lysate was detectable in the eluate. Most of 
the expressed STRAD and MO25 could be detected in the supernatant. This was 
probably due to overexpression of STRAD and MO25, relative to LKB1. Due to 
competition for expression between the three expression vectors for the same 
biosynthetic pathways in cells, it is likely that the smaller proteins, namely STRAD and 
MO25, were expressed more efficiently. Also, only the fraction of STRAD and M025 
bound to LKB1 would be present in the eluate. Coomasie staining was performed to 
ensure that the eluate was free from contamination by other proteins. The relative 
amount of LKB1 in the eluate obtained from cells expressing LKB1 mutants was 
similar to that obtained from cells expressing wild type LKB1 when quantified with 
bovine serum albumin standards (5ng of LKB1/ μl of eluate). 
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Figure 5.4: Purification of the LKB1:STRAD:MO25 complex from cell 
lysates 
GST-LKB1WT, GST-LKB1S325A, GST-LKB1S431A and GST-LKB1AA constructs were transfected along 
with FLAG-STRAD and myc-MO25 in HeLa cells. The LKB1 complex was purified by incubating 
the cell lysate with glutathione-Sepharose beads. The LKB1 complex was then eluted in buffer 
containing glutathione. Anti-GST, anti-Flag and anti-myc antibodies were used to detect LKB1, 
STRAD and MO25 in the lysate, supernatant (wash) and the eluate.  
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5.3.3 Phosphorylation of Ser-325 and Ser-431on LKB1 does not 
affect AMPK activity 
 
The effect of Ser-325 and Ser-431 phosphorylation on the ability of LKB1 to 
phosphorylate AMPK was tested in a cell-free system. GST-LKB1WT, GST-LKB1S325A, 
GST-LKB1S431A and GST-LKB1AA, in complex with STRAD and MO25, purified as 
described in the previous section, was used to phosphorylate bacterially expressed 
AMPK heterotrimer (5 μg AMPK per 20 μl reaction). AMPK activity was then 
measured by its ability to phosphorylate its peptide substrate AMARA. GST-LKB1S325A, 
GST- LKB1S431A and GST-LKB1AA, were able to phosphorylate AMPK to a similar 
extent, which was similar to GST-LKB1WT (Figure 5.5). These results suggest that in a 
cell-free system, phosphorylation of Ser-325 and Ser-431 residues of LKB1 did not 
significantly affect its ability to activate AMPK. This result is consistent with previous 
results from our laboratory showing that GST-LKB1S431A  activated the GST-AMPKα1 
kinase domain to a similar extent as GST-LKB1WT (Fogarty and Hardie, 2009).  
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Figure 5.5: Activity of GST-LKB1WT, GST-LKB1S325A, GST-LKB1S431A and 
GST-LKB1AA  
HeLa cells were transfected with GST-LKB1WT or GST-LKB1S325A or GST-LKB1S431A or GST-LKB1AA, 
along with FLAG-STRAD and myc-MO25. LKB1 complexes were purified from cell lysate using 
glutathione-Sepharose. The activity of GST-LKB1WT, GST-LKB1S325A, GST-LKB1S431A and GST-
LKB1AA was measured by assessing their ability to activate bacterially expressed AMPK 
heterotrimer using the AMARA peptide substrate. Results shown are representative of three 
individual experiments. 
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5.3.4 Phosphorylation of Ser-431 on LKB1 by p90RSK does not 
affect AMPK activity 
 
The ability of GST-LKB1S431A to activate the isolated AMPK kinase domain in a cell-
free system was shown to be similar to that of GST-LKB1WT (Fogarty and Hardie, 
2009). Moreover, HeLa cells transfected with GST-LKB1WT and treated with forskolin, 
which activated p90RSK, had similar activity to transfected cells treated with vehicle 
(Fogarty and Hardie, 2009). The aim of the next experiment was to test if 
phosphorylation of LKB1 on Ser-431 by p90RSK affected its ability to phosphorylate 
bacterially expressed AMPK heterotrimer in a cell-free system. The first step was to 
verify that recombinant p90RSK, produced in insect cells (obtained from the Division 
of Signal Transduction Therapy, University of Dundee) phosphorylated Ser-431 on 
LKB1 and to test the specificity of the anti-phosphoSer-431 (anti-pS431) antibody (also 
obtained from the Division of Signal Transduction Therapy, University of Dundee). 
GST-LKB1WT, as well as GST-LKB1S325A, GST-LKB1S431A and GST-LKB1AA 
complexes were incubated with p90RSK in the presence of Mg-ATP at 30°C for 30 
minutes on a shaker. The reaction was stopped by adding LDS buffer and the proteins 
resolved by SDS-PAGE. The blots were then probed with anti-pS431 antibody, as well 
as total LKB1 (Figure 5.6). p90RSK phosphorylated GST-LKB1WT, as well as GST-
LKB1S325A, but not GST-LKB1S431A and GST-LKB1AA in a concentration-dependent 
manner. This result was consistent with published studies and also confirmed the 
specificity of the anti-pS431 antibody. Despite the undetectable phospho-signal on 
western blotting, it is possible that some phosphorylation of the Ser-431 residue was 
present under basal conditions, which has not been quantified, A better approach would 
have been to pre-treat LKB1 with phosphatase  before incubation with p90RSK. 
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After ascertaining that LKB1 was phosphorylated on Ser-431 by p90RSK, its 
effect on AMPK activity was measured. As this involved three serial phosphorylation 
reactions, namely, p90RSK phosphorylating LKB1, LKB1 phosphorylating AMPK 
which in turn phosphorylates AMARA, and this effect had to be measured at varying 
concentrations of LKB1, the first reaction was performed during the purification of 
recombinant LKB1 complexes. HEK 293 cells were transfected with GST-LKB1WT or 
GST-LKB1S431A or GST-LKB1AA, along with FLAG- STRAD and myc-MO25. The 
LKB1 complex was purified using glutathione-Sepharose. While the LKB1 complex 
was still bound to the Sepharose beads, the beads were incubated with recombinant 
p90RSK in the presence of Mg
2+
 and ATP at 30°C for 30 minutes on a shaker.  A 1: 30 
dilution of p90RSK (which maximally phosphorylated LKB1 as shown in Figure 5.6) or 
buffer (with no p90RSK) was used to phosphorylate GST-LKB1WT, GST-LKB1S431A 
and GST-LKB1AA. The reaction was stopped by spinning the beads down and aspirating 
the supernatant (containing p90RSK), followed by several wash steps. The LKB1 
complex was then eluted in buffer containing glutathione and quantified using BSA 
standards. Varying concentrations of the eluate were then used to phosphorylate 
bacterially expressed AMPK heterotrimer. Ser-431 phosphorylation on GST-LKB1WT 
was confirmed by Western blotting and probing blots using anti-pS431 antibody (Figure 
5.7). As expected, p90RSK phosphorylated the Ser-431site on GST-LKB1WT, but not on 
GST-LKB1S431A or GST-LKB1AA, which lacked the serine residue. 
Different concentrations of the GST-LKB1WT and GST-LKB1S431A complexes, 
which had or had not been incubated with p90RSK, were then used to phosphorylate 
AMPK heterotrimer in the presence of Mg-ATP, following which, the activity of the 
AMPK heterotrimer in each reaction was measured using the AMARA peptide substrate 
(Figure 5.8). Phosphorylation of Ser-431 did not affect the ability of GST-LKB1WT to 
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activate AMPK. GST-LKB1S431A, which cannot be phosphorylated by p90RSK, 
activated AMPK to a similar extent as the GST-LKB1WT. As expected, the activity of 
GST-LKB1S431A was not affected by incubation with p90RSK. 
  
166 
 
 
 
 
 
Figure 5.7: Recombinant p90RSK phosphorylates Ser-431 on LKB1 in a 
cell-free system 
(A) HEK293 cells were transfected with GST-LKB1WT , GST- LKB1S431A or GST- LKB1AA, along 
with FLAG-STRAD and myc-MO25. The LKB1 complex was purified using glutathione-
Sepharose.  LKB1 complexes bound to the Sepharose beads were incubated with 
recombinant p90RSK in the presence of Mg- ATP. The LKB1 complex was then eluted 
with buffer containing glutathione. The lysate (L), wash (W) and eluate (E) were 
subjected to Western blotting. Anti-GST, anti-FLAG and anti-myc antibodies were used 
to detect LKB1, STRAD and MO25. 
(B) The eluate containing LKB1 complexes were subjected to Western blotting. Anti-pS431 
and anti-LKB1 antibodies were used to detect phosphorylation of LKB1 on Ser-431. 
 
 
A. 
B. 
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Figure 5.8: Phosphorylation of LKB1 on Ser-431 by p90RSK does not 
affect AMPK activity 
GST-LKB1WT or GST-LKB1S431A complex, which either had or had not been incubated with 
p90RSK, were used to phosphorylate AMPK heterotrimer in the presence of Mg- ATP, following 
which, the activity of the AMPK heterotrimer in each reaction was measured using the AMARA 
peptide substrate. 
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5.3.5 ERK does not stoichiometrically phosphorylate Ser-325 on 
LKB1 
 
As mentioned earlier in the chapter, Zheng et al published results showing that the MAP 
kinase ERK2 phosphorylated LKB1 on Ser-325 (Zheng et al., 2009). However, the 
authors did not clarify the stoichiometry of this reaction, which would serve as a 
measure of the functional role of this modification on LKB1, as well as whether ERK 
was effective as an upstream kinase phosphorylating LKB1. The main aim of the 
experiments detailed in this section was to confirm the stoichiometry of this 
phosphorylation reaction. Wild type human GST-LKB1 (GST-LKB1WT) and kinase- 
dead mutant LKB1 (GST-LKB1KD) were kinds gift from Prof. Dario Alessi. Site- 
directed mutagenesis was used to generate site-specific alanine mutants of both of these 
proteins (GST-LKB1S325A and GST-LKB1KD/S325A). The GST-LKB1KD was expressed in 
HeLa cells, which lack endogenous LKB1, and was purified as detailed previously. 
After the protein was bound to glutathione-Sepharose, the beads were treated with 
protein phosphatase to dephosphorylate the protein, followed by wash steps before 
elution of the GST-LKB1KD. HeLa cells were also transfected with DNA encoding 
GST-ERK2 (obtained from the Division of Signal Transduction Therapy, University of 
Dundee) and were then treated with phorbol 12-myristate 13-acetate (PMA), a phorbol 
ester that activates ERK in cells. The cells were then lysed and the GST-ERK2 was 
purified using glutathione-Sepharose beads as previously described. Varying 
concentrations of GST-ERK2 were then incubated with dephosphorylated GST-
LKB1KD in the presence of ATP and Mg
2+
 at 30°C on a shaker for 15 minutes. The 
kinase-dead LKB1 mutant was used instead of the wild type protein to prevent auto-
phosphorylation. The reaction was then stopped by adding LDS buffer and boiling the 
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samples. SDS-PAGE was then carried out and the membrane probed with anti-pS325 
antibody. Unfortunately no signal was seen (data not shown). This either meant that the 
antibody was unable to detect phosphoSer-325 or that ERK2 did not phosphorylate this 
site; therefore phosphorylation using [γ32P]-ATP followed by autoradiography was 
performed. The experiment was repeated by incubating the GST-ERK2 with GST-
LKB1KD in the presence of [γ
32
P]-ATP and Mg
2+ 
and the reaction was stopped by 
adding LDS buffer. The reaction mixes were resolved using SDS-PAGE, the gel was 
dried and autoradiography performed. Most of the signal obtained corresponded to 
GST-ERK2 and the intensity increased with increasing ERK concentration, suggesting 
auto-phosphorylation of GST-ERK2. A very faint band was seen corresponding to 
GST-LKB1KD, which took 24 hour exposure to become evident (Figure 5.9). The bands 
were then cut out and the [γ32P]-ATP incorporation in the samples as well as a standard 
was measured using a scintillation counter. The stoichiometry of phosphorylation was 
then calculated to be 0.1 mol/mol, suggesting that ERK2 only weakly phosphorylated 
LKB1 in this cell-free system. However, this experiment could be improved by 
repeating this experiment with a known ERK2 substrate in parallel as a positive control.  
 As ERK2 did not seem to phosphorylate LKB1 on Ser-325 significantly in a 
cell-free system, the likelihood of its ability to phosphorylate LKB1 on Ser-325 in intact 
cells seemed very low. Therefore due to the lack of promising results, further 
experiments to test whether maximal phosphorylation on both sites, Ser-325 and Ser-
431, by ERK2 and p90RSK activation, affected AMPK activity were not carried out. 
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Figure 5.9: GST-ERK weakly phosphorylates GST-LKB1KD 
GST-ERK2 was incubated with GST-LKB1KD in the presence of Mg
2+ and [γ32P]-ATP. The reaction 
mixes were resolved using SDS-PAGE, the gel was dried and autoradiography performed. The 
bands were cut and [γ32P]-ATP incorporation measured in a scintillation counter to calculate 
the stoichiometry of phosphorylation.   
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5.4 DISCUSSION  
 
PJS syndrome is caused by mutations in the LKB1 gene, which mainly affect its 
catalytic activity. However Forcet et al reported that some C-terminal tail mutations, 
notably P324L and T367M, while not affecting the sub-cellular localisation of LKB1 or 
its binding of STRAD, reduced its ability to phosphorylate and activate AMPK (Forcet 
et al., 2005). The P324L mutation lies adjacent to Ser-325, which is likely to be 
phosphorylated by a proline-directed kinase and T367M is close to the ATM 
phosphorylation site (Thr-363 in human LKB1). Previous reports also suggested that 
Ser-431 phosphorylation  was required for LKB1-mediated cell cycle arrest (Sapkota et 
al., 2001). However, our laboratory found that Ser-431 phosphorylation was not 
required for cell cycle arrest (Fogarty and Hardie, 2009). Moreover, the non-
phosphorylatable alanine mutant LKB1S431A activated the isolated AMPK-α kinase 
domain to a similar extent as wild type LKB1 (Fogarty and Hardie, 2009).  
The possible regulatory role of the C-terminal tail of LKB1 was again 
emphasised by observations that melanoma cells with constitutive activation of B-RAF, 
caused by the V600E mutation in the latter, had reduced AMPK activity. The authors 
proposed that the MEK-ERK-p90RSK pathway was activated downstream of the 
activated B-RAF, and that ERK2 phosphorylated Ser-325 and p90RSK phosphorylated 
Ser-431 on LKB1. Phosphorylation of LKB1 on both of these sites was claimed to 
reduce AMPK activity (Zheng et al., 2009). The main aim of the chapter was to test 
whether phosphorylation of Ser-325 was indeed mediated by ERK, as although LKB1 
has a proline residue after the serine at the 325 position, it does not possess the typical 
ERK phosphorylation motif, which in addition to Ser/Pro at the phosphorylation site, 
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would normally require the presence of a DEF motif (F-X-F-P) or D-domain (which are 
ERK binding motifs) (Fernandes and Allbritton, 2009).  
The aim of the first experiment was to test whether phosphorylation of Ser-325 
and Ser-431 affected AMPK activity. The ability of LKB1 containing complexes GST-
LKB1WT, GST-LKB1S325A, GST-LKB1S431A or GST-LKB1AA to activate AMPK 
heterotrimer was tested in a cell-free system. All of the mutants activated AMPK to the 
same degree as that of the wild type LKB1, suggesting that phosphorylation of the C-
terminal tail of LKB1 on Ser-325 and Ser-431 did not affect its ability to AMPK in a 
cell-free system.  
It had previously been demonstrated in our laboratory that Ser-431 
phosphorylation on LKB1did not affect activation of the isolated recombinant AMPK 
kinase domain (Fogarty and Hardie, 2009). The result that GST-LKB1WT, GST-
LKB1S431A and GST-LKB1AA, all activated AMPK heterotrimer to the same extent was 
consistent with the published results. Moreover, p90RSK-mediated Ser-431 
phosphorylation on GST- LKB1WT activated AMPK heterotrimer to the same extent as 
GST-LKB1WT that had not been phosphorylated by p90RSK.  
The next step was to test whether ERK2 significantly phosphorylated the Ser-
325 site. Phosphorylation using unlabelled Mg-ATP, followed by Western blotting did 
not give conclusive results, because no signal was detectable using the anti-pS325 
antibody. Therefore, incorporation of [γ32P]-ATP into GST-LKB1KD by ERK2 was 
measured using autoradiography. The stoichiometry of phosphorylation was also 
estimated. Most of the γ32P was incorporated into GST-ERK itself rather than LKB1, 
suggesting auto-phosphorylation. This auto-phosphorylation was concentration-
dependent.  It took a very long exposure time of around 24 hours before the LKB1 band 
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became visible after autoradiography, and even after this time, the stoichiometry of 
phosphorylation was very low. This suggested that ERK2, which was maximally 
activated by treatment of cells with PMA, only weakly phosphorylated LKB1 on Ser-
325. This was in contrast to the results of Zheng et al, which demonstrated 
phosphorylation of LKB1 on Ser-325 by ERK2. However, the authors did not report the 
stoichiometry of phosphorylation in that experiment. Despite the difference in our 
observations, the conclusion that ERK was not a good upstream kinase for the Ser-325 
site in a cell-free system meant that the likely effect of this reaction would be negligible 
in intact cells. Due to results that were not very promising, the intended final 
experiment using both ERK and p90RSK to phosphorylate Ser-325 and Ser-431 on 
LKB1, and testing its effect on AMPK activity was not carried out. It appears therefore, 
that although in melanoma cells with the B-RAF V600E mutation, AMPK activation 
has been shown to be impaired, the site-specific alanine mutations did not seem to have 
reduced AMPK activity when tested in a cell-free system. It is plausible that a different 
kinase, likely to phosphorylate LKB1 on Ser-325 better than ERK2, may also be 
activated in the melanoma cells expressing the B-RAFV600Emutation, which may 
account for the reduced ability of LKB1 to activity AMPK. Due to the lack of time, the 
testing of this hypothesis was beyond the scope of this study. 
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CHAPTER SIX: CONCLUSIONS AND PERSPECTIVES 
 
6.1 INTRODUCTION 
 
This thesis explores the role of AMPK in cancer and in the DNA damage response. The 
aim was to test the role of AMPK, both as a tumour suppressor and as a modulator of 
cell survival in conditions of genotoxic stress. Data presented in this thesis provides 
evidence that AMPK functions as a tumour suppressor in vivo, delaying death from 
lymphomas in mice that lack PTEN in their T cells. By contrast, it increases the survival 
of cells treated with chemotherapeutic agents such as etoposide that cause double 
stranded DNA breaks. Thus AMPK appears to act as a “double-edged sword” in cancer, 
providing protection against the development of tumours, while protecting tumour cells 
against the effects of cancer therapy once tumours have become established. Our data 
also suggests that AMPK activation occurs in the nucleus in response to genotoxic 
stress. One of the initial aims of the thesis was to explore the regulatory role of the C-
terminal tail of LKB1 on AMPK activity. However, Thr-366 phosphorylation of LKB1 
by ATM, in the context of DNA damage, did not appear to play a role in AMPK 
activation, as this process has been shown in this thesis to be independent of LKB1 and 
dependent instead on CaMKK-β. This chapter discusses the implications of the findings 
reported in this thesis and suggests areas for future research. 
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6.2 AMPK is activated by agents that cause double strand DNA 
breaks 
 
The work done in this thesis was prompted by reports from other groups suggesting that 
AMPK was activated in conditions of genotoxic stress (Fu, 2008, Sanli et al., 2010). It 
has been known for some time that ATM phosphorylates Thr-366 on LKB1, when cells 
were treated with ionising radiation (Sapkota et al., 2002b). It therefore seemed 
plausible that genotoxic stress might activate AMPK downstream of this ATM-LKB1 
pathway. However, data from the thesis shows that AMPK activation, in response to 
etoposide, occurs in an LKB1-independent manner. Two different cell lines that lacked 
LKB1, namely HeLa and G361 cells, showed a 2-to-3 fold activation of AMPK in 
response to etoposide. By contrast, inhibition of CaMKK-β, either by reducing its 
expression using siRNA- mediated gene silencing, or by pharmacological inhibition 
using STO-609, resulted in a marked reduction of etoposide-induced AMPK activation. 
These results showed that the AMPK activation in these cells was mediated by 
CaMKK-β. Interestingly, only the AMPK-α1 isoform was shown to be activated with 
little or no activation of AMPK-α2. This was an interesting result and may serve, in part 
to explain previous observations obtained with muscle-specific knockout (LKB1
fl/fl 
Cre
+/-
) mice, in which AMPK-α1 activity in muscle under basal and AICAR stimulated 
conditions was undiminished compared to the LKB1
fl/fl 
Cre
-/-
 controls (Sakamoto et al., 
2005). In contrast, basal and AICAR-stimulated AMPK-α2 activity was markedly 
reduced in muscle-specific LKB1 knockout compared to the LKB1
fl/fl
 Cre
-/-
 controls 
(Sakamoto et al., 2005).  
 Data from the thesis also suggests that AMPK activation in response to 
etoposide is independent of ATM. Treatment of cells with the specific ATM inhibitor, 
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KU-55933, although inhibiting phosphorylation of ATM substrates, did not reduce 
AMPK activation. This is in contrast to previous reports showing impaired AMPK 
activation in response to etoposide in cells that lack ATM (Fu, 2008). However, the data 
in that paper showed that ATM-null cells have much higher basal levels of 
phosphorylated AMPK compared to ATM+ cells, and that this was not further increased 
with etoposide. ATM+ cells, when maximally activated with etoposide have pT-172 
signal intensity comparable to that seen in untreated ATM-null cells. This is an area 
which needs clarification, ideally in LKB1-null cells which express or lack ATM. 
siRNA-mediated ATM silencing in HeLa cells was attempted during this study. 
However, the efficacy of ATM knockdown was only about 50%, and a reduction in 
AMPK activation in ATM-knock-down cells treated with etoposide was not observed. 
 Perhaps one of the most intriguing findings in this study was the lack of 
concomitant ACC activation, despite AMPK activation in HeLa and G361 cells treated 
with etoposide. Immunohistochemistry revealed that AMPK was activated almost 
exclusively in the nucleus following etoposide treatment. It has been shown that the α2 
isoform, but not the α1 isoform of AMPK is enriched in the nucleus (Salt et al., 1998). 
However, our data shows that only AMPK-α1 is activated by etoposide treatment. This 
was a very interesting result and may serve, in part to explain previous observations 
obtained with muscle-specific knockout (LKB1
fl/fl 
Cre
+/-
) mice, in which AMPK-
α1activity in muscle under basal and AICAR stimulated conditions was undiminished 
compared to the LKB1
fl/fl 
Cre
-/-
 controls (Sakamoto et al., 2005). In contrast, basal and 
AICAR-stimulated AMPK-α2 activity was markedly reduced in muscle-specific LKB1 
knockout compared to the LKB1
fl/fl
 Cre
-/-
 controls (Sakamoto et al., 2005).  
Two different anti- AMPK-α1 and anti-AMPK-α2 antibodies were tested for 
staining in HeLa cells, but the antibodies were unfortunately not specific enough for 
177 
 
 
 
immunocytochemistry. Sub-cellular fractionation was also attempted, but as the osmotic 
stress used for cell lysis activated AMPK, the small increase in nuclear AMPK by 
etoposide treatment may have been obscured by the large increase in AMPK activation 
due to the osmotic stress. It would be interesting to test whether leptomycin, an agent 
that prevents nuclear import of proteins, abolished activation of nuclear AMPK in 
response to etoposide treatment. If confirmed, this would suggest nuclear translocation 
of activated AMPK-α1 from the cytoplasm. 
 Activation of AMPK in cells treated with etoposide is temporally associated 
with an increase in nuclear calcium. This provides a mechanism by which CaMKK-β, 
and subsequently AMPK is activated, which is independent of signalling via ATM. 
However, testing whether other agents that cause double stranded DNA breaks such as 
topotecan and irinotecan also cause similar increase in nuclear calcium flux would add 
strength to this hypothesis. At present, we do not know the source of the increased 
nuclear calcium ions, the mechanism by which they are released in response to 
etoposide treatment, and whether it occurs in response to DNA damage or in response to 
some other side effect of etoposide. 
 
6.3 AMPK activation confers resistance to DNA-damaging 
drugs such as etoposide 
 
Epidemiological studies show that diabetics on metformin have a reduced risk of cancer 
compared to diabetics on other treatments (Evans, 2005, Bowker et al., 2006a). 
However, there have been conflicting reports in the literature about the role of AMPK 
as a therapeutic target in cancer. Some reports suggest that AMPK activation using 
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metformin sensitises cells to ionising radiation (Sanli et al., 2010). Agents such as 
aspirin have also been shown to activate AMPK, and this activation partially mediated 
suppression of the mTOR pathway in colorectal cancer cells (Din et al., 2012). 
However, data from our study shows that CaMKKβ-mediated activation of AMPK by 
the calcium ionophore A23187 increased cell survival of wild type MEFs in response to 
etoposide treatment, while this effect was not seen in MEFs lacking AMPK-α1 and -α2. 
The increased survival may be due to G1 cell cycle arrest mediated by AMPK 
activation, which protected cells from prolonged S phase arrest caused by etoposide. 
Cells are more vulnerable to DNA damage during the S phase when their DNA is being 
replicated and topoisomerases are active. This effect is similar to other agents such as 
roscovitine and flavopiridol, which cause G1 arrest and also protect against DNA 
damage (Crescenzi et al., 2005, Di Giovanni et al., 2005). This may have implications 
for combination chemotherapy where agents that activate AMPK, when used in 
combination with DSB-inducing drugs, may lead to poor response to chemotherapy.  
 
6.4 AMPK functions as a tumour suppressor in vivo 
 
Perhaps the most significant result in this thesis is the direct evidence that AMPK 
functions as a tumour suppressor in vivo. The data clearly demonstrates that T cell-
specific deletion of PTEN and AMPK causes death of mice from lymphomas 
significantly earlier than in mice with T cell-specific deletion of PTEN alone. The 
location of the lymphomas were also significantly different in the PTEN AMPK double 
KO mice with almost all tumours being limited to the thymus, whereas in the PTEN KO 
mice, spleen and lymph node involvement was usually seen in addition to involvement 
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of the thymus. The study also showed a marked reduction in S1P1 mRNA levels in the 
PTEN AMPK double KO cells, which suggests a role for AMPK in mediating egress of 
mature thymocytes into peripheral lymph organs. The data also suggested that the 
PTEN AMPK double KO thymocytes were larger than PTEN KO thymocytes. PTEN 
AMPK double KO thymocytes also had markedly increased phosphorylation of 
ribosomal protein S6 compared to the other two groups, which indicated a role for 
AMPK in down-regulation of mTOR in thymocytes with increased PI3K activity.  
Future work to understand the biological role of AMPK would require 
identification of the subset of cells that become tumour cells, subsequent to the deletion 
of PTEN and AMPK. Work from this study suggests that the transition from the DN to 
the DP cells, and the egress of tumour cells may be two important areas, where further 
work to delineate AMPK-dependent signalling changes in this tumour model may yield 
interesting results that might explain how AMPK deletion affects tumour formation.  
 
6.5 C-terminal phosphorylation of LKB1and AMPK activity 
 
The last chapter in the thesis briefly explored the role of C-terminal phosphorylation on 
two sites of LKB1, namely Ser-325 and Ser-431. This was prompted by reports 
suggesting that, in melanoma cells carrying the B-RAF V600E mutation, there was 
activation of ERK and p90RSK, which caused phosphorylation of these two sites on 
LKB1, inhibiting its ability to activate AMPK (Zheng et al., 2009). Previous reports 
suggest that Ser-431 phosphorylation does not affect AMPK activation (Fogarty and 
Hardie, 2009). The data from this thesis shows that mutation of both Ser-325 and Ser-
431 to alanine also does not affect the ability of LKB1 to activate AMPK in a cell-free 
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system. Moreover, ERK does not stoichiometrically phosphorylate Ser-325 on LKB1. 
Future experiments to investigate the role of LKB1 phosphorylation might involve 
construction of stable cell lines of G361 or HeLa cells expressing wild type LKB1 or 
various phosphorylation site mutants. 
 
6.7 Final summary 
 
Overall, the results presented in this thesis dissect the role played by AMPK in cancer. 
AMPK appears to function in two very different ways; on the one hand AMPK 
functions as a tumour suppressor delaying tumour onset in mice with T cell-specific 
PTEN deletion, while in tumour cells treated with DNA damaging agents, AMPK 
activation confers increased cell survival. AMPK activation therefore, may delay 
tumour formation; however, once a cancer is established, AMPK activation may be 
detrimental to therapy. However, this may depend on the type of cancer and the 
signalling pathways that have been activated or suppressed, either causally, or as a 
consequence of the cancer. Further work is required to determine tissue and cellular 
responses to AMPK activation and inhibition, in different cancers to evaluate the 
potential therapeutic benefit of modulating AMPK activity as an adjunct to existing 
treatments for cancer. This is an exciting area likely to yield real benefit to cancer 
patients. 
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